	PRISM.drugid	broad_id	compound_plate	moa	target	disease.area	indication	smiles	phase	drugid	cid	inchikey
1-Azakenpaullone	1-azakenpaullone	BRD-K03273112-001-01-8	PREP037	glycogen synthase kinase inhibitor	"CCNB1, CDK1, CDK5, GSK3B"	NA	NA	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	Preclinical	1-Azakenpaullone	6538897	NTSBZVCEIVPKBJ-UHFFFAOYSA-N
1-naphthyl-PP1	1-naphthyl-PP1	BRD-K29542628-001-03-9	PREP042	src inhibitor	SRC	NA	NA	"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12"	Preclinical	1-naphthyl-PP1	4877	XSHQBIXMLULFEV-UHFFFAOYSA-N
1-Phenylbiguanide	1-phenylbiguanide	BRD-K31491153-003-05-9	PREP044	serotonin receptor agonist	"HTR3A, HTR3B"	NA	NA	NC(=N)NC(=N)Nc1ccccc1	Preclinical	1-Phenylbiguanide	4780	CUQCMXFWIMOWRP-UHFFFAOYSA-N
10-Deacetylbaccatin III	10-deacetylbaccatin	BRD-K96631475-001-02-4	PREP031	antitumor agent	NA	NA	NA	"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C"	Preclinical	10-Deacetylbaccatin III	154272	YWLXLRUDGLRYDR-ZHPRIASZSA-N
10-Hydroxycamptothecin	10-hydroxycamptothecin	BRD-K63784565-001-06-2	PREP041	topoisomerase inhibitor	TOP1	NA	NA	"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O"	Preclinical	10-Hydroxycamptothecin	97226	HAWSQZCWOQZXHI-FQEVSTJZSA-N
Phorbol 12-myristate 13-acetate	12-O-tetradecanoylphorbol-13-acetate	BRD-K68552125-001-05-3	PREP026	PKC activator	"KCNT2, TRPV4"	NA	NA	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O	Phase 2	Phorbol 12-myristate 13-acetate	27924	PHEDXBVPIONUQT-RGYGYFBISA-N
2-Methoxyestradiol	2-methoxyestradiol	BRD-K44408410-001-17-6	PROS001_PR500	hypoxia inducible factor inhibitor	"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB"	NA	NA	"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O"	Phase 2	2-Methoxyestradiol	66414	CQOQDQWUFQDJMK-SSTWWWIQSA-N
"3-(2,3-Dichlorophenoxy)propyl-(2-hydroxyethyl)azanium"	"2,3-DCPE"	BRD-K61734568-003-02-1	PREP036	Bcl-XL downregulator	BCL2L1	NA	NA	OCCNCCCOc1cccc(Cl)c1Cl	Preclinical	"3-(2,3-Dichlorophenoxy)propyl-(2-hydroxyethyl)azanium"	2250974	QVEIRCZEBQRCTR-UHFFFAOYSA-O
2'-MeCCPA	2'-MeCCPA	BRD-K63932022-001-01-5	PREP042	adenosine receptor agonist	ADORA1	NA	NA	"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12"	Preclinical	2'-MeCCPA	44292754	MMPAUXMIDJWGFO-UHFFFAOYSA-N
3-aminobenzamide	3-amino-benzamide	BRD-K08703257-001-13-9///BRD-K08703257-001-12-1	PROS001_PR500///PREP025	PARP inhibitor	PARP1	NA	NA	"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1"	Phase 2	3-aminobenzamide	1645	GSCPDZHWVNUUFI-UHFFFAOYSA-N
3-Deazaneplanocin	3-deazaneplanocin-A	BRD-K77791657-003-01-7	PREP031	histone lysine methyltransferase inhibitor	EZH2	NA	NA	"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O"	Preclinical	3-Deazaneplanocin	73087	OMKHWTRUYNAGFG-IEBDPFPHSA-N
3'-fluorobenzylspiperone	3'-fluorobenzylspiperone	BRD-K45662124-050-01-5	PREP041	dopamine receptor ligand	DRD2	NA	NA	"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1"	Preclinical	3'-fluorobenzylspiperone	3248000	DXZKTRNEOISOCA-UHFFFAOYSA-N
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	BRD-K47337578-034-02-5	PREP043	serotonin receptor antagonist	HTR2A	NA	NA	"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1"	Preclinical	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	5234410	FTJXZACAQRDRNT-UHFFFAOYSA-N
1-(4-Chlorophenyl)guanidine	4-chlorophenylguanidine	BRD-K39160765-003-02-9	PREP040	urokinase inhibitor	PLAUR	NA	NA	NC(=N)Nc1ccc(Cl)cc1	Preclinical	1-(4-Chlorophenyl)guanidine	2757788	ZSJNJAJDBNFVCA-UHFFFAOYSA-N
4-hydroxyphenazone	4-hydroxy-phenazone	BRD-K49759007-001-11-9	PREP014	NA	NA	NA	NA	Cc1c(O)c(=O)n(-c2ccccc2)n1C	Preclinical	4-hydroxyphenazone	NA	NA
4-IPP	4-iodo-6-phenylpyrimidine	BRD-K25690923-001-02-4	PREP036	macrophage migration inhibiting factor inhibitor	MIF	NA	NA	Ic1cc(ncn1)-c1ccccc1	Preclinical	4-IPP	817368	ZTCJXHNJVLUUMR-UHFFFAOYSA-N
Biochanin A	4-methylgenistein	BRD-K73303757-001-21-6	PREP032	protein tyrosine kinase inhibitor	"CYP19A1, ESRRA, ESRRB, ESRRG, FASN"	NA	NA	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Preclinical	Biochanin A	5280373	WUADCCWRTIWANL-UHFFFAOYSA-N
4-Methylhistamine	4-methylhistamine	BRD-K70821460-300-02-4	PREP042	histamine receptor agonist	HRH4	NA	NA	Cc1nc[nH]c1CCN	Preclinical	4-Methylhistamine	37463	UGYXPZQILZRKJJ-UHFFFAOYSA-N
Pyrimidine-4-carbonitrile	4-pyrimidinecarbonitrile	BRD-K04552268-001-02-4	PREP031	NA	NA	NA	NA	N#Cc1ccncn1	Preclinical	Pyrimidine-4-carbonitrile	10313094	ZIEWSZYVEDTXGH-UHFFFAOYSA-N
4E1RCat	4E1RCat	BRD-K67173685-001-06-9	PREP044	protein synthesis inhibitor	"EIF4E, EIF4G1"	NA	NA	"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O"	Preclinical	4E1RCat	78357788	BBQRBOIMSKMFFO-PGMHBOJBSA-N
5-Fluorouracil	5-fluorouracil	BRD-K24844714-001-24-5	PREP028	thymidylate synthase inhibitor	"DPYD, TYMS"	oncology	"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma"	"Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O"	Launched	5-Fluorouracil	3385	GHASVSINZRGABV-UHFFFAOYSA-N
Desfesoterodine	5-hydroxymethyl-tolterodine	BRD-K24603946-001-02-1	PREP044	acetylcholine receptor antagonist	CHRM3	NA	NA	"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C"	Phase 1	Desfesoterodine	9819382	DUXZAXCGJSBGDW-HXUWFJFHSA-N
7-aminocephalosporanic acid	7-aminocephalosporanic-acid	BRD-K65377893-001-07-4	PREP028	beta lactamase inhibitor	NA	NA	NA	"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O"	Preclinical	7-aminocephalosporanic acid	441328	HSHGZXNAXBPPDL-HZGVNTEJSA-N
7-Hydroxystaurosporine	7-hydroxystaurosporine	BRD-K45293975-001-02-0	PREP044	"CDK inhibitor, CHK inhibitor, PKC inhibitor"	"CHEK1, MARK3, PDPK1"	NA	NA	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	Phase 2	7-Hydroxystaurosporine	72271	PBCZSGKMGDDXIJ-HQCWYSJUSA-N
7-nitroindazole	7-nitroindazole	BRD-K04430056-236-02-1	PREP015	nitric oxide synthase inhibitor	"NOS1, NOS2, NOS3"	NA	NA	"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12"	Preclinical	7-nitroindazole	1893	PQCAUHUKTBHUSA-UHFFFAOYSA-N
8-Bromo-cGMP	8-bromo-cGMP	BRD-A00077618-236-07-6	PREP036	PKA activator	PRKG1	NA	NA	Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1	Preclinical	8-Bromo-cGMP	135419186	YUFCOOWNNHGGOD-UMMCILCDSA-N
8-Hydroxy-pipat	8-hydroxy-PIPAT	BRD-A60594020-034-01-1	PREP040	dopamine receptor ligand	"DRD2, DRD3"	NA	NA	CCCN(C\C=C\I)C1CCc2cccc(O)c2C1	Preclinical	8-Hydroxy-pipat	6142670	QBXHUZJZYDSLRH-RUDMXATFSA-N
9-Aminoacridine	9-aminoacridine	BRD-K00535541-001-06-3	PREP014	NA	NA	NA	NA	"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12"	Preclinical	9-Aminoacridine	7019	XJGFWWJLMVZSIG-UHFFFAOYSA-N
A-674563	A-674563	BRD-K78177893-001-02-4	PREP042	AKT inhibitor	"AKT1, PKIA, PRKACA"	NA	NA	Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	Preclinical	A-674563	11314340	NA
A-803467	A-803467	BRD-K28570407-001-02-0	PREP014	sodium channel blocker	SCN10A	NA	NA	"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1"	Preclinical	A-803467	16038374	VHKBTPQDHDSBSP-UHFFFAOYSA-N
A61603	A61603	BRD-A83650191-004-02-8	PREP042	adrenergic receptor agonist	ADRA1A	NA	NA	CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1	Preclinical	A61603	4038180	OQFCXJDXHCDLHX-UHFFFAOYSA-N
Abemaciclib	abemaciclib	BRD-K33622447-066-01-9	PROS003_PR500	CDK inhibitor	"CDK4, CDK6"	oncology	breast cancer	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	Launched	Abemaciclib	46220502	UZWDCWONPYILKI-UHFFFAOYSA-N
Abiraterone	abiraterone	BRD-K50071428-001-03-3	PREP031	androgen biosynthesis inhibitor	"CYP11B1, CYP17A1///CYP17A1"	oncology	prostate cancer	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1	Launched	Abiraterone	132971	GZOSMCIZMLWJML-VJLLXTKPSA-N
Abiraterone-acetate	abiraterone-acetate	BRD-K50071428-001-03-3///BRD-K24048528-001-02-5	PREP020	androgen biosynthesis inhibitor	"CYP11B1, CYP17A1///CYP17A1"	oncology	prostate cancer	"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1"	Launched	Abiraterone	9821849	GZOSMCIZMLWJML-VJLLXTKPSA-N
Abt-702	ABT-702	BRD-K36021395-300-02-4	PREP037	adenosine kinase inhibitor	ADK	NA	NA	"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1"	Preclinical	Abt-702	1973	RQCXKDWOCUJWQZ-UHFFFAOYSA-N
Abt-737	ABT-737	BRD-K56301217-001-07-4	PREP039	BCL inhibitor	"BCL2, BCL2L1, BCL2L2"	NA	NA	"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1"	Phase 1/Phase 2	Abt-737	11228183	HPLNQCPCUACXLM-PGUFJCEWSA-N
Abt-751	ABT-751	BRD-K91623615-001-05-0	PREP019	tubulin polymerization inhibitor	TUBB	NA	NA	"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1"	Phase 2	Abt-751	3035714	URCVCIZFVQDVPM-UHFFFAOYSA-N
AC-264613	AC-264613	BRD-K81548480-001-01-2	PREP043	PAR agonist	F2RL1	NA	NA	"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1"	Preclinical	AC-264613	25108278	RQKXQCSEZPQBNZ-QSBCOWLBSA-N
Acdpp	ACDPP	BRD-K68633617-003-02-9	PREP024	glutamate receptor antagonist	GRM5	NA	NA	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	Preclinical	Acdpp	16759169	RNGRUHWJJPTYNR-UHFFFAOYSA-N
acesulfame-potassium	acesulfame-potassium	BRD-K50850824-237-04-8	PREP039	NA	NA	NA	NA	"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1"	Phase 3	acesulfame-potassium	23683747	WBZFUFAFFUEMEI-UHFFFAOYSA-M
Acetazolamide	acetazolamide	BRD-K43457670-001-27-8	PREP034	carbonic anhydrase inhibitor	"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7"	ophthalmology	glaucoma	CC(=O)Nc1nnc(s1)S(N)(=O)=O	Launched	Acetazolamide	1986	BZKPWHYZMXOIDC-UHFFFAOYSA-N
Acetophenazine	acetophenazine	BRD-K42938903-332-01-1	PREP020	dopamine receptor antagonist	"DRD1, DRD2"	neurology/psychiatry	psychosis	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	Launched	Acetophenazine	17676	WNTYBHLDCKXEOT-UHFFFAOYSA-N
Acetylcysteine	acetylcysteine	BRD-K59058747-001-18-3	PREP048	mucolytic agent	"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11"	gastroenterology	"acetaminophen overdose, hepatic injury"	"CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O"	Launched	Acetylcysteine	12035	PWKSKIMOESPYIA-BYPYZUCNSA-N
Acetylsalicylsalicylic acid	acetylsalicylsalicylic-acid	BRD-K46585355-001-14-3	PREP036	cyclooxygenase inhibitor	NA	NA	NA	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	Preclinical	Acetylsalicylsalicylic acid	10745	DDSFKIFGAPZBSR-UHFFFAOYSA-N
Acipimox	acipimox	BRD-K63736853-001-04-8	PREP048	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O"	Launched	Acipimox	5310993	DJQOOSBJCLSSEY-UHFFFAOYSA-N
Acivicin	acivicin	BRD-K13050541-001-01-9	PREP024	gamma glutamyltransferase Inhibitors	CTPS1	NA	NA	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O	Phase 2	Acivicin	294641	QAWIHIJWNYOLBE-OKKQSCSOSA-N
ACY-1215	ACY-1215	BRD-K82928847-001-04-7	PREP030	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8"	NA	NA	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	Phase 1/Phase 2	ACY-1215	53340666	QGZYDVAGYRLSKP-UHFFFAOYSA-N
Adapalene	adapalene	BRD-K33127281-001-05-6	PREP014	retinoid receptor agonist	"RARA, RARB, RARG, RXRA, RXRB, RXRG"	dermatology	acne vulgaris (AV)	"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O"	Launched	Adapalene	60164	LZCDAPDGXCYOEH-UHFFFAOYSA-N
alpha-D-Glucose-6-phosphate	adaprev	BRD-A73427433-240-01-3	PREP032	TGF beta receptor inhibitor	"IGF2R, M6PR"	NA	NA	OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O	Phase 3	alpha-D-Glucose-6-phosphate	439284	NBSCHQHZLSJFNQ-DVKNGEFBSA-N
Adarotene	adarotene	BRD-K00152668-001-01-5	PREP026	retinoid receptor agonist	"RARB, RARG"	NA	NA	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Phase 1	Adarotene	9864378	QAWBIEIZDDIEMW-FPYGCLRLSA-N
Adefovir dipivoxil	adefovir-dipivoxil	BRD-K96159438-001-06-3	PREP022	DNA polymerase inhibitor	NA	infectious disease	hepatitis B	"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C"	Launched	Adefovir dipivoxil	60871	WOZSCQDILHKSGG-UHFFFAOYSA-N
ADL5859	ADL5859	BRD-K39624409-003-02-6	PREP026	opioid receptor agonist	OPRD1	NA	NA	"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12"	Phase 2	ADL5859	11417954	OPIKUXLJQFYMSC-UHFFFAOYSA-N
AEE788	AEE788	BRD-K40718343-001-02-6	PREP032	"EGFR inhibitor, VEGFR inhibitor"	"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR"	NA	NA	"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1"	Phase 1/Phase 2	AEE788	10297043	OONFNUWBHFSNBT-HXUWFJFHSA-N
AEG3482	AEG3482	BRD-K77634909-001-03-5	PREP032	HSP inducer	NA	NA	NA	"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1"	Preclinical	AEG3482	698112	MQUYTXDAVCOCMX-UHFFFAOYSA-N
Afatinib	afatinib	BRD-K66175015-001-12-4///BRD-K66175015-001-09-0	PROS003_PR500///PREP021	EGFR inhibitor	"EGFR, ERBB2, ERBB4"	oncology	non-small cell lung cancer (NSCLC)	"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1"	Launched	Afatinib	10184653	ULXXDDBFHOBEHA-CWDCEQMOSA-N
Fabomotizole	afobazole	BRD-K37793595-003-01-7	PREP031	anxiolytic	NA	neurology/psychiatry	anxiety	CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1	Launched	Fabomotizole	9862937	WWNUCVSRRUDYPP-UHFFFAOYSA-N
AG14361	AG-14361	BRD-K00615600-001-12-9	PREP014	PARP inhibitor	PARP1	NA	NA	"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23"	Preclinical	AG14361	9840076	SEKJSSBJKFLZIT-UHFFFAOYSA-N
Ajmaline	ajmaline	BRD-A48300215-001-04-8	PREP021	sodium channel blocker	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O	Launched	Ajmaline	6100671	CJDRUOGAGYHKKD-RQBLFBSQSA-N
Albendazole	albendazole	BRD-K79131256-001-17-9	PREP029	tubulin polymerization inhibitor	"TUBA1A, TUBB, TUBB4B"	infectious disease	"cystic hydatid disease, parenchymal neurocysticercosis"	"CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1"	Launched	Albendazole	2082	HXHWSAZORRCQMX-UHFFFAOYSA-N
Alectinib	alectinib	BRD-K11267252-001-04-4///BRD-K11267252-001-05-1	PREP020///PROS003_PR500	ALK tyrosine kinase receptor inhibitor	"ALK, MET"	oncology	non-small cell lung cancer (NSCLC)	"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1"	Launched	Alectinib	49806720	NA
Alexidine	alexidine	BRD-A27883417-300-01-6	PREP043	phosphatidylglycerophosphatase inhibitor	PTPMT1	NA	NA	CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC	Preclinical	Alexidine	2090	LFVVNPBBFUSSHL-UHFFFAOYSA-N
Alfacalcidol	alfacalcidol	BRD-K49522529-001-02-9	PREP034	vitamin D receptor agonist	"CYP27B1, VDR"	endocrinology	vitamin D deficiency	"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C"	Launched	Alfacalcidol	5282181	OFHCOWSQAMBJIW-AVJTYSNKSA-N
Alisertib	alisertib	BRD-K75295174-001-05-0	PREP038	Aurora kinase inhibitor	AURKA	NA	NA	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O	Phase 3	Alisertib	24771867	NA
Almorexant	almorexant	BRD-K84810405-003-01-1	PREP033	orexin receptor antagonist	"HCRTR1, HCRTR2"	NA	NA	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 3	Almorexant	23727689	DKMACHNQISHMDN-RPLLCQBOSA-N
Alogliptin	alogliptin	BRD-K83003151-057-02-4	PREP020	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O"	Launched	Alogliptin	11450633	ZSBOMTDTBDDKMP-OAHLLOKOSA-N
Alpelisib	alpelisib	BRD-K54997624-001-06-0	PROS002_PR500	PI3K inhibitor	"PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	Phase 3	Alpelisib	56649450	NA
Altretamine	altretamine	BRD-K67043667-001-26-4	PREP022	DNA synthesis inhibitor	NA	oncology	ovarian cancer	"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C"	Launched	Altretamine	2123	UUVWYPNAQBNQJQ-UHFFFAOYSA-N
Alvespimycin	alvespimycin	BRD-K83988098-001-02-0///BRD-K83988098-003-03-4	PROS005_PR500///PREP031	HSP inhibitor	HSP90AA1	NA	NA	"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O"	Phase 2	Alvespimycin	5288674	KUFRQPKVAWMTJO-LMZWQJSESA-N
Alvocidib	alvocidib	BRD-K87909389-003-03-4	PROS002_PR500	CDK inhibitor	"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM"	NA	NA	"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl"	Phase 2	Alvocidib	5287969	NA
AM-251	AM-251	BRD-K92000912-001-12-6	PREP037	cannabinoid receptor antagonist	"CNR1, GPR18, GPR55"	NA	NA	"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1"	Preclinical	AM-251	2125	BUZAJRPLUGXRAB-UHFFFAOYSA-N
AM-404	AM-404	BRD-K55462201-001-07-3	PREP025	"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist"	"CNR1, CNR2, FAAH, TRPV1"	NA	NA	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	Preclinical	AM-404	6604822	IJBZOOZRAXHERC-DOFZRALJSA-N
AM-580	AM-580	BRD-K06854232-001-19-9	PREP044	retinoid receptor agonist	RARA	NA	NA	"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O"	Preclinical	AM-580	2126	SZWKGOZKRMMLAJ-UHFFFAOYSA-N
Ambazone	ambazone	BRD-K11244467-001-08-5	PREP046	DNA damage inducer	NA	NA	NA	"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1"	Phase 1	Ambazone	1549158	ANZIOUQAFBXNHU-UHFFFAOYSA-N
Amfenac	amfenac	BRD-K82122102-323-01-1	PREP034	cyclooxygenase inhibitor	"PTGS1, PTGS2"	neurology/psychiatry	pain relief	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	Launched	Amfenac	2136	SOYCMDCMZDHQFP-UHFFFAOYSA-N
AMG-208	AMG-208	BRD-K32285926-001-02-1	PREP038	tyrosine kinase inhibitor	MET	NA	NA	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	Phase 1	AMG-208	24864821	HEAIZQNMNCHNFD-UHFFFAOYSA-N
AMG-232	AMG-232	BRD-K64925568-001-01-8	PREP019	MDM inhibitor	MDM2	NA	NA	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	Phase 1/Phase 2	AMG-232	58573469	DRLCSJFKKILATL-YWCVFVGNSA-N
AMG-458	AMG458	BRD-K21782625-001-02-4	PREP033	MET inhibitor	MET	NA	NA	"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1"	Preclinical	AMG-458	24764449	GLBZSOQDAOLMGC-UHFFFAOYSA-N
AMG-900	AMG900	BRD-K21728777-001-02-3	PREP045	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	Phase 1	AMG-900	24856041	IVUGFMLRJOCGAS-UHFFFAOYSA-N
Aminoglutethimide	aminoglutethimide	BRD-A25234499-001-19-1///BRD-A25234499-001-18-3	PROS003_PR500///PREP017	glucocorticoid receptor antagonist	"CYP11A1, CYP19A1"	"endocrinology, oncology"	"Cushing's syndrome, breast cancer"	"CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1"	Launched	Aminoglutethimide	2145	ROBVIMPUHSLWNV-UHFFFAOYSA-N
Aminopurvalanol A	aminopurvalanol-a	BRD-K07762753-001-04-4	PREP032	"CDK inhibitor, tyrosine kinase inhibitor"	"CDK1, CDK2, CDK5, CDK6"	NA	NA	"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1"	Preclinical	Aminopurvalanol A	6604931	RAMROQQYRRQPDL-HNNXBMFYSA-N
Amisulpride	amisulpride	BRD-A60197193-001-14-6	PREP028	dopamine receptor antagonist	"DRD2, DRD3, HTR2A, HTR7"	neurology/psychiatry	"psychosis, bipolar disorder, schizophrenia"	"CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC"	Launched	Amisulpride	2159	NTJOBXMMWNYJFB-UHFFFAOYSA-N
Ammonium-lactate	ammonium-lactate	BRD-M29182745-001-01-4	PREP048	NA	HCAR1	dermatology	"xerosis cutis, ichthyosis vulgaris"	N.CC(O)C(O)=O	Launched	Ammonium-lactate	155903690	RZOBLYBZQXQGFY-HSHFZTNMSA-N
Amonafide	amonafide	BRD-K56334280-001-05-1	PREP038	topoisomerase inhibitor	"TOP2A, TOP2B"	NA	NA	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	Phase 3	Amonafide	50515	UPALIKSFLSVKIS-UHFFFAOYSA-N
Amoxicillin	amoxicillin	BRD-K55044200-001-15-3	PREP034	penicillin binding protein inhibitor	"CYP2C19, SLC15A1, SLC15A2, SLC22A6"	"infectious disease, gastroenterology"	"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections"	"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O"	Launched	Amoxicillin	33613	LSQZJLSUYDQPKJ-NJBDSQKTSA-N
Amprolio	amprolium	BRD-K90027121-003-01-7	PREP014	thiamine uptake blocker	NA	infectious disease	coccidiosis	"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1"	Launched	Amprolio	73341	LCTXBFGHZLGBNU-UHFFFAOYSA-M
Amsacrine	amsacrine	BRD-K68346641-001-01-4	PREP021	topoisomerase inhibitor	"KCNH2, TOP2A"	hematologic malignancy	"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)"	"COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12"	Launched	Amsacrine	2179	XCPGHVQEEXUHNC-UHFFFAOYSA-N
Anagrelide	anagrelide	BRD-K62200014-003-10-5	PROS001_PR500	phosphodiesterase inhibitor	PDE3A	"hematology, hematologic malignancy"	"thrombocythemia, myeloproliferative neoplasms"	"Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl"	Launched	Anagrelide	135409400	OTBXOEAOVRKTNQ-UHFFFAOYSA-N
Anastrozole	anastrozole	BRD-K52172416-001-11-4	PREP024	aromatase inhibitor	CYP19A1	oncology	breast cancer	"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N"	Launched	Anastrozole	2187	YBBLVLTVTVSKRW-UHFFFAOYSA-N
Anguidin	anguidine	BRD-K45724504-001-01-6	PREP019	protein synthesis inhibitor	SLC5A1	NA	NA	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1	Phase 2	Anguidin	422111	AUGQEEXBDZWUJY-UHFFFAOYSA-N
Anisomycin	anisomycin	BRD-K91370081-001-25-1	PREP040	DNA synthesis inhibitor	"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1"	NA	NA	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	Preclinical	Anisomycin	253602	YKJYKKNCCRKFSL-RDBSUJKOSA-N
Rimiducid	AP1903	BRD-K28383148-001-01-4	PREP044	NA	NA	NA	NA	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	Phase 1/Phase 2	Rimiducid	16135625	GQLCLPLEEOUJQC-ZTQDTCGGSA-N
AP26113	AP26113	BRD-K56032964-001-02-1	PREP026	ALK tyrosine kinase receptor inhibitor	"ALK, EGFR"	NA	NA	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	Phase 2	AP26113	57390074	OVDSPTSBIQCAIN-UHFFFAOYSA-N
Apatinib	apatinib	BRD-K25244359-066-03-4	PREP018	RET tyrosine kinase inhibitor	"CSK, KDR, KIT, RET"	NA	NA	"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1"	Phase 3	Apatinib	11315474	WPEWQEMJFLWMLV-UHFFFAOYSA-N
Aphidicolin	aphidicolin	BRD-K85140930-001-12-7	PREP044	RNA synthesis inhibitor	NA	NA	NA	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	Phase 1	Aphidicolin	2210	NOFOAYPPHIUXJR-UHFFFAOYSA-N
PDK1 inhibitor AR-12	AR-12	BRD-K90497590-001-04-2	PREP046	phosphoinositide dependent kinase inhibitor	PDPK1	NA	NA	"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F"	Phase 1	PDK1 inhibitor AR-12	10027278	YULUCECVQOCQFQ-UHFFFAOYSA-N
AR-42	AR-42	BRD-K13167095-001-02-9	PREP047	HDAC inhibitor	HDAC1	NA	NA	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	Phase 1	AR-42	6918848	NA
Arctigenin	arctigenin	BRD-K53523901-001-04-4	PREP037	MEK inhibitor	"CHUK, MAP2K1"	NA	NA	"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O"	Preclinical	Arctigenin	64981	NQWVSMVXKMHKTF-JKSUJKDBSA-N
Arcyriaflavin a	arcyriaflavin-a	BRD-K72726508-001-02-1	PREP043	CDK inhibitor	"CCND1, CDK4"	NA	NA	"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21"	Preclinical	Arcyriaflavin a	5327723	KAJXOWFGKYKMMZ-UHFFFAOYSA-N
Aripiprazole	aripiprazole	BRD-K70358946-001-15-7	PREP023	"serotonin receptor agonist, serotonin receptor antagonist"	"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7"	neurology/psychiatry	"depression, schizophrenia, bipolar disorder"	"Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl"	Launched	Aripiprazole	60795	CEUORZQYGODEFX-UHFFFAOYSA-N
Varlitinib	ARRY-334543	BRD-K46386702-001-02-1	PROS001_PR500	EGFR inhibitor	ERBB2	NA	NA	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1	Phase 2	Varlitinib	42642648	UWXSAYUXVSFDBQ-CYBMUJFWSA-N
Artemisinin	artemisinin	BRD-K13112821-001-17-4	PREP017	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4"	Launched	Artemisinin	68827	BLUAFEHZUWYNDE-NNWCWBAJSA-N
Artesunate	artesunate	BRD-K54634444-001-05-9	PREP031	DNA synthesis inhibitor	NA	infectious disease	malaria	"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4"	Launched	Artesunate	6917864	FIHJKUPKCHIPAT-AHIGJZGOSA-N
AS-1949490	AS-1949490	BRD-K61936403-001-01-7	PREP041	SHIP2 phosphatase inhibitor	INPP5D	NA	NA	"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1"	Preclinical	AS-1949490	44473434	RFZPGNRLOKVZJY-AWEZNQCLSA-N
Pimasertib	AS-703026	BRD-K89014967-001-04-3	PROS004_PR500	MEK inhibitor	"MAP2K1, MAP2K2"	NA	NA	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	Phase 2	Pimasertib	44187362	VIUAUNHCRHHYNE-JTQLQIEISA-N
Aspirin	aspirin	BRD-K11433652-001-17-0	PREP021	cyclooxygenase inhibitor	"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53"	"neurology/psychiatry, endocrinology, dental"	"headache, fever, toothache, muscle pain"	"CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O"	Launched	Aspirin	2244	BSYNRYMUTXBXSQ-UHFFFAOYSA-N
AST-1306	AST-1306	BRD-K26838195-075-04-9	PREP024	EGFR inhibitor	"EGFR, ERBB2"	NA	NA	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	Phase 1	AST-1306	24739943	MVZGYPSXNDCANY-UHFFFAOYSA-N
Astemizole	astemizole	BRD-K37249724-001-25-7	PREP015	histamine receptor antagonist	"HRH1, KCNH1, KCNH2"	NA	NA	"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1"	Withdrawn	Astemizole	2247	GXDALQBWZGODGZ-UHFFFAOYSA-N
"N,N-Dimethylarginine"	asymmetrical-dimethylarginine	BRD-K36269323-300-02-6	PREP026	nitric oxide synthase inhibitor	"NOS2, NOS3"	NA	NA	CN(C)C(=N)NCCC[C@H](N)C(O)=O	Phase 1	"N,N-Dimethylarginine"	123831	YDGMGEXADBMOMJ-LURJTMIESA-N
AT-7519	AT-7519	BRD-K13390322-001-06-3	PROS004_PR500	CDK inhibitor	"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9"	NA	NA	Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1	Phase 2	AT-7519	11338033	NA
AT-9283	AT-9283	BRD-K24576554-001-04-8	PREP024	"Aurora kinase inhibitor, JAK inhibitor"	"AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A"	NA	NA	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1	Phase 2	AT-9283	135398495	LOLPPWBBNUVNQZ-UHFFFAOYSA-N
Onalespib	AT13387	BRD-K58435339-001-03-0	PROS002_PR500	HSP antagonist	HSP90AA1	NA	NA	"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O"	Phase 2	Onalespib	11955716	NA
AT7867	AT7867	BRD-K12040459-001-06-0	PREP025	AKT inhibitor	"AKT2, GSK3B, PKIA, PRKACA"	NA	NA	"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1"	Preclinical	AT7867	11175137	NA
Esatenolol	atenolol-(-)	BRD-K44993696-001-12-3	PREP042	adrenergic receptor antagonist	NA	NA	NA	"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1"	Phase 2	Esatenolol	175540	METKIMKYRPQLGS-LBPRGKRZSA-N
Atenolol-(+/-)	atenolol-(+/-)	BRD-A20239487-001-24-9	PREP028	adrenergic receptor antagonist	"ADRB1, ADRB2"	cardiology	"hypertension, angina pectoris"	"CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1"	Launched	Atenolol-(+/-)	NA	NA
Atipamezole	atipamezole	BRD-K39252998-003-01-5	PREP034	adrenergic receptor antagonist	NA	neurology/psychiatry	reverse sedative	"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1"	Launched	Atipamezole	71310	HSWPZIDYAHLZDD-UHFFFAOYSA-N
Atiprimod	atiprimod	BRD-K38527262-300-01-0	PROS001_PR500	"JAK inhibitor, STAT inhibitor"	"JAK2, STAT3"	NA	NA	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	Phase 2	Atiprimod	129869	SERHTTSLBVGRBY-UHFFFAOYSA-N
Atorvastatin	atorvastatin	BRD-K69726342-238-02-4	PREP016	HMGCR inhibitor	"AHR, DPP4, HMGCR"	"neurology/psychiatry, cardiology"	"stroke, heart attack"	"CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1"	Launched	Atorvastatin	60823	XUKUURHRXDUEBC-KAYWLYCHSA-N
aurora-a-inhibitor-i	aurora-a-inhibitor-i	BRD-K53561341-001-07-5	PREP047	Aurora kinase inhibitor	AURKA	NA	NA	"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1"	Preclinical	aurora-a-inhibitor-i	44139710	AKSIZPIFQAYJGF-UHFFFAOYSA-N
AV-412	AV-412	BRD-K23190681-001-01-1	PREP045	protein tyrosine kinase inhibitor	"EGFR, ERBB2"	NA	NA	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	Phase 1	AV-412	11700696	GTWJVFFZCKODEV-UHFFFAOYSA-N
Avanafil	avanafil	BRD-K65781196-001-03-0	PREP029	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl"	Launched	Avanafil	9869929	WEAJZXNPAWBCOA-INIZCTEOSA-N
Spebrutinib	AVL-292	BRD-K87782578-001-01-4	PROS001_PR500	Bruton's tyrosine kinase (BTK) inhibitor	"BTK, YES1"	NA	NA	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	Phase 2	Spebrutinib	59174488	KXBDTLQSDKGAEB-UHFFFAOYSA-N
Avn-944	AVN-944	BRD-K62196610-001-01-6	PROS004_PR500	inosine monophosphate dehydrogenase inhibitor	"IMPDH1, IMPDH2"	NA	NA	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	Phase 2	Avn-944	9918559	GYCPCOJTCINIFZ-OXJNMPFZSA-N
Axitinib	axitinib	BRD-K29905972-001-06-3	PROS001_PR500	"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"CSF1, FLT1, FLT4, KDR, PLK4"	oncology	renal cell carcinoma (RCC)	"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1"	Launched	Axitinib	6450551	RITAVMQDGBJQJZ-FMIVXFBMSA-N
AZ-628	AZ-628	BRD-K05804044-001-06-0///BRD-K05804044-001-18-5	PREP036///PROS001_PR500	RAF inhibitor	"BRAF, RAF1"	NA	NA	"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1"	Preclinical	AZ-628	11676786	ZGBGPEDJXCYQPH-UHFFFAOYSA-N
AZ20	AZ20	BRD-K42436189-001-01-2	PREP041	ATR kinase inhibitor	"ATR, MTOR"	NA	NA	"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O"	Preclinical	AZ20	46244454	NA
AZ-3146	AZ3146	BRD-K59146805-001-03-7	PREP015	monopolar spindle 1 kinase inhibitor	NA	NA	NA	"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1"	Preclinical	AZ-3146	56973724	NA
AZ960	AZ960	BRD-K64888243-001-03-7	PREP014	JAK inhibitor	JAK2	NA	NA	"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1"	Preclinical	AZ960	25099184	SUNXHXDJOIXABJ-NSHDSACASA-N
Azacitidine	azacitidine	BRD-K03406345-001-21-1///BRD-K03406345-001-27-8	PROS001_PR500///PREP030	DNA methyltransferase inhibitor	"DNMT1, DNMT3A"	"hematologic malignancy, hematology"	"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)"	"Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1"	Launched	Azacitidine	9444	NMUSYJAQQFHJEW-KVTDHHQDSA-N
Elaiophylin	azalomycin-b	BRD-K96104201-001-01-5	PREP032	bacterial 50S ribosomal subunit inhibitor	NA	NA	NA	CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1	Preclinical	Elaiophylin	155816671	OSERMIPXNLXAPD-BMJPDPRUSA-N
Azathioprine	azathioprine	BRD-K32821942-001-21-3	PREP015	dehydrogenase inhibitor	"HPRT1, IMPDH1, PPAT"	"transplant, rheumatology"	"renal homotransplantation, rheumatoid arthritis"	"Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O"	Launched	Azathioprine	2265	LMEKQMALGUDUQG-UHFFFAOYSA-N
Azd-1480	AZD1480	BRD-K65928735-001-04-3	PREP038	JAK inhibitor	"JAK1, JAK2, JAK3"	NA	NA	"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1"	Phase 1	Azd-1480	16659841	NA
AZD2014	AZD2014	BRD-K99113996-001-02-0	PROS001_PR500	mTOR inhibitor	MTOR	NA	NA	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 2	AZD2014	25262792	NA
AZD-2461	AZD2461	BRD-K85014146-001-02-5	PREP045	PARP inhibitor	NA	NA	NA	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	Phase 1	AZD-2461	44199317	HYNBNUYQTQIHJK-UHFFFAOYSA-N
AZD-2858	AZD2858	BRD-K85849709-001-01-5	PREP047	glycogen synthase kinase inhibitor	GSK3B	NA	NA	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	Preclinical	AZD-2858	NA	NA
AZD-3463	AZD3463	BRD-K24593301-001-02-3	PREP014	"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor"	"ALK, IGF1R"	NA	NA	"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1"	Preclinical	AZD-3463	56599293	GCYIGMXOIWJGBU-UHFFFAOYSA-N
Azd4547	AZD4547	BRD-K28392481-001-05-1	PREP027	FGFR inhibitor	"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR"	NA	NA	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1	Phase 2/Phase 3	Azd4547	51039095	NA
Capivasertib	AZD5363	BRD-K99023089-001-03-7	PREP027	AKT inhibitor	"AKT1, AKT2, AKT3"	NA	NA	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	Phase 2	Capivasertib	25227436	JDUBGYFRJFOXQC-KRWDZBQOSA-N
AZD5438	AZD5438	BRD-K72414522-001-06-7	PREP026	CDK inhibitor	KCNH2	NA	NA	"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1"	Phase 1	AZD5438	16747683	NA
AZD6482	AZD6482	BRD-K58772419-001-07-0	PREP039	PI3K inhibitor	"PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1"	Phase 1	AZD6482	44137675	IRTDIKMSKMREGO-OAHLLOKOSA-N
AZD7762	AZD7762	BRD-K86525559-001-07-8	PREP018	CHK inhibitor	"CHEK1, CHEK2"	NA	NA	"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1"	Phase 1	AZD7762	11152667	IAYGCINLNONXHY-LBPRGKRZSA-N
AZD8055	AZD8055	BRD-K69932463-001-10-6	PREP026	mTOR inhibitor	MTOR	NA	NA	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 1	AZD8055	25262965	KVLFRAWTRWDEDF-IRXDYDNUSA-N
AZD8330	AZD8330	BRD-K37687095-001-06-9	PREP039	MEK inhibitor	NA	NA	NA	"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O"	Phase 1	AZD8330	16666708	RWEVIPRMPFNTLO-UHFFFAOYSA-N
Sapitinib	AZD8931	BRD-K98572433-001-02-9	PROS002_PR500	EGFR inhibitor	"EGFR, ERBB2, ERBB3"	NA	NA	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	Phase 2	Sapitinib	11488320	DFJSJLGUIXFDJP-UHFFFAOYSA-N
Alvelestat	AZD9668	BRD-K31476763-001-01-5	PREP026	elastase inhibitor	ELANE	NA	NA	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	Phase 2	Alvelestat	46861623	QNQZWEGMKJBHEM-UHFFFAOYSA-N
Azilsartan	azilsartan	BRD-K81074237-001-02-3	PREP034	angiotensin receptor antagonist	"AGTR1, AGTR2"	cardiology	hypertension	"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1"	Launched	Azilsartan	135415867	KGSXMPPBFPAXLY-UHFFFAOYSA-N
Azithromycin	azithromycin	BRD-K74501079-001-18-1	PREP028	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	"pelvic inflammatory disease, pneumonia"	"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O"	Launched	Azithromycin	447043	MQTOSJVFKKJCRP-BICOPXKESA-N
Azodicarbonamide	azodicarbonamide	BRD-K87036601-001-01-6	PREP032	DNA synthesis inhibitor	NA	NA	NA	"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O"	Phase 2	Azodicarbonamide	5462814	XOZUGNYVDXMRKW-AATRIKPKSA-N
2-Nitroimidazole	azomycin-(2-nitroimidazole)	BRD-K26824830-001-02-0	PREP014	protein synthesis inhibitor	NA	NA	NA	"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1"	Preclinical	2-Nitroimidazole	10701	YZEUHQHUFTYLPH-UHFFFAOYSA-N
Azactam	aztreonam	BRD-K62607865-001-09-7	PREP031	bacterial cell wall synthesis inhibitor	NA	infectious disease	"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections"	"C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O"	Launched	Azactam	5742832	WZPBZJONDBGPKJ-VEHQQRBSSA-N
Bafetinib	bafetinib	BRD-A75975749-001-01-4	PMTS008	"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor"	"ABL1, BCR, LYN"	NA	NA	CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1	Phase 2	Bafetinib	11387605	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
Baicalein	baicalein	BRD-K72327355-001-14-7	PREP036	lipoxygenase inhibitor	"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH"	NA	NA	"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1"	Preclinical	Baicalein	5281605	FXNFHKRTJBSTCS-UHFFFAOYSA-N
Baicalin	baicalin	BRD-K49962337-001-02-9	PREP028	beta glucuronidase inhibitor	PREP	NA	NA	"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O"	Launched	Baicalin	64982	IKIIZLYTISPENI-ZFORQUDYSA-N
Balapiravir	balapiravir	BRD-K47976015-001-01-2	PREP038	RNA polymerase inhibitor	NA	NA	NA	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	Phase 2	Balapiravir	11691726	VKXWOLCNTHXCLF-DXEZIKHYSA-N
BAM7	BAM7	BRD-K07442505-001-03-6	PREP041	BAX activator	BAX	NA	NA	CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1	Preclinical	BAM7	3101542	WRLVHADVOGFZOZ-UHFFFAOYSA-N
BAN-ORL-24	BAN-ORL-24	BRD-K47049295-300-01-5	PREP036	nociceptin/orphanin FQ receptor antagonist	OPRL1	NA	NA	"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1"	Preclinical	BAN-ORL-24	10296561	MAKMQGKJURAJEN-RUZDIDTESA-N
Barasertib	barasertib	BRD-K31928526-001-02-1	PROS001_PR500	Aurora kinase inhibitor	"AURKA, AURKB"	NA	NA	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O	Phase 2/Phase 3	Barasertib	11497983	NA
Azd-1152hqpa	barasertib-HQPA	BRD-K63923597-001-10-0	PREP026	Aurora kinase inhibitor	AURKB	NA	NA	"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1"	Phase 2/Phase 3	Azd-1152hqpa	16007391	QYZOGCMHVIGURT-UHFFFAOYSA-N
Bardoxolone methyl	bardoxolone	BRD-K20545304-001-01-6	PREP024///PROS002_PR500	"nuclear factor erythroid derived, like (NRF2) activator"	"NOS2, PPARG///PPARG, STAT3"	NA	NA	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O///COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 1///Phase 3	Bardoxolone	400769	WPTTVJLTNAWYAO-KPOXMGGZSA-N
Bardoxolone methyl	bardoxolone-methyl	BRD-K69694239-001-02-2	PREP024///PROS002_PR500	"nuclear factor erythroid derived, like (NRF2) activator"	"NOS2, PPARG///PPARG, STAT3"	NA	NA	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O///COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 1///Phase 3	Bardoxolone methyl	400769	WPTTVJLTNAWYAO-KPOXMGGZSA-N
Baricitinib	baricitinib	BRD-K53581288-001-02-9	PREP033	JAK inhibitor	"JAK1, JAK2"	NA	NA	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 3	Baricitinib	44205240	XUZMWHLSFXCVMG-UHFFFAOYSA-N
Batimastat	batimastat	BRD-K82818427-001-02-2///BRD-K82818427-001-04-8	PREP030///PROS003_PR500	matrix metalloprotease inhibitor	"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8"	NA	NA	"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO"	Phase 3	Batimastat	5362422	XFILPEOLDIKJHX-QYZOEREBSA-N
Bay-11-7082	BAY-11-7082	BRD-K15025317-001-15-1	PREP041	NFkB pathway inhibitor	RELA	NA	NA	"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N"	Preclinical	Bay-11-7082	5353431	DOEWDSDBFRHVAP-KRXBUXKQSA-N
Bay 11-7085	BAY-11-7085	BRD-K48684885-001-04-2	PREP037	NFkB pathway inhibitor	NFKBIA	NA	NA	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical	Bay 11-7085	5353432	NA
BAY-87-2243	BAY-87-2243	BRD-K70463136-001-01-5	PREP019	hypoxia inducible factor inhibitor	HIF1A	NA	NA	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Phase 1	BAY-87-2243	67377767	CDJNNOJINJAXPV-UHFFFAOYSA-N
BAY-K-8644-(s)-(-)	BAY-K-8644-(s)-(-)	BRD-K14329163-001-03-9	PREP014	L-type calcium channel activator	CACNA1C	NA	NA	COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O	Preclinical	BAY-K-8644-(s)-(-)	6603728	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N
Beclomethasone dipropionate	beclomethasone-dipropionate	BRD-K97810537-001-13-6	PREP021	glucocorticoid receptor agonist	"GPR97, NR3C1"	allergy	allergic rhinitis	"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C"	Launched	Beclomethasone dipropionate	21700	KUVIULQEHSCUHY-XYWKZLDCSA-N
Bekanamycin	bekanamycin	BRD-K73425385-065-04-8	PREP031	bacterial 30S ribosomal subunit inhibitor	NA	infectious disease	gram-negative bacterial infections	"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O"	Launched	Bekanamycin	439318	SKKLOUVUUNMCJE-FQSMHNGLSA-N
Belinostat	belinostat	BRD-K17743125-001-08-4	PROS003_PR500	HDAC inhibitor	"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	Launched	Belinostat	6918638	NCNRHFGMJRPRSK-MDZDMXLPSA-N
Bendamustine	bendamustine	BRD-K17068645-003-04-2	PREP030	DNA inhibitor	NA	hematologic malignancy	"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)"	"Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl"	Launched	Bendamustine	65628	NA
Bendroflumethiazide	bendroflumethiazide	BRD-A80017228-001-25-7	PREP029	sodium/potassium/chloride transporter inhibitor	"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3"	cardiology	hypertension	"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F"	Launched	Bendroflumethiazide	2315	HDWIHXWEUNVBIY-UHFFFAOYSA-N
Benzoylthiamine monophosphate	benfotiamine	BRD-K07359318-001-03-9	PREP029	antioxidant	AGER	rheumatology	lumbago	"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1"	Launched	Benzoylthiamine monophosphate	3032771	BTNNPSLJPBRMLZ-LGMDPLHJSA-N
Bentazepam	bentazepam	BRD-K89490285-001-08-1	PMTS008	benzodiazepine receptor agonist	NA	neurology/psychiatry	"anxiety, sedative, muscle relaxant"	O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1	Launched	Bentazepam	135412795	AIZFEOPQVZBNGH-UHFFFAOYSA-N
Benzethonium	benzethonium	BRD-K72723676-003-17-8	PREP022	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1"	Launched	Benzethonium	2335	SIYLLGKDQZGJHK-UHFFFAOYSA-N
Benzocaine	benzocaine	BRD-K75466013-001-14-4	PREP023	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1"	Launched	Benzocaine	2337	BLFLLBZGZJTVJG-UHFFFAOYSA-N
Benzydamine	benzydamine	BRD-K28542495-003-13-5	PREP035	prostanoid receptor antagonist	NA	"dental, otolaryngology"	"mouth inflammation, throat inflammation"	"CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12"	Launched	Benzydamine	12555	CNBGNNVCVSKAQZ-UHFFFAOYSA-N
Cetalkonium	benzyldimethylhexadecylammonium	BRD-K23403298-003-01-9	PREP032	cationic surfactant	NA	NA	NA	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical	Cetalkonium	31203	QDYLMAYUEZBUFO-UHFFFAOYSA-N
Bephenium hydroxynaphthoate	bephenium-hydroxynaphthoate	BRD-K47878171-086-06-0	PREP029	anthelmintic agent	NA	infectious disease	ascariasis	"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1"	Launched	Bephenium hydroxynaphthoate	54678490	PMPQCPQAHTXCDK-UHFFFAOYSA-M
Berberine	berberine	BRD-K14796088-003-26-8	PREP018	LDL receptor activator	LDLR	NA	NA	"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC"	Phase 2/Phase 3	Berberine	2353	YBHILYKTIRIUTE-UHFFFAOYSA-N
beta-Lapachone	beta-lapachone	BRD-K28061410-001-06-6	PMTS008	topoisomerase inhibitor	TOP1	NA	NA	"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O"	Phase 2	beta-Lapachone	3885	QZPQTZZNNJUOLS-UHFFFAOYSA-N
2-Naphthol	beta-naphthol	BRD-K21164796-001-02-8	PREP047	NA	NA	NA	NA	Oc1ccc2ccccc2c1	Preclinical	2-Naphthol	8663	JWAZRIHNYRIHIV-UHFFFAOYSA-N
Betamethasone	betamethasone	BRD-A02180903-001-04-5	PREP021	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO"	Launched	Betamethasone	9782	UREBDLICKHMUKA-DVTGEIKXSA-N
Betamethasone dipropionate	betamethasone-dipropionate	BRD-K58148589-001-03-6	PREP030	anti-inflammatory agent	NA	dermatology	corticosteroid-responsive dermatoses	"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C"	Launched	Betamethasone dipropionate	21800	CIWBQSYVNNPZIQ-XYWKZLDCSA-N
Betulinic acid	betulinic-acid	BRD-K45401373-001-20-9	PREP044	"apoptosis stimulant, NFkB pathway inhibitor"	GPBAR1	NA	NA	"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O"	Phase 1/Phase 2	Betulinic acid	64971	QGJZLNKBHJESQX-FZFNOLFKSA-N
Bexarotene	bexarotene	BRD-K92441787-001-04-1	PROS003_PR500	retinoid receptor agonist	"RXRA, RXRB, RXRG"	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	Launched	Bexarotene	82146	NAVMQTYZDKMPEU-UHFFFAOYSA-N
Pitolisant	BF2.649	BRD-K21673112-003-01-3	PREP038	histamine receptor antagonist	HRH3	NA	NA	"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1"	Phase 3	Pitolisant	9948102	NNACHAUCXXVJSP-UHFFFAOYSA-N
BGT-226 free base	BGT226	BRD-K29415052-050-04-8	PREP046	PI3K inhibitor	"MTOR, PIK3CA, PIK3CB, PIK3CG"	NA	NA	"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1"	Phase 1/Phase 2	BGT-226 free base	11978790	BMMXYEBLEBULND-UHFFFAOYSA-N
BI-2536	BI-2536	BRD-K64890080-001-13-8	PREP033	PLK inhibitor	"BRD4, PLK1, PLK2, PLK3"	NA	NA	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	Phase 2	BI-2536	11364421	XQVVPGYIWAGRNI-JOCHJYFZSA-N
BI-78D3	BI-78D3	BRD-K73982490-001-02-9	PREP046	JNK inhibitor	MAPK8	NA	NA	"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1"	Preclinical	BI-78D3	2747117	QFRLDZGQEZCCJZ-UHFFFAOYSA-N
bid1870	BI-D1870	BRD-A81370665-001-03-6	PREP043	ribosomal protein inhibitor	"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6"	NA	NA	"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12"	Preclinical	bid1870	NA	NA
BIBR-1532	BIBR-1532	BRD-K04623885-001-07-5	PREP037	telomerase inhibitor	TERT	NA	NA	"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1"	Preclinical	BIBR-1532	9927531	PGFQXGLPJUCTOI-WYMLVPIESA-N
BIBU-1361	BIBU-1361	BRD-K49294207-300-03-8	PREP037	EGFR inhibitor	EGFR	NA	NA	"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1"	Preclinical	BIBU-1361	17756796	JUGSLZCFNSTKBN-UHFFFAOYSA-N
Falnidamol	BIBX-1382	BRD-K70914287-300-02-8	PREP019	EGFR inhibitor	"EGFR, ERBB2"	NA	NA	"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1"	Phase 1	Falnidamol	6918508	FTFRZXFNZVCRSK-UHFFFAOYSA-N
Bicalutamide	bicalutamide	BRD-A29485665-001-12-8	PREP016	androgen receptor antagonist	AR	oncology	prostate cancer	"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F"	Launched	Bicalutamide	2375	LKJPYSCBVHEWIU-UHFFFAOYSA-N
Bifemelane	bifemelane	BRD-K18779551-003-07-8	PREP030	acetylcholine release enhancer	"MAOA, MAOB"	"ophthalmology, neurology/psychiatry"	"glaucoma, senile dementia"	"CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1"	Launched	Bifemelane	2377	QSQQPMHPCBLLGX-UHFFFAOYSA-N
B-7100	BIIB021	BRD-K51967704-001-03-6	PROS004_PR500	HSP inhibitor	HSP90AA1	NA	NA	"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C"	Phase 2	B-7100	16736529	QULDDKSCVCJTPV-UHFFFAOYSA-N
Bindarit	bindarit	BRD-K36467523-001-02-8	PREP045	NFkB pathway inhibitor	"CCL2, CCL7, CCL8"	NA	NA	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	Phase 2	Bindarit	71354	MTHORRSSURHQPZ-UHFFFAOYSA-N
Birinapant	birinapant	BRD-K71221037-001-01-6	PREP027	XIAP inhibitor	"BIRC2, XIAP"	NA	NA	"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC"	Phase 2	Birinapant	49836020	NA
Bis(maltolato)oxovanadium(IV)	bis(maltolato)oxovanadium(IV)	BRD-K16180792-001-01-7	PMTS008	tyrosine phosphatase inhibitor	PTPN1	NA	NA	Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	Phase 2	Bis(maltolato)oxovanadium(IV)	3035454	XUOLEICXAPEOSI-UHFFFAOYSA-L
Bisacodyl	bisacodyl	BRD-K39987650-001-24-1	PREP029	laxative	NA	gastroenterology	constipation	"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1"	Launched	Bisacodyl	2391	KHOITXIGCFIULA-UHFFFAOYSA-N
Bisindolylmaleimide IX	bisindolylmaleimide-ix	BRD-K06543683-066-02-1	PREP037	PKC inhibitor	"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1"	NA	NA	"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12"	Preclinical	Bisindolylmaleimide IX	5083	DSXXEELGXBCYNQ-UHFFFAOYSA-N
Bitopertin	bitopertin	BRD-K13756951-001-01-4	PREP027	"glycine transporter inhibitor, GlyT-1 inhibitor"	"SLC6A5, SLC6A9"	NA	NA	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	Phase 3	Bitopertin	24946690	YUUGYIUSCYNSQR-LBPRGKRZSA-N
BIX-01294	BIX-01294	BRD-K26818574-305-04-3	PREP043	histone lysine methyltransferase inhibitor	"EHMT1, EHMT2"	NA	NA	"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1"	Preclinical	BIX-01294	25150857	OSXFATOLZGZLSK-UHFFFAOYSA-N
BIX-02188	BIX-02188	BRD-K20290250-001-02-1	PREP048	MEK inhibitor	MAP2K5	NA	NA	"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1"	Preclinical	BIX-02188	135398492	WGPXKFOFEXJMBD-UHFFFAOYSA-N
Blebbistatin	blebbistatin-(-)	BRD-K61295575-001-03-6	PREP040	ATPase inhibitor	NA	NA	NA	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1	Preclinical	Blebbistatin	3476986	LZAXPYOBKSJSEX-UHFFFAOYSA-N
Bms-265246	BMS-265246	BRD-K62814476-001-03-3	PREP032	CDK inhibitor	"CDK1, CDK2"	NA	NA	"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F"	Preclinical	Bms-265246	135402864	SCFMWQIQBVZOQR-UHFFFAOYSA-N
BMS-345541 free base	BMS-345541	BRD-K13566078-001-02-3	PREP041	IKK inhibitor	"CHUK, IKBKB"	NA	NA	"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12"	Preclinical	BMS-345541 free base	9926054	NA
SNS-032	BMS-387032	BRD-K43389698-001-09-9	PREP019	"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor"	"CDK2, CDK7, CDK9"	NA	NA	"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1"	Phase 1	SNS-032	3025986	NA
BMS-599626	BMS-599626	BRD-K07106112-003-03-8	PREP026	"EGFR inhibitor, protein tyrosine kinase inhibitor"	"EGFR, ERBB2, ERBB4"	NA	NA	"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12"	Phase 1	BMS-599626	10437018	LUJZZYWHBDHDQX-QFIPXVFZSA-N
Temsavir	BMS-626529	BRD-K97883416-001-01-4	PREP018	HIV attachment inhibitor	NA	NA	NA	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3	Temsavir	11317439	QRPZBKAMSFHVRW-UHFFFAOYSA-N
BMS-690514	BMS-690514	BRD-K76239644-001-01-8///BRD-K76239644-001-02-6	PREP018///PROS001_PR500	"EGFR inhibitor, VEGFR inhibitor"	"EGFR, ERBB2, FLT3, KDR"	NA	NA	"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1"	Phase 2	BMS-690514	11349170	CSGQVNMSRKWUSH-IAGOWNOFSA-N
Bms-707035	BMS-707035	BRD-K49555808-001-03-9	PREP024	HIV integrase inhibitor	NA	NA	NA	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	Phase 2	Bms-707035	54682040	VNIWZCGZPBJWBI-UHFFFAOYSA-N
Bms-754807	BMS-754807	BRD-K13049116-001-05-7///BRD-K13049116-001-04-0	PREP027///PROS002_PR500	IGF-1 inhibitor	"AKT1, IGF1R"	NA	NA	"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1"	Phase 2	Bms-754807	24785538	LQVXSNNAFNGRAH-QHCPKHFHSA-N
Bms-986020	BMS-986020	BRD-K23952234-236-01-8	PREP038	lysophosphatidic acid receptor antagonist	LPAR1	NA	NA	"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1"	Phase 2	Bms-986020	49792850	GQBRZBHEPUQRPL-LJQANCHMSA-N
BNC105	BNC105	BRD-K20468903-001-01-6	PMTS008	tubulin polymerization inhibitor	NA	NA	NA	"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O"	Phase 2	BNC105	24786555	RADMJHVVIZTENA-UHFFFAOYSA-N
7-Benzylidenenaltrexone	BNTX	BRD-A55484088-050-02-5	PREP041	opioid receptor antagonist	"OPRD1, OPRK1, OPRM1"	NA	NA	"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1"	Preclinical	7-Benzylidenenaltrexone	5310988	WXOUFNFMPVMGFZ-BDQAUFNLSA-N
Bortezomib	bortezomib	BRD-K88510285-001-17-8///BRD-K88510285-001-11-1	PROS005_PR500///PREP015	"NFkB pathway inhibitor, proteasome inhibitor"	"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA"	hematologic malignancy	"multiple myeloma, mantle cell lymphoma (MCL)"	"CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O"	Launched	Bortezomib	387447	GXJABQQUPOEUTA-RDJZCZTQSA-N
Bosentan	bosentan	BRD-K74763371-002-04-0	PREP029	endothelin receptor antagonist	"EDNRA, EDNRB"	pulmonary	pulmonary arterial hypertension (PAH)	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	Launched	Bosentan	104865	GJPICJJJRGTNOD-UHFFFAOYSA-N
Bosutinib	bosutinib	BRD-K99964838-001-11-9	PREP017	"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor"	"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK"	hematologic malignancy	chronic myeloid leukemia (CML)	"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl"	Launched	Bosutinib	5328940	UBPYILGKFZZVDX-UHFFFAOYSA-N
Brefeldin A	brefeldin-a	BRD-K77841042-001-14-1	PREP047	protein synthesis inhibitor	"ARF1, CYTH2"	NA	NA	"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1"	Preclinical	Brefeldin A	5287620	KQNZDYYTLMIZCT-KQPMLPITSA-N
Brequinar	brequinar	BRD-K96123349-236-02-8	PROS002_PR500	dihydroorotate dehydrogenase inhibitor	DHODH	NA	NA	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	Phase 2	Brequinar	23223059	PZOHOALJQOFNTB-UHFFFAOYSA-N
Brigatinib	brigatinib	BRD-K56981171-001-01-0///BRD-K56981171-001-02-8	PMTS008///PROS001_PR500	"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor"	"ALK, EGFR"	oncology	non-small cell lung cancer (NSCLC)	"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1"	Launched	Brigatinib	68165256	AILRADAXUVEEIR-UHFFFAOYSA-N
Brilliant green	brilliant-green	BRD-K60348325-065-09-9	PREP028	NA	NA	NA	NA	CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC	Launched	Brilliant green	12449	NNBFNNNWANBMTI-UHFFFAOYSA-M
Brivaracetam	brivaracetam	BRD-K00634421-001-01-0	PMTS008	voltage-gated sodium channel blocker	SV2A	neurology/psychiatry	seizures	"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1"	Launched	Brivaracetam	9837243	MSYKRHVOOPPJKU-BDAKNGLRSA-N
Bromosporine	bromosporine	BRD-K44665581-001-01-8	PREP015	bromodomain inhibitor	NA	NA	NA	"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1"	Preclinical	Bromosporine	72943187	UYBRROMMFMPJAN-UHFFFAOYSA-N
Broxaldine	broxaldine	BRD-K36222532-001-01-8	PREP033	NA	NA	NA	NA	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	Preclinical	Broxaldine	77262	IJTPLVAAROHGGB-UHFFFAOYSA-N
Broxyquinoline	broxyquinoline	BRD-K23301018-001-11-7	PREP019	antiprotozoal agent	NA	NA	NA	"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12"	Phase 1	Broxyquinoline	2453	ZDASUJMDVPTNTF-UHFFFAOYSA-N
Bruceantin	bruceantin	BRD-A36057565-001-01-0	PREP033	protein synthesis inhibitor	NA	NA	NA	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O	Phase 2	Bruceantin	5281304	IRQXZTBHNKVIRL-GOTQHHPNSA-N
Didesmethylsibutramine hydrochloride	BTS-54505	BRD-A68304895-003-02-2	PREP023	dopamine reuptake inhibitor	"SLC6A2, SLC6A3, SLC6A4"	NA	NA	"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1"	Withdrawn	Didesmethylsibutramine hydrochloride	134771	KHRVYINTXCWNRF-UHFFFAOYSA-N
Dibutyryl cAMP	bucladesine	BRD-A94624445-236-17-0	PREP025	"adenosine receptor agonist, cAMP stimulant"	PRKACA	dermatology	skin ulcer	"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC"	Launched	Dibutyryl cAMP	9687	CJGYSWNGNKCJSB-YVLZZHOMSA-N
Bumetanide	bumetanide	BRD-K38197229-001-29-9	PREP022	solute carrier family member inhibitor	"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5"	cardiology	"edema, congestive heart failure"	"CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O"	Launched	Bumetanide	2471	MAEIEVLCKWDQJH-UHFFFAOYSA-N
Buparlisib	buparlisib	BRD-K42191735-001-05-3	PREP046	PI3K inhibitor	"PIK3CA, PIK3CG"	NA	NA	"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F"	Phase 3	Buparlisib	16654980	CWHUFRVAEUJCEF-UHFFFAOYSA-N
Nylidrin	buphenine	BRD-A36267905-003-18-4	PREP021	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1"	Launched	Nylidrin	4567	PTGXAUBQBSGPKF-UHFFFAOYSA-N
Busulfan	busulfan	BRD-K23204545-001-16-4	PREP020	DNA inhibitor	NA	hematologic malignancy	chronic myeloid leukemia (CML)	"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O"	Launched	Busulfan	2478	COVZYZSDYWQREU-UHFFFAOYSA-N
Butyl 4-aminobenzoate	butamben	BRD-K27217864-001-22-3	PREP028	sodium channel blocker	NA	NA	NA	CCCCOC(=O)c1ccc(N)cc1	Withdrawn	Butyl 4-aminobenzoate	2482	IUWVALYLNVXWKX-UHFFFAOYSA-N
l-Buthionine sulfoximine	buthionine-sulfoximine	BRD-A47706533-001-02-6	PREP019	glutathione transferase inhibitor	GCLM	NA	NA	CCCCS(=N)(=O)CC[C@H](N)C(O)=O	Phase 1	l-Buthionine sulfoximine	119565	KJQFBVYMGADDTQ-CVSPRKDYSA-N
Butylscopolamine	butylscopolamine-bromide	BRD-A53951045-004-01-6	PREP028	cholinergic receptor antagonist	NA	gastroenterology	abdominal pain	CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1	Launched	Butylscopolamine	160883	YBCNXCRZPWQOBR-MWGADRMYSA-N
Ulixertinib	BVD-523	BRD-K28965160-001-01-1	PREP027	MAP kinase inhibitor	NA	NA	NA	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	Phase 1/Phase 2	Ulixertinib	11719003	KSERXGMCDHOLSS-LJQANCHMSA-N
BVT-948	BVT-948	BRD-K68567222-001-01-2	PREP043	tyrosine phosphatase inhibitor	"PTPN1, PTPN11, PTPN2"	NA	NA	"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O"	Preclinical	BVT-948	6604934	LLPBUXODFQZPFH-UHFFFAOYSA-N
Dadle	BW-180C	BRD-K57927309-001-01-7	PREP018	opioid receptor agonist	"OPRD1, OPRM1"	NA	NA	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	Phase 2	Dadle	6917707	ZHUJMSMQIPIPTF-IBURTVSXSA-N
BX-912	BX-912	BRD-K49669041-001-08-4	PREP043	pyruvate dehydrogenase kinase inhibitor	"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1"	NA	NA	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1	Preclinical	BX-912	11754511	NA
Cabazitaxel	cabazitaxel	BRD-K06858286-001-01-3	PREP017	microtubule inhibitor	"TUBA4A, TUBB, TUBB1"	oncology	prostate cancer	CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C	Launched	Cabazitaxel	9854073	BMQGVNUXMIRLCK-OAGWZNDDSA-N
Cabozantinib	cabozantinib	BRD-K51544265-001-04-2	PREP016	"RET tyrosine kinase inhibitor, VEGFR inhibitor"	"KDR, MET"	oncology	medullary thyroid cancer (MTC)	"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC"	Launched	Cabozantinib	25102847	NA
Caffeic acid	caffeic-acid	BRD-K09900591-001-26-7	PREP015	"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor"	"ALOX5, MIF"	NA	NA	"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1"	Preclinical	Caffeic acid	689043	QAIPRVGONGVQAS-DUXPYHPUSA-N
Caffeic acid phenethyl ester	caffeic-acid-phenethyl-ester	BRD-K96188950-001-16-9	PREP047	HIV integrase inhibitor	RELA	NA	NA	"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O"	Preclinical	Caffeic acid phenethyl ester	5281787	SWUARLUWKZWEBQ-VQHVLOKHSA-N
Calcitriol	calcitriol	BRD-K27316855-001-13-3	PREP029	vitamin D receptor agonist	VDR	"endocrinology, orthopedics"	"hypocalcemia, hypoparathyroidism, osteoporosis"	"C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C"	Launched	Calcitriol	5280453	GMRQFYUYWCNGIN-NKMMMXOESA-N
Camptothecin	camptothecin	BRD-K37890730-001-15-1	PREP038	topoisomerase inhibitor	TOP1	NA	NA	"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O"	Phase 3	Camptothecin	24360	VSJKWCGYPAHWDS-FQEVSTJZSA-N
Camylofine-chlorhydrate	camylofine-chlorhydrate	BRD-A91733352-300-04-5	PREP016	NA	NA	gastroenterology	abdominal pain	"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1"	Launched	Camylofine-chlorhydrate	51590030	RYOOHIUJEJZCFT-GOSISDBHSA-N
Candesartan	candesartan	BRD-K84091759-001-07-1	PREP020	angiotensin receptor antagonist	AGTR1	cardiology	"hypertension, congestive heart failure"	"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1"	Launched	Candesartan	2541	HTQMVQVXFRQIKW-UHFFFAOYSA-N
Canertinib	canertinib	BRD-K50168500-001-07-9	PROS001_PR500	EGFR inhibitor	"AKT1, EGFR, ERBB2, ERBB4"	NA	NA	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	Phase 3	Canertinib	156414	NA
Canrenone	canrenone	BRD-A20644369-001-08-6	PREP034	mineralocorticoid receptor antagonist	NR3C2	NA	NA	C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1	Withdrawn	Canrenone	13789	UJVLDDZCTMKXJK-WNHSNXHDSA-N
Capecitabine	capecitabine	BRD-K61192372-001-08-9	PROS003_PR500	"DNA synthesis inhibitor, thymidylate synthase inhibitor"	TYMS	oncology	"breast cancer, colorectal cancer"	"CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O"	Launched	Capecitabine	60953	GAGWJHPBXLXJQN-UORFTKCHSA-N
Capsaicin	capsaicin	BRD-K50590187-001-19-9	PREP023	TRPV agonist	"CFTR, TRPV1"	"neurology/psychiatry, rheumatology"	"muscle pain, rheumatoid arthritis"	"COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O"	Launched	Capsaicin	1548943	YKPUWZUDDOIDPM-SOFGYWHQSA-N
Captamine	captamine	BRD-K81645907-001-01-1	PREP048	NA	NA	NA	NA	CN(C)CCS	Preclinical	Captamine	25799	DENMGZODXQRYAR-UHFFFAOYSA-N
Carbachol	carbachol	BRD-K75037734-003-13-9	PREP023	cholinergic receptor agonist	"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2"	ophthalmology	intraocular pressure	"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O"	Launched	Carbachol	2551	VPJXQGSRWJZDOB-UHFFFAOYSA-O
Carboplatin	carboplatin	BRD-K90947825-001-02-7	PREP048	"DNA alkylating agent, DNA inhibitor"	NA	oncology	ovarian cancer	"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1"	Launched	Carboplatin	426756	VSRXQHXAPYXROS-UHFFFAOYSA-N
Carboxyamidotriazole	carboxyamidotriazole	BRD-K68408772-001-05-4	PMTS008	calcium channel blocker	CXCL8	NA	NA	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	Phase 3	Carboxyamidotriazole	108144	WNRZHQBJSXRYJK-UHFFFAOYSA-N
"6,6'-Dithiodinicotinic acid"	carboxypyridine-disulfide	BRD-K26530649-001-01-6	PMTS008	NA	NA	NA	NA	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	Phase 2	"6,6'-Dithiodinicotinic acid"	85040	GSASOFRDSIKDSN-UHFFFAOYSA-N
Carfilzomib	carfilzomib	BRD-K15179879-001-03-2	PROS003_PR500	proteasome inhibitor	"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9"	hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	Launched	Carfilzomib	11556711	BLMPQMFVWMYDKT-NZTKNTHTSA-N
Cariporide	cariporide	BRD-K21670884-001-01-9	PREP045	sodium/hydrogen exchanger inhibitor	SLC9A1	NA	NA	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	Phase 3	Cariporide	151172	IWXNYAIICFKCTM-UHFFFAOYSA-N
Carmofur	carmofur	BRD-K11630072-001-13-2	PROS004_PR500	thymidylate synthase inhibitor	TYMS	oncology	"breast cancer, colorectal cancer"	"CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O"	Launched	Carmofur	2577	AOCCBINRVIKJHY-UHFFFAOYSA-N
"1,3-Bis(2-chloroethyl)-1-nitrosourea"	carmustine	BRD-K36234266-001-09-8	PREP048	"DNA alkylating agent, DNA inhibitor"	GSR	"hematologic malignancy, oncology"	"non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma"	[O-][N+]N(CCCl)C(=O)NCCCl	Launched	"1,3-Bis(2-chloroethyl)-1-nitrosourea"	2578	DLGOEMSEDOSKAD-UHFFFAOYSA-N
Carvedilol	carvedilol	BRD-A10977446-001-12-1	PREP028	adrenergic receptor antagonist	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA"	cardiology	"myocardial infarction, hypertension"	"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12"	Launched	Carvedilol	2585	OGHNVEJMJSYVRP-UHFFFAOYSA-N
"1-(4-Carboxyphenyl)-3,3-dimethyltriazene"	CB-10-277	BRD-K59929863-001-01-9	PREP038	DNA synthesis inhibitor	NA	NA	NA	CN(C)\N=N\c1ccc(cc1)C(O)=O	Phase 1	"1-(4-Carboxyphenyl)-3,3-dimethyltriazene"	23606	GUAZPUYTLMUTMA-UHFFFAOYSA-N
CCG-50014	CCG-50014	BRD-K08893438-001-04-9	PREP041	G protein signaling inhibitor	"RGS4, RGS8"	NA	NA	"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O"	Preclinical	CCG-50014	2733079	QUIIIYITNGOFEI-UHFFFAOYSA-N
CID 67042344	CCMI	BRD-K16338837-001-02-6	PREP043	acetylcholine receptor allosteric modulator	CHRNA7	NA	NA	"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1"	Preclinical	CID 67042344	67042344	VMAKIACTLSBBIY-UHFFFAOYSA-N
CCT-128930	CCT128930	BRD-K76406695-001-02-9	PREP043	AKT inhibitor	"PKIA, PRKACA"	NA	NA	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	Preclinical	CCT-128930	17751819	RZIDZIGAXXNODG-UHFFFAOYSA-N
CCT129202	CCT129202	BRD-K57136142-001-02-4	PREP036	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1"	Preclinical	CCT129202	16202152	QYKHWEFPFAGNEV-UHFFFAOYSA-N
CCT137690	CCT137690	BRD-K03289018-001-02-7	PREP040	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1"	Preclinical	CCT137690	25154041	GFLQCBTXTRCREJ-UHFFFAOYSA-N
CD-437	CD-437	BRD-K28907958-001-04-3	PREP040	retinoid receptor agonist	RARG	NA	NA	"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2"	Preclinical	CD-437	2758573	SNIGEINPLSDHBQ-UHFFFAOYSA-N
Cebranopadol	cebranopadol	BRD-K48141473-001-01-7	PREP047	opioid receptor agonist	"OPRL1, OPRM1"	NA	NA	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1	Phase 3	Cebranopadol	11848225	CSMVOZKEWSOFER-UHFFFAOYSA-N
Cediranib	cediranib	BRD-K86930074-001-05-0	PREP039	"KIT inhibitor, VEGFR inhibitor"	"CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB"	NA	NA	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	Phase 3	Cediranib	9933475	NA
Cefdinir	cefdinir	BRD-K15766189-001-09-8	PREP031	bacterial cell wall synthesis inhibitor	MPO	"infectious disease, otolaryngology, pulmonary"	"pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis"	"Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O"	Launched	Cefdinir	6915944	RTXOFQZKPXMALH-GHXIOONMSA-N
Cefditorin pivoxil	cefditoren-pivoxil	BRD-K72167406-001-02-1	PREP030	bacterial cell wall synthesis inhibitor	NA	"infectious disease, pulmonary, otolaryngology"	"pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis"	"CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1"	Launched	Cefditorin pivoxil	6917926	AFZFFLVORLEPPO-ITQWOMERSA-N
Cefpiramide	cefpiramide	BRD-K92872987-001-02-9	PREP021	bacterial cell wall synthesis inhibitor	NA	infectious disease	gram-negative bacterial infections	"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1"	Launched	Cefpiramide	636405	PWAUCHMQEXVFJR-PMAPCBKXSA-N
Agerafenib	CEP-32496	BRD-K20722021-001-02-1	PREP046	RAF inhibitor	"BRAF, RAF1"	NA	NA	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	Phase 1/Phase 2	Agerafenib	56846693	DKNUPRMJNUQNHR-UHFFFAOYSA-N
CEP-33779	CEP-33779	BRD-K37237504-001-02-7	PREP046	JAK inhibitor	JAK2	NA	NA	"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1"	Preclinical	CEP-33779	57336812	RFZKSQIFOZZIAQ-UHFFFAOYSA-N
Cep-37440	CEP-37440	BRD-K72827473-001-01-0	PREP019	ALK tyrosine kinase receptor inhibitor	ALK	NA	NA	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	Phase 1	Cep-37440	71721648	BCSHRERPHLTPEE-NRFANRHFSA-N
Cephalomannine	cephalomannine	BRD-K68904758-001-03-5	PREP033	DNA polymerase inhibitor	NA	NA	NA	"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1"	Preclinical	Cephalomannine	6436208	DBXFAPJCZABTDR-WBYYIXQISA-N
Cetrimonium	cetrimonium	BRD-K47079459-004-04-6	PREP031	NA	NA	dermatology	cosmetic	"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C"	Launched	Cetrimonium	2681	RLGQACBPNDBWTB-UHFFFAOYSA-N
Cetylpyridinium	cetylpyridinium	BRD-K87700323-003-05-1	PREP045	NA	NA	dental	"gingivitis, mouth inflammation"	"CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1"	Launched	Cetylpyridinium	2683	NEUSVAOJNUQRTM-UHFFFAOYSA-N
Nvp-cgm097	CGM097	BRD-K79584249-001-01-3	PREP038	MDM inhibitor	MDM2	NA	NA	"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1"	Phase 1	Nvp-cgm097	53240420	CLRSLRWKONPSRQ-CPOWQTMSSA-N
CGP-37849	CGP-37849	BRD-A90272038-001-01-7	PREP035	glutamate receptor antagonist	"GRIN2A, GRIN2B, GRIN2C, GRIN2D"	NA	NA	"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O"	Phase 1	CGP-37849	5950212	BDYHNCZIGYIOGJ-DUXPYHPUSA-N
"4,5-dianilinophthalimide"	CGP-52411	BRD-K13087974-001-02-5	PREP041	EGFR inhibitor	EGFR	NA	NA	"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12"	Preclinical	"4,5-dianilinophthalimide"	1697	AAALVYBICLMAMA-UHFFFAOYSA-N
CGP-54626	CGP-54626	BRD-A74208568-003-01-5	PREP025	GABA receptor antagonist	"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8"	NA	NA	"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1"	Preclinical	CGP-54626	197584	JGGVBBYJRQOPPA-BBRMVZONSA-N
CGS-15943	CGS-15943	BRD-K49049886-001-08-7	PREP036	adenosine receptor antagonist	"ADORA1, ADORA2A, ADORA2B, ADORA3"	NA	NA	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	Preclinical	CGS-15943	2690	MSJODEOZODDVGW-UHFFFAOYSA-N
Unii-K9Q4R9S81O	CGS-20625	BRD-K68103045-001-02-9	PREP027	"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist"	"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6"	NA	NA	"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O"	Phase 1	Unii-K9Q4R9S81O	163844	UBLXQFIFWUEVGJ-UHFFFAOYSA-N
CH5132799	CH5132799	BRD-K28352084-001-02-3	PREP044	PI3K inhibitor	"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1"	Phase 1	CH5132799	49784945	JEGHXKRHKHPBJD-UHFFFAOYSA-N
Chicago Sky Blue 6B	chicago-sky-blue-6b	BRD-K56483981-342-06-4	PREP047	"glutamate inhibitor, macrophage migration inhibiting factor inhibitor"	MIF	NA	NA	COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1	Preclinical	Chicago Sky Blue 6B	6364572	UPKAWFACSJWKND-ZXLMSEFPSA-J
Chidamide	chidamide	BRD-K28537285-001-01-8	PMTS008	HDAC inhibitor	"HDAC10, HDAC3"	NA	NA	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Launched	Chidamide	9800555	WXHHICFWKXDFOW-BJMVGYQFSA-N
CHIR-124	CHIR-124	BRD-K02241333-001-02-7	PREP042	CHK inhibitor	CHEK1	NA	NA	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	Preclinical	CHIR-124	135399748	MOVBBVMDHIRCTG-LJQANCHMSA-N
CHIR-98014	CHIR-98014	BRD-K42973005-001-04-0	PREP036	glycogen synthase kinase inhibitor	"GSK3A, GSK3B"	NA	NA	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	Preclinical	CHIR-98014	53396311	MDZCSIDIPDZWKL-UHFFFAOYSA-N
Chir-99021	CHIR-99021	BRD-K16189898-003-03-3	PREP041	glycogen synthase kinase inhibitor	"CDK1, GSK3A, GSK3B, MAPK1"	NA	NA	"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl"	Preclinical	Chir-99021	9956119	AQGNHMOJWBZFQQ-UHFFFAOYSA-N
Chlorambucil	chlorambucil	BRD-K29458283-001-29-9	PREP016	DNA inhibitor	NA	hematologic malignancy	"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma"	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	Launched	Chlorambucil	2708	JCKYGMPEJWAADB-UHFFFAOYSA-N
Chloramphenicol palmitate	chloramphenicol-palmitate	BRD-K96424892-001-02-9	PREP023	protein synthesis inhibitor	NA	"infectious disease, endocrinology"	"meningitis, fever, cholera"	CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	Chloramphenicol palmitate	443382	PXKHGMGELZGJQE-ILBGXUMGSA-N
Chlorhexidine	chlorhexidine	BRD-K52256627-300-06-6	PREP020	membrane integrity inhibitor	NA	"dermatology, infectious disease, dental"	"cosmetic, skin infections, gingivitis"	Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1	Launched	Chlorhexidine	9552079	GHXZTYHSJHQHIJ-UHFFFAOYSA-N
Chlorindanol	chlorindanol	BRD-K01653460-001-01-1	PREP032	NA	NA	NA	NA	Oc1ccc(Cl)c2CCCc12	Preclinical	Chlorindanol	8961	ATAJVFBUUIBIEO-UHFFFAOYSA-N
Chlormidazole	chlormidazole	BRD-K60443845-001-08-6	PREP048	fungal lanosterol demethylase inhibitor	NA	infectious disease	fungal infection	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	Launched	Chlormidazole	71821	WNAQOLSMVPFGTE-UHFFFAOYSA-N
Chlorogenic acid	chlorogenic-acid	BRD-K47114202-001-14-6	PREP031	antioxidant	SLC37A4	"neurology/psychiatry, pulmonary, allergy"	"headache, chest congestion, allergic rhinitis"	"O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O"	Launched	Chlorogenic acid	1794427	CWVRJTMFETXNAD-JUHZACGLSA-N
Chloropyramine	chloropyramine	BRD-K83257731-003-23-5	PREP022	histamine receptor antagonist	HRH1	"cardiology, ophthalmology, allergy, pulmonary"	"edema, conjunctivitis, allergic rhinitis, asthma"	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	Launched	Chloropyramine	25295	ICKFFNBDFNZJSX-UHFFFAOYSA-N
Chloroxine	chloroxine	BRD-K17075857-001-18-4	PREP031	opioid receptor antagonist	OPRK1	"gastroenterology, infectious disease, dermatology"	"diarrhea, inflammatory bowel disease, giardiasis, dandruff"	"Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12"	Launched	Chloroxine	2722	WDFKMLRRRCGAKS-UHFFFAOYSA-N
Chlorpropamide	chlorpropamide	BRD-K97746869-001-27-0	PREP028	ATP channel blocker	"ABCC8, KCNJ10, KCNJ11"	endocrinology	diabetes mellitus	"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1"	Launched	Chlorpropamide	2727	RKWGIWYCVPQPMF-UHFFFAOYSA-N
Chlorpyrifos	chlorpyrifos	BRD-K08303368-001-10-0	PREP028	acetylcholinesterase inhibitor	ACHE	NA	NA	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	Launched	Chlorpyrifos	2730	SBPBAQFWLVIOKP-UHFFFAOYSA-N
Chlorquinaldol	chlorquinaldol	BRD-K90374350-001-09-2	PREP016	other antibiotic	NA	infectious disease	fungal infection	"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1"	Launched	Chlorquinaldol	6301	GPTXWRGISTZRIO-UHFFFAOYSA-N
Cholecalciferol	cholecalciferol	BRD-K62779383-001-05-5	PREP035	NA	VDR	endocrinology	vitamin D deficiency	"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C"	Launched	Cholecalciferol	5280795	QYSXJUFSXHHAJI-YRZJJWOYSA-N
Chromocarb	chromocarb	BRD-K94720315-001-10-4	PREP029	antispasmodic	NA	NA	NA	"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1"	Launched	Chromocarb	2741	RVMGXWBCQGAWBR-UHFFFAOYSA-N
3-Phenoxypyridine monosulfate	CI-844	BRD-K83022601-001-01-0	PREP033	NA	NA	NA	NA	O(c1ccccc1)c1cccnc1	Phase 2	3-Phenoxypyridine monosulfate	6917736	SYULDLBUMBEIIY-UHFFFAOYSA-N
Cibenzoline	cibenzoline	BRD-K34251960-036-01-6	PMTS008	sodium channel blocker	NA	NA	NA	C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1	Launched	Cibenzoline	2747	IPOBOOXFSRWSHL-UHFFFAOYSA-N
Ciclesonide	ciclesonide	BRD-K35245662-001-01-2	PREP020	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	allergy	allergic rhinitis	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1	Launched	Ciclesonide	6918155	LUKZNWIVRBCLON-GXOBDPJESA-N
Ciclopirox	ciclopirox	BRD-K13044802-213-20-7	PREP035	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1"	Launched	Ciclopirox	2749	SCKYRAXSEDYPSA-UHFFFAOYSA-N
(2E)-2-Benzylidene-3-(cyclohexylamino)inden-1-ol	CID-5458317	BRD-A08840375-001-01-3	PREP043	MAP kinase phosphatase inhibitor	MAPK3	NA	NA	O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1	Preclinical	(2E)-2-Benzylidene-3-(cyclohexylamino)inden-1-ol	155903705	BJJVCNWHNQAAGB-HMMYKYKNSA-N
Cidofovir	cidofovir	BRD-K96153583-001-05-1	PREP034	DNA polymerase inhibitor	NA	infectious disease	"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis"	"Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1"	Launched	Cidofovir	60613	VWFCHDSQECPREK-LURJTMIESA-N
Cilostamide	cilostamide	BRD-K28578425-001-07-0	PREP041	phosphodiesterase inhibitor	"PDE3A, PDE3B"	NA	NA	"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1"	Preclinical	Cilostamide	2753	UIAYVIIHMORPSJ-UHFFFAOYSA-N
Cimetidine	cimetidine	BRD-K34157611-001-16-0	PREP016	histamine receptor antagonist	"HRH2, SLC29A4, SLC47A1, SLC47A2"	"gastroenterology, hematologic malignancy, endocrinology"	"duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma"	"CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N"	Launched	Cimetidine	2756	AQIXAKUUQRKLND-UHFFFAOYSA-N
Cinacalcet	cinacalcet	BRD-K73838513-003-05-5	PROS003_PR500	calcium channel activator	CASR	"endocrinology, nephrology, oncology"	"hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia"	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	Launched	Cinacalcet	156419	VDHAWDNDOKGFTD-MRXNPFEDSA-N
Cinalukast	cinalukast	BRD-K53720352-001-03-2	PREP045	leukotriene receptor antagonist	CYSLTR1	NA	NA	"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O"	Phase 2	Cinalukast	6436135	BZMKNPGKXJAIDV-VAWYXSNFSA-N
Cinnarazine	cinnarazine	BRD-K07220430-001-18-4	PREP014	calcium channel blocker	NA	"neurology/psychiatry, gastroenterology, ophthalmology"	"Meniere's disease, nausea, vomiting, Cogan's syndrome"	"C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1"	Launched	Cinnarazine	5353532	SSKFWBSXNIWCBH-VCHYOVAHSA-N
Cinromide	cinromide	BRD-K66241279-001-01-8	PREP019	NA	NA	NA	NA	CCNC(=O)\C=C\c1cccc(Br)c1	Phase 3	Cinromide	688145	LDCXGZCEMNMWIL-VOTSOKGWSA-N
Ciprofibrate	ciprofibrate	BRD-A49358627-001-14-6	PREP021	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O"	Launched	Ciprofibrate	2763	KPSRODZRAIWAKH-UHFFFAOYSA-N
Cisplatin	cisplatin	BRD-K69172251-001-08-9	PREP048	"DNA alkylating agent, DNA synthesis inhibitor"	XIAP	oncology	"testicular carcinoma, ovarian cancer, bladder cancer"	"N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl"	Launched	Cisplatin	24191118	DQLATGHUWYMOKM-UHFFFAOYSA-L
CL-218872	CL-218872	BRD-K00662280-001-09-4	PREP039	benzodiazepine receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2"	NA	NA	"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F"	Phase 1	CL-218872	107950	GUOQUXNJZHGPQF-UHFFFAOYSA-N
Cladribine	cladribine	BRD-K93034159-001-25-8	PREP023	"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor"	"ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B"	hematologic malignancy	hairy cell leukemia	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	Launched	Cladribine	20279	PTOAARAWEBMLNO-KVQBGUIXSA-N
Clebopride	clebopride	BRD-K17294426-050-12-3	PREP023	dopamine receptor antagonist	"ACHE, DRD2"	gastroenterology	nausea	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	Launched	Clebopride	2780	BVPWJMCABCPUQY-UHFFFAOYSA-N
Clenbuterol	clenbuterol	BRD-A75726477-003-21-3	PREP029	adrenergic receptor agonist	"ADRB1, ADRB2, ADRB3, NGF, TNF"	pulmonary	"chronic obstructive pulmonary disease (COPD), asthma"	CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1	Launched	Clenbuterol	2783	STJMRWALKKWQGH-UHFFFAOYSA-N
Clindamycin phosphate	clindamycin-phosphate	BRD-K27771035-001-02-5	PREP039	protein synthesis inhibitor	NA	obstetrics/gynecology	bacterial vaginosis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	Clindamycin phosphate	443385	UFUVLHLTWXBHGZ-MGZQPHGTSA-N
Clobetasol propionate	clobetasol-propionate	BRD-K10799896-001-26-2	PREP017	glucocorticoid receptor agonist	"NR3C1, PLA2G1B"	dermatology	corticosteroid-responsive dermatoses	"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl"	Launched	Clobetasol propionate	32798	CBGUOGMQLZIXBE-XGQKBEPLSA-N
Clobutinol	clobutinol	BRD-A43809092-003-02-1	PREP025	antitussive	NA	NA	NA	CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1	Withdrawn	Clobutinol	26937	KVHHQGIIZCJATJ-UHFFFAOYSA-N
Clocortolone pivalate	clocortolone-pivalate	BRD-K38003476-001-09-1	PREP023	steroid	"NR3C1, PLA2G1B"	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C	Launched	Clocortolone pivalate	5282493	SXYZQZLHAIHKKY-GSTUPEFVSA-N
Clofarabine	clofarabine	BRD-K34022604-001-06-6	PREP017	ribonucleotide reductase inhibitor	"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B"	hematologic malignancy	acute lymphoblastic leukemia (ALL)	"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F"	Launched	Clofarabine	119182	WDDPHFBMKLOVOX-UHFFFAOYSA-N
Clofazimine	clofazimine	BRD-K56614220-001-19-0	PREP016	GK0582 inhibitor	NA	infectious disease	leprosy	"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1"	Launched	Clofazimine	2794	WDQPAMHFFCXSNU-UHFFFAOYSA-N
Clofibrate	clofibrate	BRD-K45252063-001-13-6	PREP022	PPAR receptor agonist	"LPL, PPARA"	"endocrinology, cardiology"	"hyperlipidemia, cholesterol"	"CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1"	Launched	Clofibrate	2796	KNHUKKLJHYUCFP-UHFFFAOYSA-N
Clofoctol	clofoctol	BRD-K02900412-001-11-3	PREP021	protein synthesis inhibitor	NA	infectious disease	gram-positive bacterial infections	"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1"	Launched	Clofoctol	2799	HQVZOORKDNCGCK-UHFFFAOYSA-N
Clomifene	clomifene	BRD-K29950728-048-17-4	PREP017	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1"	Launched	Clomifene	2800	GKIRPKYJQBWNGO-UHFFFAOYSA-N
Clonazepam	clonazepam	BRD-K38183498-001-02-0	PREP016	GABA benzodiazepine site receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO"	neurology/psychiatry	"seizures, panic disorders"	[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1	Launched	Clonazepam	2802	DGBIGWXXNGSACT-UHFFFAOYSA-N
Clopamide	clopamide	BRD-A85651701-001-19-7	PREP034	sodium/chloride cotransporter inhibitor	NA	cardiology	hypertension	CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched	Clopamide	2804	LBXHRAWDUMTPSE-UHFFFAOYSA-N
Clotrimazole	clotrimazole	BRD-K15916496-001-27-9	PREP017	"cytochrome P450 inhibitor, imidazoline receptor ligand"	"CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8"	infectious disease	"vulvovaginal candidiasis, oropharyngeal candidiasis"	"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1"	Launched	Clotrimazole	2812	VNFPBHJOKIVQEB-UHFFFAOYSA-N
MK2a Inhibitor	CMPD-1	BRD-K54095730-001-03-1	PREP037	p38 MAPK inhibitor	"GNRHR, MAPK14"	NA	NA	"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1"	Preclinical	MK2a Inhibitor	11382492	ODYAQBDIXCVKAE-UHFFFAOYSA-N
CNX-2006	CNX-2006	BRD-K24869513-001-02-1	PREP046	EGFR inhibitor	EGFR	NA	NA	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	Preclinical	CNX-2006	56968072	BFSRTTWIPACGMI-UHFFFAOYSA-N
CNX-774	CNX-774	BRD-K48443249-001-01-0	PREP036	Bruton's tyrosine kinase (BTK) inhibitor	BTK	NA	NA	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	Preclinical	CNX-774	59174579	VVLHQJDAUIPZFH-UHFFFAOYSA-N
Cobicistat	cobicistat	BRD-K51040301-001-02-1	PREP030	cytochrome P450 inhibitor	"CYP3A4, CYP3A43, CYP3A5, CYP3A7"	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Launched	Cobicistat	25151504	ZCIGNRJZKPOIKD-CQXVEOKZSA-N
Cobimetinib	cobimetinib	BRD-K03390685-001-01-7	PROS001_PR500	MEK inhibitor	NA	oncology	melanoma	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	Launched	Cobimetinib	16222096	BSMCAPRUBJMWDF-KRWDZBQOSA-N
colchicine	colchicine	BRD-K00259736-001-16-4	PREP020	microtubule inhibitor	"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8"	"rheumatology, endocrinology"	"gout, fever"	"COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC"	Launched	colchicine	6167	IAKHMKGGTNLKSZ-INIZCTEOSA-N
Colforsin daropate	colforsin-daproate	BRD-K19388745-003-01-7	PREP014	adenylyl cyclase activator	NA	NA	NA	CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	Launched	Colforsin daropate	444029	RSOZZQTUMVBTMR-XGUNBQNXSA-N
"1,2-Dipalmitoyl-sn-glycero-3-phosphocholine"	colfosceril-palmitate	BRD-A95886749-001-03-5	PREP035	pulmonary surfactant	NA	pulmonary	respiratory distress syndrome (RDS)	"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC"	Launched	"1,2-Dipalmitoyl-sn-glycero-3-phosphocholine"	160339	KILNVBDSWZSGLL-KXQOOQHDSA-O
Colistin B sulfate	colistin-b-sulfate	BRD-A36456202-001-01-3	PREP021	bacterial permeability inducer	NA	infectious disease	gram-negative bacterial infections	CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O	Launched	Colistin B sulfate	139031463	ARWLUFSLVSQRNF-UHFFFAOYSA-N
Combretastatin A4	combretastatin-A-4	BRD-K61195623-001-01-4	PREP038	tubulin polymerization inhibitor	NA	NA	NA	COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1	Phase 2	Combretastatin A4	5351344	HVXBOLULGPECHP-WAYWQWQTSA-N
Costunolide	costunolide	BRD-K26833429-001-02-8	PREP036	telomerase inhibitor	NA	NA	NA	"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1"	Preclinical	Costunolide	5281437	HRYLQFBHBWLLLL-AHNJNIBGSA-N
CP-673451	CP-673451	BRD-K43621685-001-02-5	PREP033	PDGFR tyrosine kinase receptor inhibitor	"KIT, PDGFRA, PDGFRB"	NA	NA	"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1"	Preclinical	CP-673451	10158940	DEEOXSOLTLIWMG-UHFFFAOYSA-N
CP724714	CP-724714	BRD-K76908866-001-07-6	PROS002_PR500	"EGFR inhibitor, protein tyrosine kinase inhibitor"	ERBB2	NA	NA	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	Phase 2	CP724714	9874913	NA
Otenabant	"CP-945,598"	BRD-K09090949-001-01-9	PREP047	cannabinoid receptor antagonist	CNR1	NA	NA	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	Phase 3	Otenabant	10052040	UNAZAADNBYXMIV-UHFFFAOYSA-N
4-Acetamido-N-tert-butylbenzamide	CPI-1189	BRD-K11073688-001-01-6	PREP039	tumor necrosis factor release inhibitor	TNF	NA	NA	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	Phase 2	4-Acetamido-N-tert-butylbenzamide	151118	DJKNRCWSXSZACF-UHFFFAOYSA-N
CPP	CPP	BRD-K66094457-001-01-5	PREP035	glutamate receptor antagonist	"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D"	NA	NA	"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1"	Phase 2	CPP	NA	NA
CR8-(R)	CR8-(R)	BRD-K40331046-305-01-5	PREP037	CDK inhibitor	CCNA2	NA	NA	"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1"	Preclinical	CR8-(R)	10224714	HOCBJBNQIQQQGT-LJQANCHMSA-N
Creatine	creatine	BRD-K19615002-001-02-3	PREP021	NA	"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8"	NA	NA	CN(CC(O)=O)C(N)=N	Launched	Creatine	586	CVSVTCORWBXHQV-UHFFFAOYSA-N
Crenolanib	crenolanib	BRD-K22127577-001-03-7	PREP027	PDGFR tyrosine kinase receptor inhibitor	"CSF1R, FLT3, KIT, PDGFRA, PDGFRB"	NA	NA	"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1"	Phase 2	Crenolanib	10366136	NA
Crizotinib	crizotinib	BRD-K78431006-001-10-2///BRD-K78431006-001-15-1	PREP030///PROS004_PR500	ALK tyrosine kinase receptor inhibitor	"ALK, MET"	oncology	non-small cell lung cancer (NSCLC)	"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl"	Launched	Crizotinib	54613769	SCJHEFQWKWHQTO-GFCCVEGCSA-N
(S)-Crizotinib	crizotinib-(S)	BRD-K40308497-001-01-2	PREP029	MTH1 inhibitor	NUDT1	NA	NA	"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl"	Preclinical	(S)-Crizotinib	56671814	KTEIFNKAUNYNJU-LBPRGKRZSA-N
Levcromakalim	cromakalim	BRD-M89827113-001-01-5	PREP025	NA	KCNJ8	NA	NA	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	Phase 2	Levcromakalim	93504	TVZCRIROJQEVOT-CABCVRRESA-N
Gentian violet cation	crystal-violet	BRD-K60025295-003-06-6	PREP038	other antibiotic	NA	NA	NA	"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C"	Launched	Gentian violet cation	3468	LGLFFNDHMLKUMI-UHFFFAOYSA-N
1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine	CS-110266	BRD-K15519488-050-01-3	PREP045	dopamine receptor agonist	SLC6A3	NA	NA	"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1"	Preclinical	1-[1-(1-Benzothiophen-2-yl)cyclohexyl]piperidine	123692	RGSVXQJPSWZXOP-UHFFFAOYSA-N
Cudc-101	CUDC-101	BRD-K41278234-001-03-0	PREP024	EGFR inhibitor	"EGFR, ERBB2"	NA	NA	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	Phase 1	Cudc-101	24756910	NA
Fimepinostat	CUDC-907	BRD-K77638923-001-02-0	PREP033	PI3K inhibitor	"HDAC2, PIK3R1"	NA	NA	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Phase 2	Fimepinostat	54575456	JOWXJLIFIIOYMS-UHFFFAOYSA-N
Curcumin	curcumin	BRD-K07572174-001-39-4	PREP035	"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor"	"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH"	NA	NA	"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1"	Launched	Curcumin	969516	VFLDPWHFBUODDF-FCXRPNKRSA-N
Silmitasertib	CX-4945	BRD-K81458380-001-04-9	PREP024	casein kinase inhibitor	"CSNK2A1, CSNK2A2, DAPK3, HIPK3"	NA	NA	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	Phase 1/Phase 2	Silmitasertib	24748573	NA
CX-5461	CX-5461	BRD-K12787259-001-04-3	PREP018	RNA polymerase inhibitor	NA	NA	NA	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	Phase 1	CX-5461	25257557	NA
CYC-116	CYC116	BRD-K64866502-001-03-9	PREP026	Aurora kinase inhibitor	"AURKA, AURKB, KDR"	NA	NA	"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1"	Phase 1	CYC-116	6420138	GPSZYOIFQZPWEJ-UHFFFAOYSA-N
Ancitabine	cyclocytidine	BRD-K67536197-003-11-4	PREP041	"DNA synthesis inhibitor, RNA synthesis inhibitor"	NA	NA	NA	"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O"	Preclinical	Ancitabine	25051	BBDAGFIXKZCXAH-CCXZUQQUSA-N
Cycloheximide	cycloheximide	BRD-K36055864-001-19-2	PREP014	protein synthesis inhibitor	RPL3	NA	NA	"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1"	Preclinical	Cycloheximide	6197	YPHMISFOHDHNIV-FSZOTQKASA-N
Cyclophosphamide	cyclophosphamide	BRD-A09722536-002-18-0	PREP023	DNA alkylating agent	"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7"	"hematologic malignancy, oncology"	"Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer"	"ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1"	Launched	Cyclophosphamide	2907	CMSMOCZEIVJLDB-UHFFFAOYSA-N
Cyclosporin A	cyclosporin-a///cyclosporine	BRD-A69815203-001-07-6///BRD-K13533483-001-16-2	PREP016///PMTS005	calcineurin inhibitor	"PPP3CA///ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3"	"rheumatology, dermatology///transplant, rheumatology, dermatology"	"rheumatoid arthritis, psoriasis///organ rejection, rheumatoid arthritis, psoriasis"	"CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C///CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C"	Launched	Cyclosporin A	5280754	PMATZTZNYRCHOR-IMVLJIQESA-N
Cyqualon	cyclovalone	BRD-K59866480-001-07-3	PMTS008	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1"	Launched	Cyqualon	1550234	DHKKONBXGAAFTB-OTYYAQKOSA-N
Cyclovirobuxin-d	cyclovirobuxin-d	BRD-K27799744-001-02-8	PREP030	calcium channel modulator	NA	NA	NA	"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C"	Preclinical	Cyclovirobuxin-d	NA	NA
Cyproheptadine	cyproheptadine	BRD-K28143534-001-02-2	PREP032	histamine receptor antagonist	"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7"	"allergy, otolaryngology, ophthalmology, dermatology"	"allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism"	"CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12"	Launched	Cyproheptadine	2913	JJCFRYNCJDLXIK-UHFFFAOYSA-N
Cyproterone acetate	cyproterone-acetate	BRD-K41141507-001-16-2	PREP022	androgen receptor antagonist	"ADORA1, AR"	oncology	prostate cancer	"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O"	Launched	Cyproterone acetate	9880	UWFYSQMTEOIJJG-FDTZYFLXSA-N
Cyromazine	cyromazine	BRD-K36711084-001-02-0	PREP017	NA	NA	NA	NA	"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1"	Launched	Cyromazine	47866	LVQDKIWDGQRHTE-UHFFFAOYSA-N
Lexibulin	CYT-997	BRD-K23363278-001-02-1	PREP047	tubulin polymerization inhibitor	TUBB	NA	NA	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	Phase 2	Lexibulin	11351021	MTJHLONVHHPNSI-IBGZPJMESA-N
Momelotinib	cyt387	BRD-K87737963-001-06-0	PROS002_PR500	NA	"JAK1, JAK2, JAK3"	NA	NA	"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1"	Phase 3	Momelotinib	25062766	NA
Cytarabine	cytarabine	BRD-K71847383-001-12-5	PREP014	ribonucleotide reductase inhibitor	"POLA1, POLB, POLD1, POLE"	hematologic malignancy	"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)"	"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1"	Launched	Cytarabine	5351180	KCURWTAZOZXKSJ-UHFFFAOYSA-N
Cytochalasin B	cytochalasin-b	BRD-K47000838-001-01-6	PREP039	microtubule inhibitor	ACTB	NA	NA	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C	Phase 2	Cytochalasin B	5311281	GBOGMAARMMDZGR-TYHYBEHESA-N
Cytochlor	cytochlor	BRD-K48988407-001-01-2	PREP047	NA	NA	NA	NA	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 1	Cytochlor	100802	NGGRGTWYSXYVDK-RRKCRQDMSA-N
CK1 Inhibitor	D-4476	BRD-K09132007-001-07-5	PREP015	TGF beta receptor inhibitor	"CSNK1A1, CSNK1D, TGFB1"	NA	NA	"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1"	Preclinical	CK1 Inhibitor	6419753	DPDZHVCKYBCJHW-UHFFFAOYSA-N
(5-Methoxy-1H-indol-2-yl)-phenylmethanone	D-64131	BRD-K26997899-001-02-2	PREP015	microtubule inhibitor	TUBB	NA	NA	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	Preclinical	(5-Methoxy-1H-indol-2-yl)-phenylmethanone	3921152	ICMIJSRDISNKOC-UHFFFAOYSA-N
D-7193	D-7193	BRD-K32372024-001-01-0	PREP048	NA	NA	NA	NA	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	Phase 2	D-7193	99280	YTPQSLLEROSACP-OCAPTIKFSA-N
D-Serine	D-Serine	BRD-K71822263-001-03-2	PREP022	glutamate receptor agonist	"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3"	NA	NA	N[C@H](CO)C(O)=O	Launched	D-Serine	71077	MTCFGRXMJLQNBG-UWTATZPHSA-N
Dabrafenib	dabrafenib	BRD-K09951645-001-11-8///BRD-K09951645-001-06-8	PROS001_PR500///PREP020	RAF inhibitor	"BRAF, LIMK1, NEK11, RAF1, SIK1"	oncology	melanoma	"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F"	Launched	Dabrafenib	44462760	NA
DTIC-Dome	dacarbazine	BRD-K35520305-001-17-7///BRD-K35520305-001-16-9	PREP023///PROS002_PR500	DNA alkylating agent	"PGD, POLA2"	"oncology, hematologic malignancy"	"melanoma, Hodgkin's lymphoma"	"CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O"	Launched	DTIC-Dome	5353562	FDKXTQMXEQVLRF-ZHACJKMWSA-N
Dacinostat	dacinostat	BRD-K56957086-001-06-3	PREP045	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	NA	NA	"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1"	Phase 1	Dacinostat	6445533	BWDQBBCUWLSASG-MDZDMXLPSA-N
Daclatasvir	daclatasvir	BRD-K82861010-001-02-5	PREP021	HCV inhibitor	NA	infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	Daclatasvir	25154714	FKRSSPOQAMALKA-CUPIEXAXSA-N
PF-00299804	dacomitinib	BRD-K57169635-001-04-5	PROS002_PR500	EGFR inhibitor	"EGFR, ERBB2, ERBB4"	NA	NA	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	Phase 3	PF-00299804	11511120	LVXJQMNHJWSHET-AATRIKPKSA-N
Dalcetrapib	dalcetrapib	BRD-K18849474-001-04-4	PREP018	cholesteryl ester transfer protein inhibitor	CETP	NA	NA	"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C"	Phase 3	Dalcetrapib	6918540	YZQLWPMZQVHJED-UHFFFAOYSA-N
Danazol	danazol	BRD-A92537424-001-04-7	PREP035	"estrogen receptor antagonist, progesterone receptor agonist"	"AR, CCL2, ESR1, GNRHR, GNRHR2, PGR"	"obstetrics/gynecology, cardiology"	"endometriosis, angioedema"	C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C	Launched	Danazol	28417	POZRVZJJTULAOH-LHZXLZLDSA-N
Danusertib	danusertib	BRD-K07881437-001-04-6	PREP018	"Aurora kinase inhibitor, growth factor receptor inhibitor"	"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK"	NA	NA	"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1"	Phase 2	Danusertib	11442891	XKFTZKGMDDZMJI-HSZRJFAPSA-N
Dapivirine	dapivirine	BRD-K12885236-001-02-7	PREP018	non-nucleoside reverse transcriptase inhibitor	"CYP3A4, CYP3A5"	NA	NA	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	Phase 3	Dapivirine	214347	ILAYIAGXTHKHNT-UHFFFAOYSA-N
Darapladib	darapladib	BRD-K19085898-001-01-8	PREP045	phospholipase inhibitor	PLA2G7	NA	NA	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	Phase 3	Darapladib	9939609	WDPFJWLDPVQCAJ-UHFFFAOYSA-N
Darifenacin	darifenacin	BRD-K95773607-004-03-8	PREP034	acetylcholine receptor antagonist	"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5"	urology	urinary incontinence	"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1"	Launched	Darifenacin	444031	HXGBXQDTNZMWGS-RUZDIDTESA-N
Dasatinib	dasatinib	BRD-K49328571-001-15-0	PROS005_PR500	"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor"	"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1"	hematologic malignancy	"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)"	"Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1"	Launched	Dasatinib	3062316	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
Daunorubicin	daunorubicin	BRD-K43389675-003-20-9///BRD-K43389675-001-02-1	PREP020///PROS001_PR500	"RNA synthesis inhibitor, topoisomerase inhibitor"	"TOP2A, TOP2B"	hematologic malignancy	"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)"	"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O"	Launched	Daunorubicin	30323	STQGQHZAVUOBTE-VGBVRHCVSA-N
Dcebio	DCEBIO	BRD-K89299012-001-06-0	PREP046	potassium channel activator	"KCNN2, KCNN3, KCNN4"	NA	NA	"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12"	Preclinical	Dcebio	656765	LKHRMULASXZCLG-UHFFFAOYSA-N
Decitabine	decitabine	BRD-K79254416-001-22-6///BRD-K79254416-001-21-8	PREP022///PROS004_PR500	DNA methyltransferase inhibitor	"DNMT1, DNMT3A"	"hematologic malignancy, hematology"	"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)"	"Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1"	Launched	Decitabine	451668	XAUDJQYHKZQPEU-KVQBGUIXSA-N
Defactinib	defactinib	BRD-K43578482-001-01-4	PREP025	focal adhesion kinase inhibitor	PTK2	NA	NA	"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1"	Phase 2	Defactinib	25117126	FWLMVFUGMHIOAA-UHFFFAOYSA-N
Deferasirox	deferasirox	BRD-K97010173-001-04-1	PREP035	chelating agent	CYP3A4	hematology	"transfusional hemosiderosis, thalassemia, iron overload"	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	Launched	Deferasirox	214348	BOFQWVMAQOTZIW-UHFFFAOYSA-N
Deflazacort	deflazacort	BRD-K96006502-001-02-6	PREP029	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Launched	Deflazacort	189821	FBHSPRKOSMHSIF-GRMWVWQJSA-N
Ridaforolimus	deforolimus	BRD-K62304154-001-04-2	PREP047	mTOR inhibitor	MTOR	NA	NA	"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O"	Phase 3	Ridaforolimus	11520894	BUROJSBIWGDYCN-GAUTUEMISA-N
Dehydrocholic acid	dehydrocholate-acid	BRD-A11551002-001-04-6	PREP015	NA	NA	NA	NA	CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	Preclinical	Dehydrocholic acid	6674	OHXPGWPVLFPUSM-KLRNGDHRSA-N
Delanzomib	delanzomib	BRD-K59325863-001-02-8	PREP027	proteasome inhibitor	"CMA1, CTSG, CYP3A4, ELANE"	NA	NA	"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O"	Phase 1/Phase 2	Delanzomib	24800541	SJFBTAPEPRWNKH-CCKFTAQKSA-N
Demecarium	demecarium	BRD-K51471001-303-04-7	PREP015	acetylcholinesterase inhibitor	"ACHE, BCHE"	ophthalmology	"intraocular pressure, glaucoma"	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	Demecarium	5966	RWZVPVOZTJJMNU-UHFFFAOYSA-N
Deoxycorticosterone acetate	deoxycorticosterone-acetate	BRD-K24556098-001-16-7	PREP017	progestogen hormone	NR3C2	NA	NA	"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C"	Preclinical	Deoxycorticosterone acetate	5952	VPGRYOFKCNULNK-ACXQXYJUSA-N
Dequalinium	dequalinium	BRD-K77685957-300-09-1	PREP034	PKC inhibitor	"KCNN1, KCNN3"	NA	NA	"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12"	Launched	Dequalinium	2993	PCSWXVJAIHCTMO-UHFFFAOYSA-P
Desonide	desonide	BRD-K21528677-001-02-8	PREP031	glucocorticoid receptor agonist	"NR3C1, PLA2G1B"	gastroenterology	Crohn's disease	"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO"	Launched	Desonide	5311066	WBGKWQHBNHJJPZ-LECWWXJVSA-N
Desoxycortone	desoxycortone	BRD-K98521173-001-19-4	PREP041	mineralocorticoid receptor agonist	"NR3C1, NR3C2"	NA	NA	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO	Preclinical	Desoxycortone	6166	ZESRJSPZRDMNHY-YFWFAHHUSA-N
Dexamethasone acetate	dexamethasone-acetate	BRD-K47635719-001-21-1	PREP022	glucocorticoid receptor agonist	NA	"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology"	"hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis"	"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O"	Launched	Dexamethasone acetate	236702	AKUJBENLRBOFTD-RPRRAYFGSA-N
Dexrazoxane	dexrazoxane	BRD-K07265709-003-05-6	PREP020	"chelating agent, topoisomerase inhibitor"	"TOP2A, TOP2B"	cardiology	cardiomyopathy	"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1"	Launched	Dexrazoxane	71384	BMKDZUISNHGIBY-ZETCQYMHSA-N
Dianhydrogalactitol	dianhydrogalactitol	BRD-K68502831-001-01-2	PREP048	DNA alkylating agent	NA	NA	NA	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	Phase 1	Dianhydrogalactitol	31789	AAFJXZWCNVJTMK-UHFFFAOYSA-N
Diaveridine	diaveridine	BRD-K97464279-001-03-5	PREP045	dihydrofolate reductase inhibitor	NA	NA	NA	COc1ccc(Cc2cnc(N)nc2N)cc1OC	Launched	Diaveridine	21453	LDBTVAXGKYIFHO-UHFFFAOYSA-N
6-diazo-5-oxo-L-norleucine	diazooxonorleucine	BRD-K38458514-001-01-8	PREP030	glutamate receptor antagonist	NA	NA	NA	N[C@@H](CCC(=O)C=[N+]=N)C(O)=O	Phase 2	6-diazo-5-oxo-L-norleucine	5351132	MKZFABOMIIHLIT-ARJAWSKDSA-N
Dichlorisone acetate	dichlorisone-acetate	BRD-K54187111-001-09-2	PREP044	NA	NA	NA	NA	"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C"	Phase 2	Dichlorisone acetate	5388959	YNNURTVKPVJVEI-GSLJADNHSA-N
Dichloroacetate	dichloroacetate	BRD-M97302542-001-03-6///BRD-M97302542-001-04-4	PREP048///PROS001_PR500	pyruvate dehydrogenase kinase inhibitor	PDK1	NA	NA	"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl"	Phase 3	Dichloroacetate	25975	JXTHNDFMNIQAHM-UHFFFAOYSA-M
Dichlorvos	dichlorvos	BRD-K23779958-001-05-8	PREP048	acetylcholinesterase inhibitor	NA	NA	NA	COP(=O)(OC)OC=C(Cl)Cl	Launched	Dichlorvos	3039	OEBRKCOSUFCWJD-UHFFFAOYSA-N
Diclazuril	diclazuril	BRD-A06426627-001-03-5	PREP028	antiprotozoal agent	NA	infectious disease	equine protozoal myeloencephalitis (EPM)	"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O"	Launched	Diclazuril	456389	ZSZFUDFOPOMEET-UHFFFAOYSA-N
Dicyclomine	dicycloverine	BRD-K68507560-003-24-6	PREP028	acetylcholine receptor antagonist	"CHRM1, CHRM2, CHRM3"	gastroenterology	irritable bowel syndrome	"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1"	Launched	Dicyclomine	3042	CURUTKGFNZGFSE-UHFFFAOYSA-N
Dienogest	dienogest	BRD-K50853363-001-02-3	PREP045	progesterone receptor agonist	PGR	"endocrinology, obstetrics/gynecology"	"contraceptive, endometriosis"	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N	Launched	Dienogest	68861	AZFLJNIPTRTECV-FUMNGEBKSA-N
Difluprednate	difluprednate	BRD-K33720171-001-01-0	PREP033	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O	Launched	Difluprednate	443936	WYQPLTPSGFELIB-JTQPXKBDSA-N
Digitoxigenin	digitoxigenin	BRD-K18518344-001-15-9	PREP037	ATPase inhibitor	ATP1A1	NA	NA	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1	Preclinical	Digitoxigenin	4369270	XZTUSOXSLKTKJQ-CESUGQOBSA-N
Digitoxin	digitoxin	BRD-A93236127-001-04-5	PREP023	ATPase inhibitor	ATP1A1	NA	NA	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	Digitoxin	441207	WDJUZGPOPHTGOT-XUDUSOBPSA-N
Digoxigenin	digoxigenin	BRD-K18619710-001-14-4	PREP037	steroid	NA	NA	NA	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1	Preclinical	Digoxigenin	15478	SHIBSTMRCDJXLN-KCZCNTNESA-N
Digoxin	digoxin	BRD-A94756469-001-04-7	PREP028	ATPase inhibitor	ATP1A1	cardiology	"congestive heart failure, atrial fibrillation (AF)"	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	Digoxin	2724385	LTMHDMANZUZIPE-PUGKRICDSA-N
dihydroartemisinin	dihydroartemisinin	BRD-K62213621-001-01-6	PREP014	antimalarial agent	NA	infectious disease	malaria	"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4"	Launched	dihydroartemisinin	3000518	BJDCWCLMFKKGEE-ISOSDAIHSA-N
Dihydroergocristine	dihydroergocristine	BRD-K97440753-066-18-1	PREP034	"adrenergic receptor antagonist, prolactin inhibitor"	"ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7"	NA	NA	"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O"	Launched	Dihydroergocristine	107715	DEQITUUQPICUMR-HJPBWRTMSA-N
Dihydromyricetin	dihydromyricetin	BRD-K01614093-001-02-6	PREP036	NA	NA	NA	NA	"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1"	Preclinical	Dihydromyricetin	161557	KJXSIXMJHKAJOD-LSDHHAIUSA-N
Dimethisoquin	dimethisoquin	BRD-K73391359-003-10-2	PREP025	local anesthetic	NA	neurology/psychiatry	local anesthetic	CCCCc1cc2ccccc2c(OCCN(C)C)n1	Launched	Dimethisoquin	6857	XNMYNYSCEJBRPZ-UHFFFAOYSA-N
Dinaciclib	dinaciclib	BRD-K13662825-001-07-5	PROS005_PR500	CDK inhibitor	"CDK1, CDK2, CDK5, CDK9"	NA	NA	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	Phase 3	Dinaciclib	46926350	NA
Dioscin	dioscin	BRD-K37723606-001-01-5	PREP033	apoptosis stimulant	CXCR3	NA	NA	C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1	Preclinical	Dioscin	119245	VNONINPVFQTJOC-ZGXDEBHDSA-N
Diphemanil	diphemanil	BRD-K93441486-067-12-8	PREP030	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	Launched	Diphemanil	6127	LCTZPQRFOZKZNK-UHFFFAOYSA-N
Diphenyleneiodonium	diphenyleneiodonium	BRD-K65814004-003-02-9	PREP042	nitric oxide synthase inhibitor	"NOS2, NOS3"	NA	NA	[I+]1c2ccccc2-c2ccccc12	Preclinical	Diphenyleneiodonium	3101	QFXKXRXFBRLLPQ-UHFFFAOYSA-N
Dirithromycin	dirithromycin	BRD-K52756523-001-24-7	PREP035	bacterial 50S ribosomal subunit inhibitor	NA	pulmonary	bronchitis	"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O"	Launched	Dirithromycin	6473883	WLOHNSSYAXHWNR-DWIOZXRMSA-N
Disulfiram	disulfiram	BRD-K32744045-001-31-2	PREP015	"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist"	"ALDH2, DBH"	neurology/psychiatry	abstinence from alcohol	"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC"	Launched	Disulfiram	3117	AUZONCFQVSMFAP-UHFFFAOYSA-N
DMH1	DMH1	BRD-K39381259-001-01-0	PREP043	ALK tyrosine kinase receptor inhibitor	ACVR1	NA	NA	"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12"	Preclinical	DMH1	50997747	JMIFGARJSWXZSH-UHFFFAOYSA-N
Docetaxel	docetaxel	BRD-K30577245-341-01-9///BRD-K30577245-001-05-0	PREP017///PROS005_PR500	tubulin polymerization inhibitor	"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1"	oncology	"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)"	"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C"	Launched	Docetaxel	148124	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Dofetilide	dofetilide	BRD-K86887724-001-10-6	PREP035	potassium channel blocker	"KCNH1, KCNH2, KCNJ12, KCNK2"	NA	NA	"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1"	Withdrawn	Dofetilide	71329	IXTMWRCNAAVVAI-UHFFFAOYSA-N
Dolastatin 10	dolastatin-10	BRD-K78567475-001-01-4	PREP039	tubulin polymerization inhibitor	TUBB	NA	NA	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Phase 2	Dolastatin 10	9810929	OFDNQWIFNXBECV-VFSYNPLYSA-N
Dolutegravir	dolutegravir	BRD-K36386086-001-01-1	PREP022	HIV integrase inhibitor	"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1"	infectious disease	human immunodeficiency virus (HIV-1)	C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Launched	Dolutegravir	54726191	RHWKPHLQXYSBKR-BMIGLBTASA-N
Domiphen	domiphen	BRD-K30431096-004-01-3	PREP042	NA	NA	NA	NA	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	Preclinical	Domiphen	3149	YXUPZGKORWTXID-UHFFFAOYSA-N
Domperidone	domperidone	BRD-K38305202-001-17-4	PREP035	dopamine receptor antagonist	"DRD2, DRD3"	infectious disease	fescue toxicosis	"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1"	Launched	Domperidone	3151	FGXWKSZFVQUSTL-UHFFFAOYSA-N
Dorzolamide	dorzolamide	BRD-K71075609-003-01-0	PREP022	carbonic anhydrase inhibitor	"CA1, CA12, CA14, CA2, CA4, CA7"	ophthalmology	"intraocular pressure, glaucoma"	CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	Dorzolamide	5284549	IAVUPMFITXYVAF-XPUUQOCRSA-N
Dovitinib	dovitinib	BRD-K85402309-001-06-6///BRD-K85402309-043-01-9	PREP044///PROS001_PR500	"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB"	NA	NA	"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O"	Phase 3	Dovitinib	9886808	KCOYQXZDFIIGCY-ZZEZOPTASA-N
Doxercalciferol	doxercalciferol	BRD-K82928892-001-02-5	PREP020	vitamin D receptor agonist	VDR	"nephrology, endocrinology"	"chronic kidney disease (CKD), hyperparathyroidism"	"CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C"	Launched	Doxercalciferol	5281107	HKXBNHCUPKIYDM-CGMHZMFXSA-N
Doxifluridine	doxifluridine	BRD-K58262659-001-09-7	PREP035	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O"	Launched	Doxifluridine	18343	ZWAOHEXOSAUJHY-ZIYNGMLESA-N
Doxorubicin	doxorubicin	BRD-K92093830-003-30-8	PREP015	topoisomerase inhibitor	TOP2A	"hematologic malignancy, oncology"	"acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma"	"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO"	Launched	Doxorubicin	32874	MWWSFMDVAYGXBV-FGBJBKNOSA-N
Doxycycline	doxycycline	BRD-A08545410-311-03-4///BRD-A08545410-003-07-8	PREP034///PREP031	metalloproteinase inhibitor	MMP8	dental	periodontitis	"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12"	Launched	Doxycycline	54671203	SGKRLCUYIXIAHR-AKNGSSGZSA-N
DPI-201106	DPI-201106	BRD-A64553394-001-04-4	PREP019	sodium channel activator	ADRB2	NA	NA	OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	DPI-201106	5190	BYBYHCOEAFHGJL-UHFFFAOYSA-N
Dronedarone	dronedarone	BRD-K05524748-003-04-4	PREP028	adrenergic receptor antagonist	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A"	cardiology	atrial fibrillation (AF)	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	Launched	Dronedarone	208898	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
Drospirenone	drospirenone	BRD-K04394237-001-03-7	PREP034	mineralocorticoid receptor antagonist	"AR, NR3C2, PGR"	endocrinology	contraceptive	"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1"	Launched	Drospirenone	68873	METQSPRSQINEEU-HXCATZOESA-N
Arg-gly-asp-ser	DU-728	BRD-K08859203-001-01-9	PREP046	structural glycoprotein antagonist	"ITGA2B, ITGB3"	NA	NA	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	Phase 1	Arg-gly-asp-ser	107775	NNRFRJQMBSBXGO-CIUDSAMLSA-N
Noopept	DVD-111	BRD-K22520627-001-01-7	PREP045	NA	NA	NA	NA	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	Phase 2	Noopept	180496	PJNSMUBMSNAEEN-AWEZNQCLSA-N
E-7449	E7449	BRD-K05444225-001-01-7	PREP045	PARP inhibitor	"PARP1, PARP2, TNKS, TNKS2"	NA	NA	"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23"	Phase 1/Phase 2	E-7449	135565981	JLFSBHQQXIAQEC-UHFFFAOYSA-N
Ebastine	ebastine	BRD-K13314656-001-01-0	PREP035	histamine receptor antagonist	"CYP3A4, HRH1"	allergy	"allergic rhinitis, urticaria"	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	Ebastine	3191	MJJALKDDGIKVBE-UHFFFAOYSA-N
Ecamsule-triethanolamine	ecamsule-triethanolamine	BRD-A47953250-001-01-7	PREP020	NA	NA	dermatology	"skin protectant, sunscreen lotion"	CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C	Launched	Ecamsule-triethanolamine	131634633	HEAHZSUCFKFERC-MPPVQRIUSA-N
Echinomycin	echinomycin	BRD-A68969091-001-12-7	PREP045	DNA intercalating agent	NA	NA	NA	CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1	Phase 2	Echinomycin	3197	AUJXLBOHYWTPFV-UHFFFAOYSA-N
Efonidipine-Monoethanolate	efonidipine-monoethanolate	BRD-M92675308-003-07-1	PREP039	"L-type calcium channel blocker, T-type calcium channel blocker"	"CACNA1C, CACNA1G"	NA	NA	"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1"	Launched	Efonidipine-Monoethanolate	NA	NA
Elacridar	elacridar	BRD-K88807631-001-01-3	PMTS008	P glycoprotein inhibitor	ABCB1	NA	NA	"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC"	Phase 1	Elacridar	119373	OSFCMRGOZNQUSW-UHFFFAOYSA-N
Elesclomol	elesclomol	BRD-K82135108-001-04-3	PROS001_PR500	oxidative stress inducer	HSPA1A	NA	NA	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	Phase 3	Elesclomol	300471	BKJIXTWSNXCKJH-UHFFFAOYSA-N
Eltrombopag	eltrombopag	BRD-K40496271-396-01-1	PREP035	thrombopoietin receptor agonist	MPL	"hematology, infectious disease"	"anemia, hepatitis C, thrombocytopenia"	"CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1"	Launched	Eltrombopag	135449332	SVOQIEJWJCQGDQ-UHFFFAOYSA-N
Embelin	embelin	BRD-K86727142-001-12-4	PREP024	"HCV inhibitor, XIAP inhibitor"	XIAP	NA	NA	"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O"	Preclinical	Embelin	3218	NA
EMD-53998	EMD-53998	BRD-A65248799-001-01-7	PREP038	phosphodiesterase inhibitor	TNNC1	NA	NA	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C	Phase 1	EMD-53998	187079	IZLRMTJLQCLMKF-UHFFFAOYSA-N
Emetine	emetine	BRD-A25687296-300-04-3	PREP019	protein synthesis inhibitor	RPS2	NA	NA	"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12"	Phase 2	Emetine	10219	AUVVAXYIELKVAI-CKBKHPSWSA-N
IWR-1-endo	endo-IWR-1	BRD-K61314889-001-04-4	PREP043	PARP inhibitor	"TNKS, TNKS2"	NA	NA	"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O"	Preclinical	IWR-1-endo	44483163	ZGSXEXBYLJIOGF-ALFLXDJESA-N
ENMD-2076	ENMD-2076	BRD-K68488863-001-04-9	PREP026	"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor"	"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC"	NA	NA	CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1	Phase 2	ENMD-2076	16041424	BLQYVHBZHAISJM-CMDGGOBGSA-N
Enocitabine	enocitabine	BRD-K32007074-001-02-9	PREP035	DNA synthesis inhibitor	"CMPK1, RRM1, TYMS"	NA	NA	"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1"	Launched	Enocitabine	71734	SAMRUMKYXPVKPA-VFKOLLTISA-N
Enoximone	enoximone	BRD-K21152241-001-07-3	PMTS008	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C	Launched	Enoximone	53708	ZJKNESGOIKRXQY-UHFFFAOYSA-N
Entinostat	entinostat	BRD-K77908580-001-09-6	PREP027	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC9"	NA	NA	"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1"	Phase 3	Entinostat	4261	INVTYAOGFAGBOE-UHFFFAOYSA-N
Enzalutamide	enzalutamide	BRD-K56851771-001-06-8	PREP022	androgen receptor antagonist	AR	oncology	prostate cancer	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	Launched	Enzalutamide	15951529	WXCXUHSOUPDCQV-UHFFFAOYSA-N
Epiandrosterone	epiandrosterone	BRD-K42756753-001-01-9	PREP033	steroid	G6PD	NA	NA	C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	Epiandrosterone	441302	QGXBDMJGAMFCBF-LUJOEAJASA-N
Epinastine	epinastine	BRD-A98990573-003-01-3	PREP014	histamine receptor antagonist	"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7"	ophthalmology	conjunctivitis	NC1=NCC2N1c1ccccc1Cc1ccccc21	Launched	Epinastine	3241	WHWZLSFABNNENI-UHFFFAOYSA-N
Epinephrine	epinephrine	BRD-K63126190-003-01-6	PREP021	"adrenergic receptor agonist, neurotransmitter"	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF"	"cardiology, allergy, pulmonary"	"cardiac arrest, anaphylactic shock, asthma"	"CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1"	Launched	Epinephrine	5816	UCTWMZQNUQWSLP-VIFPVBQESA-N
Epirubicin	epirubicin	BRD-K04548931-003-16-5	PREP023	topoisomerase inhibitor	"CHD1, TOP2A"	oncology	breast cancer	"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO"	Launched	Epirubicin	41867	AOJJSUZBOXZQNB-VTZDEGQISA-N
Eplerenone	eplerenone	BRD-K19761926-001-03-6	PREP034	cytochrome P450 inhibitor	NR3C2	cardiology	"congestive heart failure, hypertension"	"COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13"	Launched	Eplerenone	443872	JUKPWJGBANNWMW-VWBFHTRKSA-N
Epothilone A	epothilone-a	BRD-K71823332-001-03-7	PREP036	microtubule stabilizing agent	NA	NA	NA	C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Preclinical	Epothilone A	448799	HESCAJZNRMSMJG-KKQRBIROSA-N
Epothilone B	epothilone-b	BRD-K68164687-001-01-6	PREP027	"microtubule stabilizing agent, tubulin polymerization inhibitor"	"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B"	NA	NA	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 3	Epothilone B	448013	NA
Epothilone D	epothilone-d	BRD-K52762805-001-01-2	PREP025	"microtubule stabilizing agent, tubulin polymerization inhibitor"	"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B"	NA	NA	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 2	Epothilone D	447865	XOZIUKBZLSUILX-GIQCAXHBSA-N
Eprinex	eprinomectin	BRD-A91366704-001-01-9	PREP025	benzodiazepine receptor agonist	NA	infectious disease	"gastrointestinal roundworms, lungworms"	CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C	Launched	Eprinex	6450531	WPNHOHPRXXCPRA-TVXIRPTOSA-N
Eprobemide	eprobemide	BRD-K17979676-001-01-2	PREP020	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	Launched	Eprobemide	65659	YYFGRAGNYHYWEZ-UHFFFAOYSA-N
Eprosartan	eprosartan	BRD-K67977190-066-02-3	PREP017	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O"	Launched	Eprosartan	5281037	OROAFUQRIXKEMV-LDADJPATSA-N
Eptifibatide	eptifibatide	BRD-A90547603-001-02-5	PREP016	platelet aggregation inhibitor	"ITGA2B, ITGB3"	cardiology	"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)"	NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O	Launched	Eptifibatide	448812	CZKPOZZJODAYPZ-LROMGURASA-N
EPZ5676	EPZ-5676	BRD-K26531771-001-02-2	PREP015	histone lysine methyltransferase inhibitor	DOT1L	NA	NA	"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1"	Phase 1	EPZ5676	57345410	LXFOLMYKSYSZQS-XKHGBIBOSA-N
Equol	equol	BRD-K54847683-001-04-0	PREP034	estrogen receptor agonist	"ESR1, ESR2"	NA	NA	"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1"	Launched	Equol	91469	ADFCQWZHKCXPAJ-GFCCVEGCSA-N
ER-27319	ER-27319	BRD-K11927976-050-02-9	PREP033	"mediator release inhibitor, SYK inhibitor"	SYK	NA	NA	"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O"	Preclinical	ER-27319	9799508	IIELZHYJYZBSGG-UHFFFAOYSA-N
Erastin	erastin	BRD-A25004090-001-08-4	PREP044	ion channel antagonist	VDAC2	NA	NA	"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1"	Preclinical	Erastin	11214940	BKQFRNYHFIQEKN-UHFFFAOYSA-N
Ercalcitriol	ercalcitriol	BRD-K84163249-001-01-9	PREP046	vitamin D receptor agonist	VDR	NA	NA	"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C"	Phase 1	Ercalcitriol	9547243	ZGLHBRQAEXKACO-XJRQOBMKSA-N
Erdafitinib	erdafitinib	BRD-K84868168-001-01-0	PMTS008	FGFR inhibitor	"FGFR1, FGFR2, FGFR3, FGFR4"	NA	NA	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	Phase 2	Erdafitinib	67462786	OLAHOMJCDNXHFI-UHFFFAOYSA-N
Erlotinib	erlotinib	BRD-K70401845-001-15-7///BRD-K70401845-003-09-6	PROS003_PR500///PREP016	EGFR inhibitor	"EGFR, NR1I2"	oncology	"non-small cell lung cancer (NSCLC), pancreatic cancer"	"COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC"	Launched	Erlotinib	176871	GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Erteberel	erteberel	BRD-K80608265-001-01-6	PREP039	estrogen receptor agonist	"ESR1, ESR2"	NA	NA	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	Phase 2	Erteberel	10286159	XIESSJVMWNJCGZ-VKJFTORMSA-N
Erythritol	erythritol	BRD-K79315489-001-07-8	PREP048	NA	NA	NA	NA	"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO"	Launched	Erythritol	222285	UNXHWFMMPAWVPI-ZXZARUISSA-N
Estradiol	estradiol	BRD-K18910433-001-36-6	PREP028	estrogen receptor agonist	"ESR1, ESR2, GPER1, KCNMA1, NR1I2"	endocrinology	contraceptive	"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O"	Launched	Estradiol	5757	VOXZDWNPVJITMN-ZBRFXRBCSA-N
Estradiol benzoate	estradiol-benzoate	BRD-A74765037-001-01-1	PREP015	contraceptive agent	ESR1	NA	NA	C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O	Preclinical	Estradiol benzoate	222757	UYIFTLBWAOGQBI-BZDYCCQFSA-N
Estradiol cypionate	estradiol-cypionate	BRD-A91452556-001-04-0	PREP017	estrogen receptor agonist	ESR1	endocrinology	"hypoestrogenism, menopause"	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1	Launched	Estradiol cypionate	9403	UOACKFBJUYNSLK-XRKIENNPSA-N
Estramustine	estramustine	BRD-A70858459-001-01-7	PROS003_PR500///PREP014	"DNA alkylating agent///DNA synthesis inhibitor, microtubule inhibitor"	"ESR1, ESR2, MAP1A, MAP2"	oncology	prostate cancer	C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O///C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched	Estramustine phosphate	259331	ADFOJJHRTBFFOF-RBRWEJTLSA-N
Estramustine phosphate	estramustine-phosphate	BRD-K00077635-304-01-2	PROS003_PR500///PREP014	"DNA alkylating agent///DNA synthesis inhibitor, microtubule inhibitor"	"ESR1, ESR2, MAP1A, MAP2"	oncology	prostate cancer	C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O///C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched	Estramustine phosphate	259329	ADFOJJHRTBFFOF-RBRWEJTLSA-N
Estrone	estrone	BRD-K81839095-001-30-1	PREP016	"estrogen receptor agonist, estrogenic hormone"	"ESR1, ESR2"	NA	NA	"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O"	Launched	Estrone	5870	DNXHEGUUPJUMQT-CBZIJGRNSA-N
Ethacridine lactate monohydrate	ethacridine-lactate-monohydrate	BRD-K24715592-406-02-1	PREP041	DNA intercalating agent	NA	NA	NA	"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1"	Preclinical	Ethacridine lactate monohydrate	165457	NYEPHMYJRNWPLA-UHFFFAOYSA-N
Ethinyl estradiol	ethinyl-estradiol	BRD-K48195008-001-19-9	PREP021	"estrogen receptor agonist, estrogenic hormone"	"ESR1, ESR2, NR1I2"	endocrinology	contraceptive	"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C"	Launched	Ethinyl estradiol	5991	BFPYWIDHMRZLRN-SLHNCBLASA-N
Etofylline clofibrate	etofylline-clofibrate	BRD-K49840922-001-05-1	PREP023	platelet aggregation inhibitor	PPARA	NA	NA	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	Launched	Etofylline clofibrate	41109	KYAKGJDISSNVPZ-UHFFFAOYSA-N
Etomoxir	etomoxir	BRD-K32405725-001-02-8	PREP039	carnitine palmitoyltransferase inhibitor	CPT1A	NA	NA	CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	Phase 2	Etomoxir	123823	DZLOHEOHWICNIL-UHFFFAOYSA-N
Etoposide	etoposide	BRD-K37798499-001-27-2	PREP017///PMTS008	topoisomerase inhibitor	"TOP2A, TOP2B///TOP2A"	oncology	"non-small cell lung cancer (NSCLC)///testicular carcinoma, small cell lung cancer"	"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12///COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12"	Launched	Etoposide	36462	VJJPUSNTGOMMGY-MRVIYFEKSA-N
Etoposide	etoposide-phosphate	BRD-K72533376-001-01-2	PREP017///PMTS008	topoisomerase inhibitor	"TOP2A, TOP2B///TOP2A"	oncology	"non-small cell lung cancer (NSCLC)///testicular carcinoma, small cell lung cancer"	"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12///COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12"	Launched	Etoposide	6918092	VJJPUSNTGOMMGY-MRVIYFEKSA-N
ETP-46464	ETP-46464	BRD-K24556407-001-02-3	PREP040	ATR kinase inhibitor	NA	NA	NA	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	Preclinical	ETP-46464	72199292	NA
Evacetrapib	evacetrapib	BRD-K16551357-001-03-2	PREP019	cholesteryl ester transfer protein inhibitor	CETP	NA	NA	"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1"	Phase 3	Evacetrapib	49836058	IHIUGIVXARLYHP-UXNJHFGPSA-N
Everolimus	everolimus	BRD-K13514097-001-04-6///BRD-K13514097-001-05-3	PROS003_PR500///PREP020	mTOR inhibitor	MTOR	"oncology, neurology/psychiatry, genetics, urology"	"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma"	"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO"	Launched	Everolimus	6442177	HKVAMNSJSFKALM-GKUWKFKPSA-N
Evodiamine	evodiamine	BRD-A68631409-001-05-4	PREP032	"ATPase inhibitor, TRPV agonist"	TRPV1	NA	NA	"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12"	Preclinical	Evodiamine	442088	TXDUTHBFYKGSAH-SFHVURJKSA-N
NF-kB Activation Inhibitor	EVP4593	BRD-K68395654-001-03-1	PREP040	NFkB pathway inhibitor	NA	NA	NA	"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1"	Preclinical	NF-kB Activation Inhibitor	509554	NA
Exatecan	exatecan-mesylate	BRD-K92150287-066-01-2	PREP026	topoisomerase inhibitor	TOP1	NA	NA	"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45"	Phase 3	Exatecan	151115	ZVYVPGLRVWUPMP-FYSMJZIKSA-N
Exemestane	exemestane	BRD-K33425534-001-12-5	PREP023	aromatase inhibitor	CYP19A1	oncology	breast cancer	"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O"	Launched	Exemestane	60198	BFYIZQONLCFLEV-DAELLWKTSA-N
Famciclovir	famciclovir	BRD-K45033733-001-12-2	PREP022	DNA polymerase inhibitor	NA	"dental, infectious disease"	"cold sore, genitial herpes, shingles"	"CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O"	Launched	Famciclovir	3324	GGXKWVWZWMLJEH-UHFFFAOYSA-N
famotidine	famotidine	BRD-K00673382-001-18-9	PREP020	histamine receptor antagonist	HRH2	gastroenterology	heartburn	"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1"	Launched	famotidine	5702160	XUFQPHANEAPEMJ-UHFFFAOYSA-N
Favipiravir	favipiravir	BRD-K04264130-001-01-4	PREP018	RNA polymerase inhibitor	NA	NA	NA	NC(=O)c1nc(F)cnc1O	Phase 3	Favipiravir	492405	ZCGNOVWYSGBHAU-UHFFFAOYSA-N
5-Fluoro-2-Deoxycytidine	fdcyd	BRD-K18157228-001-01-7	PREP024	DNA methyltransferase inhibitor	NA	NA	NA	Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	Phase 2	5-Fluoro-2-Deoxycytidine	240980	IDYKCXHJJGMAEV-UHFFFAOYSA-N
Felbamate	felbamate	BRD-K99107520-001-24-1	PREP030	glutamate receptor antagonist	"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B"	neurology/psychiatry	epilepsy	"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1"	Launched	Felbamate	3331	WKGXYQFOCVYPAC-UHFFFAOYSA-N
Fenaclon	fenaclon	BRD-K08791496-001-01-0	PREP046	NA	NA	NA	NA	ClCCC(=O)NCCc1ccccc1	Preclinical	Fenaclon	9376	BITWVVLBVUMFHU-UHFFFAOYSA-N
Fenbendazole	fenbendazole	BRD-K51318897-001-15-3	PREP021	tubulin polymerization inhibitor	TUBB	infectious disease	"gastrointestinal parasites, gastrointestinal roundworms"	"COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1"	Launched	Fenbendazole	3334	HDDSHPAODJUKPD-UHFFFAOYSA-N
Fendiline	fendiline	BRD-A71033472-003-23-9	PREP036	calcium channel blocker	HTR2B	NA	NA	CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1	Preclinical	Fendiline	3336	NMKSAYKQLCHXDK-UHFFFAOYSA-N
Fenofibrate	fenofibrate	BRD-K50388907-001-30-4	PREP031	PPAR receptor agonist	"MMP25, PPARA"	endocrinology	"hypercholesterolemia, hypertriglyceridemia"	"CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1"	Launched	Fenofibrate	3339	YMTINGFKWWXKFG-UHFFFAOYSA-N
Fenoprofen	fenoprofen	BRD-A81129465-001-03-8	PREP020	prostaglandin inhibitor	"PTGS1, PTGS2, SLC5A8"	rheumatology	"rheumatoid arthritis, osteoarthritis"	"CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1"	Launched	Fenoprofen	3342	RDJGLLICXDHJDY-UHFFFAOYSA-N
Fenretinide	fenretinide	BRD-K89085489-001-23-2	PMTS008	"apoptosis stimulant, retinoid receptor agonist"	RARA	NA	NA	"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1"	Phase 3	Fenretinide	5288209	AKJHMTWEGVYYSE-FXILSDISSA-N
Unii-9fut9FH3EX	FERb-033	BRD-K61642990-001-01-0	PREP037	EGFR inhibitor	ERBB2	NA	NA	"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O"	Preclinical	Unii-9fut9FH3EX	135931707	LRRMQNGSYOUANY-OMCISZLKSA-N
Fexinidazole	fexinidazole	BRD-K37069697-001-01-3	PREP025	NA	NA	NA	NA	CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	Phase 2/Phase 3	Fexinidazole	68792	MIWWSGDADVMLTG-UHFFFAOYSA-N
Roxadustat	FG-4592	BRD-K14385366-001-04-4	PREP026	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN2	NA	NA	"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12"	Phase 3	Roxadustat	11256664	YOZBGTLTNGAVFU-UHFFFAOYSA-N
ARRY-520	filanesib	BRD-K37379014-001-02-0///BRD-K37379014-001-01-2	PROS005_PR500///PREP026	"kinesin inhibitor, kinesin-like spindle protein inhibitor"	KIF11	NA	NA	"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F"	Phase 3	ARRY-520	44224257	LLXISKGBWFTGEI-FQEVSTJZSA-N
Filgotinib	filgotinib	BRD-K16803204-001-01-6	PREP044	JAK inhibitor	"JAK1, JAK2, JAK3, TYK2"	NA	NA	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	Phase 2	Filgotinib	49831257	RIJLVEAXPNLDTC-UHFFFAOYSA-N
Finafloxacin	finafloxacin	BRD-K98384930-003-01-5	PREP045	bacterial DNA gyrase inhibitor	NA	"infectious disease, pulmonary"	"intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis"	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	Launched	Finafloxacin	11567473	FYMHQCNFKNMJAV-HOTGVXAUSA-N
"N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide"	FK-3311	BRD-K38350380-001-01-8	PREP045	cyclooxygenase inhibitor	PTGS2	NA	NA	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	Phase 2	"N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide"	164009	DIIYLGZNZGPXRR-UHFFFAOYSA-N
Daporinad	FK-866	BRD-K58550667-001-08-7	PROS005_PR500	niacinamide phosphoribosyltransferase inhibitor	NAMPT	NA	NA	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	Phase 2	Daporinad	6914657	KPBNHDGDUADAGP-VAWYXSNFSA-N
FK-888	FK-888	BRD-K83508485-001-02-7	PREP018	tachykinin antagonist	"TACR1, TACR2"	NA	NA	"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12"	Phase 2	FK-888	107967	BFNKQTIJVFGCKQ-PDJGWCFMSA-N
Fleroxacin	fleroxacin	BRD-K61717546-001-05-0	PREP035	topoisomerase inhibitor	NA	"infectious disease, gastroenterology"	"gonorrhea, enteritis, diarrhea, respiratory tract infections"	"CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O"	Launched	Fleroxacin	3357	XBJBPGROQZJDOJ-UHFFFAOYSA-N
FLI-06	FLI-06	BRD-A44500574-001-01-8	PREP015	notch signaling inhibitor	NA	NA	NA	"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1"	Preclinical	FLI-06	3103157	SWWVFYHSSOWZMF-UHFFFAOYSA-N
Florfenicol	florfenicol	BRD-A30886737-001-02-9	PREP029	protein synthesis inhibitor	NA	pulmonary	bovine respiratory disease (BRD)	"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl"	Launched	Florfenicol	114811	AYIRNRDRBQJXIF-NXEZZACHSA-N
Floxuridine	floxuridine	BRD-K47832606-001-30-1	PREP014	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O"	Launched	Floxuridine	5790	ODKNJVUHOIMIIZ-RRKCRQDMSA-N
Flubendazole	flubendazole	BRD-K86003836-001-10-5	PREP039	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1"	Launched	Flubendazole	35802	CPEUVMUXAHMANV-UHFFFAOYSA-N
2-fluoroAraA (fludarabine)	fludarabine	BRD-K66788707-001-14-3	PREP028	ribonucleotide reductase inhibitor	"ADA, RRM1, RRM2"	hematologic malignancy	chronic lymphocytic leukemia (CLL)	"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O"	Launched	2-fluoroAraA (fludarabine)	657237	HBUBKKRHXORPQB-FJFJXFQQSA-N
Fludarabine phosphate	fludarabine-phosphate	BRD-K71106091-001-06-1	PREP016	ribonucleotide reductase inhibitor	"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B"	hematologic malignancy	chronic lymphocytic leukemia (CLL)	"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O"	Launched	Fludarabine phosphate	30751	GIUYCYHIANZCFB-FJFJXFQQSA-N
Flurandrenolide	fludroxycortide	BRD-A49765801-001-04-1	PREP029	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	"infectious disease, dermatology"	"skin infections, psoriasis"	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	Flurandrenolide	15209	POPFMWWJOGLOIF-XWCQMRHXSA-N
Flufenamic acid	flufenamic-acid	BRD-K44067360-001-30-3	PREP014	chloride channel blocker	"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5"	NA	NA	"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F"	Preclinical	Flufenamic acid	3371	LPEPZBJOKDYZAD-UHFFFAOYSA-N
Flumatinib	flumatinib	BRD-K68870568-066-01-5	PREP018	Bcr-Abl kinase inhibitor	"ABL1, PDGFRB"	NA	NA	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Phase 3	Flumatinib	46848036	BJCJYEYYYGBROF-UHFFFAOYSA-N
Flumethasone	flumethasone	BRD-K61496577-001-20-2	PREP035	glucocorticoid receptor agonist	"NR3C1, PLA2G1B"	dermatology	corticosteroid-responsive dermatoses	"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO"	Launched	Flumethasone	16490	WXURHACBFYSXBI-GQKYHHCASA-N
Flumethasone pivalate	flumethasone-pivalate	BRD-A50064262-001-04-7	PREP046	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	NA	NA	C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C	Launched	Flumethasone pivalate	443980	JWRMHDSINXPDHB-OJAGFMMFSA-N
Fluocinolone acetonide	fluocinolone-acetonide	BRD-K94353609-001-21-6	PREP031	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	dermatology	seborrheic dermatitis	"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO"	Launched	Fluocinolone acetonide	6215	FEBLZLNTKCEFIT-VSXGLTOVSA-N
Fluorometholone	fluorometholone	BRD-A13133631-001-04-0	PREP028	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12	Launched	Fluorometholone	9878	FAOZLTXFLGPHNG-KNAQIMQKSA-N
fluoromethylcholine	fluoromethylcholine	BRD-K51199656-003-01-4	PREP023	NA	NA	NA	NA	C[N+](C)(CF)CCO	Launched	fluoromethylcholine	404592	PBVFROWIWWGIFK-UHFFFAOYSA-N
Fluroxene	fluroxene	BRD-K56908511-001-01-2	PREP048	local anesthetic	NA	NA	NA	"FC(F)(F)COC=C, FC(F)(F)COC=C"	Preclinical	Fluroxene	9844	DLEGDLSLRSOURQ-UHFFFAOYSA-N
Flutamide	flutamide	BRD-K28307902-001-21-7	PREP017	androgen receptor antagonist	"AHR, AR"	oncology	prostate cancer	"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O"	Launched	Flutamide	3397	MKXKFYHWDHIYRV-UHFFFAOYSA-N
Fluticasone propionate	fluticasone-propionate	BRD-K62310379-001-10-5	PREP022	glucocorticoid receptor agonist	"NR3C1, NR3C2, PGR, PLA2G4A"	dermatology	corticosteroid-responsive dermatoses	"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF"	Launched	Fluticasone propionate	444036	WMWTYOKRWGGJOA-CENSZEJFSA-N
Fluvastatin	fluvastatin	BRD-K66296774-236-11-3	PREP031	HMGCR inhibitor	HMGCR	"endocrinology, cardiology"	"hypercholesterolemia, congenital heart defects"	"CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12"	Launched	Fluvastatin	446155	FJLGEFLZQAZZCD-MCBHFWOFSA-N
Foretinib	foretinib	BRD-K03449891-001-08-6	PROS004_PR500	VEGFR inhibitor	"FLT1, FLT4, KDR, MET"	NA	NA	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	Phase 2	Foretinib	42642645	CXQHYVUVSFXTMY-UHFFFAOYSA-N
Formestane	formestane	BRD-A26503646-001-16-6	PREP030	aromatase inhibitor	CYP19A1	oncology	breast cancer	"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O"	Launched	Formestane	11273	OSVMTWJCGUFAOD-KZQROQTASA-N
Forodesine	forodesine	BRD-K16505263-003-02-9	PMTS008	purinergic receptor antagonist	PNP	NA	NA	"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O"	Phase 2	Forodesine	135409409	IWKXDMQDITUYRK-KUBHLMPHSA-N
Forskolin	forskolin	BRD-K09602097-001-13-6	PREP024	adenylyl cyclase activator	"ADCY2, ADCY5, GNAS"	NA	NA	"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C"	Launched	Forskolin	47936	OHCQJHSOBUTRHG-KGGHGJDLSA-N
Fosbretabulin	fosbretabulin	BRD-K06814349-304-02-7///BRD-K06814349-304-01-9	PROS002_PR500///PREP047	"tubulin polymerization inhibitor, VE-cadherin antagonist"	CDH5	NA	NA	"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O"	Phase 3	Fosbretabulin	5351387	WDOGQTQEKVLZIJ-WAYWQWQTSA-N
Foscarnet	foscarnet	BRD-K85146014-314-05-4	PREP048	DNA polymerase inhibitor	NA	infectious disease	"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)"	"OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O"	Launched	Foscarnet	3415	ZJAOAACCNHFJAH-UHFFFAOYSA-N
FPH1-(BRD-6125)	FPH1-(BRD-6125)	BRD-K61250484-001-02-3	PREP044	hepatocyte function enhancer	NA	NA	NA	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	Preclinical	FPH1-(BRD-6125)	NA	NA
FR-122047	FR-122047	BRD-K30990140-003-02-4	PREP015	cyclooxygenase inhibitor	NA	NA	NA	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	Preclinical	FR-122047	196841	UBHKJRYGKOSQDJ-UHFFFAOYSA-N
FR-139317	FR-139317	BRD-K19318328-001-01-3	PREP019	endothelin receptor antagonist	EDNRA	NA	NA	"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O"	Phase 1	FR-139317	107810	LIOKMIQQPDDTNO-UPRLRBBYSA-N
Frentizole	frentizole	BRD-K07202345-001-19-4	PREP038	immunosuppressant	NA	NA	NA	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	Phase 1	Frentizole	33334	JHBWYQRKOUBPCA-UHFFFAOYSA-N
Tegafur	ftorafur	BRD-K99383816-001-03-5	PREP031	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O"	Launched	Tegafur	5386	WFWLQNSHRPWKFK-UHFFFAOYSA-N
Fudosteine	fudosteine	BRD-K54838207-001-03-8	PREP034	mucolytic agent	NA	pulmonary	chest congestion	"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O"	Launched	Fudosteine	134669	KINWYTAUPKOPCQ-YFKPBYRVSA-N
Fulvestrant	fulvestrant	BRD-A85667082-001-12-7	PREP014	estrogen receptor antagonist	"ESR1, ESR2, GPER1"	oncology	breast cancer	"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31"	Launched	Fulvestrant	104741	VWUXBMIQPBEWFH-WCCTWKNTSA-N
G-1	G-1	BRD-K62696033-001-01-4	PREP036	G protein-coupled receptor agonist	GPER1	NA	NA	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br	Preclinical	G-1	5322399	VHSVKVWHYFBIFJ-HKZYLEAXSA-N
Galeterone	galeterone	BRD-A07986123-001-02-8	PREP046	androgen receptor modulator	"AR, CYP17A1"	NA	NA	C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12	Phase 3	Galeterone	11188409	PAFKTGFSEFKSQG-PAASFTFBSA-N
Gambogic acid	gambogic-acid	BRD-K08542803-001-02-3///BRD-K08542803-001-03-1	PROS005_PR500///PREP018	caspase activator	BCL2	NA	NA	"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C"	Phase 2	Gambogic acid	11599836	GEZHEQNLKAOMCA-JDDSCDDDSA-N
gamma-Aminobutyric acid	gamma-aminobutyric-acid	BRD-K77245796-003-01-6	PREP042	benzodiazepine receptor agonist	"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1"	NA	NA	NCCCC(O)=O	Preclinical	gamma-Aminobutyric acid	119	BTCSSZJGUNDROE-UHFFFAOYSA-N
Ganetespib	ganetespib	BRD-K38852836-001-02-1	PROS005_PR500	HSP inhibitor	HSP90AA1	NA	NA	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	Phase 3	Ganetespib	135564985	RVAQIUULWULRNW-UHFFFAOYSA-N
Gastrodin	gastrodin	BRD-K81613478-001-01-8	PREP045	NA	NA	NA	NA	OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	Gastrodin	115067	PUQSUZTXKPLAPR-UJPOAAIJSA-N
Ipatasertib	GDC-0068	BRD-K71480163-001-01-4	PREP018	AKT inhibitor	"AKT1, AKT2, AKT3, PRKG1"	NA	NA	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	Phase 2	Ipatasertib	24788740	GRZXWCHAXNAUHY-NSISKUIASA-N
Gdc-0152	GDC-0152	BRD-K68938568-001-01-7	PREP026	XIAP inhibitor	"BIRC2, BIRC3, BIRC7, XIAP"	NA	NA	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	Phase 1	Gdc-0152	46940575	WZRFLSDVFPIXOV-LRQRDZAKSA-N
Gdc-0349	GDC-0349	BRD-K43187018-001-03-3	PREP032	Pim kinase inhibitor	PIK3CA	NA	NA	"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1"	Phase 1	Gdc-0349	59239165	RGJOJUGRHPQXGF-INIZCTEOSA-N
GDC-0879	GDC-0879	BRD-K67578145-001-09-7	PREP042	RAF inhibitor	BRAF	NA	NA	"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1"	Preclinical	GDC-0879	11717001	NA
Pictilisib	GDC-0941	BRD-K52911425-001-09-8	PREP018	PI3K inhibitor	"PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1	Phase 2	Pictilisib	17755052	LHNIIDJUOCFXAP-UHFFFAOYSA-N
Apitolisib	GDC-0980	BRD-K23228615-001-02-8	PROS004_PR500	"mTOR inhibitor, PI3K inhibitor"	"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK"	NA	NA	"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1"	Phase 2	Apitolisib	25254071	YOVVNQKCSKSHKT-HNNXBMFYSA-N
Gefitinib	gefitinib	BRD-K64052750-001-17-5///BRD-K64052750-001-22-5	PREP022///PROS002_PR500	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1"	Launched	Gefitinib	123631	XGALLCVXEZPNRQ-UHFFFAOYSA-N
Gemcitabine	gemcitabine	BRD-K15108141-001-06-6	PREP034	ribonucleotide reductase inhibitor	"CMPK1, RRM1, RRM2, TYMS"	oncology	"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer"	"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1"	Launched	Gemcitabine	356653	OKKDEIYWILRZIA-UHFFFAOYSA-N
Genipin	genipin	BRD-K28824103-001-02-8	PREP030	choleretic agent	NA	NA	NA	"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO"	Preclinical	Genipin	442424	AZKVWQKMDGGDSV-BCMRRPTOSA-N
Genz-644282	genz-644282	BRD-K99475619-001-01-2	PREP018	topoisomerase inhibitor	TOP1	NA	NA	CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O	Phase 1	Genz-644282	10294813	BAORCAMWLWRZQG-UHFFFAOYSA-N
Gestrinone	gestrinone	BRD-K97472745-001-01-8	PREP034	progesterone receptor antagonist	"AR, ESR1, PGR"	obstetrics/gynecology	endometriosis	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C	Launched	Gestrinone	27812	BJJXHLWLUDYTGC-ANULTFPQSA-N
GGTI-298	GGTI-298	BRD-K19669037-001-01-1	PREP043	GGTase inhibitor	CDKN1A	NA	NA	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	Preclinical	GGTI-298	9811606	XVWPFYDMUFBHBF-CLOONOSVSA-N
Gidazepam	gidazepam	BRD-K22588750-001-07-0	PMTS008	GABA benzodiazepine site receptor agonist	NA	NA	NA	NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1	Launched	Gidazepam	121919	XLGCMZLSEXRBSG-UHFFFAOYSA-N
Gilteritinib	gilteritinib	BRD-K72280606-001-01-2	PMTS010	FLT3 inhibitor	FLT3	NA	NA	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	Phase 3	Gilteritinib	49803313	NA
Gimeracil	gimeracil	BRD-K35687421-001-02-5	PREP017	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl"	Launched	Gimeracil	54679224	ZPLQIPFOCGIIHV-UHFFFAOYSA-N
Ginkgolide-A	ginkgolide-a	BRD-A95121829-001-08-9	PREP043	GABA receptor antagonist	"GLRA1, GLRB"	NA	NA	C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Preclinical	Ginkgolide-A	9909368	FPUXKXIZEIDQKW-VKMVSBOZSA-N
Givinostat	givinostat	BRD-K13810148-311-03-2	PREP046	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	NA	NA	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	Phase 2	Givinostat	9804992	YALNUENQHAQXEA-UHFFFAOYSA-N
golgicide-a	golgicide-a	BRD-A57886255-001-01-1	PREP047	ARF inhibitor	GBF1	NA	NA	Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1	Preclinical	golgicide-a	1085377	NJZHEQOUHLZCOX-WOSRLPQWSA-N
Golvatinib	golvatinib	BRD-K69001009-001-02-8	PROS001_PR500	VEGFR inhibitor	"KDR, MET"	NA	NA	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	Phase 2	Golvatinib	16118392	UQRCJCNVNUFYDX-UHFFFAOYSA-N
Gossypol	gossypol	BRD-K19295594-015-14-3	PREP019	"BCL inhibitor, MCL1 inhibitor"	BCL2	NA	NA	"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O"	Phase 2	Gossypol	3503	QBKSWRVVCFFDOT-UHFFFAOYSA-N
GS-39783	GS-39783	BRD-K75478907-001-02-3	PREP036	GABA receptor modulator	GABBR1	NA	NA	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	Preclinical	GS-39783	6604928	GSGVDKOCBKBMGG-UHFFFAOYSA-N
Entospletinib	GS-9973	BRD-K76719364-001-02-5	PMTS010	syk inhibitor	SYK	NA	NA	"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1"	Phase 2	Entospletinib	59473233	XSMSNFMDVXXHGJ-UHFFFAOYSA-N
GSK-3 inhibitor IX	GSK-3-inhibitor-IX	BRD-K04923131-001-15-4	PREP047	"glycogen synthase kinase inhibitor, lipoxygenase inhibitor"	"GSK3A, GSK3B"	NA	NA	"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12"	Preclinical	GSK-3 inhibitor IX	448949	SAQUSDSPQYQNBG-UHFFFAOYSA-N
GSK-J4	GSK-J4	BRD-K98203492-003-04-1	PREP047	histone lysine demethylase inhibitor	"KDM6A, KDM6B"	NA	NA	"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1"	Preclinical	GSK-J4	71729975	NA
GSK1070916	GSK1070916	BRD-K36740062-001-06-6	PREP046	Aurora kinase inhibitor	"AURKA, AURKB, AURKC, CYP2D6, CYP3A4"	NA	NA	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	Phase 1	GSK1070916	46885626	QTBWCSQGBMPECM-UHFFFAOYSA-N
GSK1292263	GSK1292263	BRD-K60341624-001-02-2	PREP019	glucose dependent insulinotropic receptor agonist	GRPR	NA	NA	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	Phase 2	GSK1292263	24996872	AYJRTVVIBJSSKN-UHFFFAOYSA-N
GSK-1838705A	GSK1838705A	BRD-K06749501-001-02-1	PREP042	insulin growth factor receptor inhibitor	"ALK, IGF1R, INSR, RPS6KA1"	NA	NA	"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12"	Preclinical	GSK-1838705A	25182616	NA
GSK-1904529A	GSK1904529A	BRD-K04833372-001-06-2	PREP042	"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand"	"IGF1R, INSR"	NA	NA	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	Preclinical	GSK-1904529A	25124816	MOSKATHMXWSZTQ-UHFFFAOYSA-N
Afuresertib	GSK2110183	BRD-K25412176-001-01-9	PREP026	AKT inhibitor	"AKT1, AKT2, AKT3"	NA	NA	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	Phase 2	Afuresertib	46843057	AFJRDFWMXUECEW-LBPRGKRZSA-N
Omipalisib	GSK2126458	BRD-K07972848-001-02-0	PREP044	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	Phase 1	Omipalisib	25167777	CGBJSGAELGCMKE-UHFFFAOYSA-N
GSK256066	GSK256066	BRD-K37590257-001-02-8	PREP024	phosphodiesterase inhibitor	PDE4A	NA	NA	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	Phase 2	GSK256066	9827968	JFHROPTYMMSOLG-UHFFFAOYSA-N
GSK2656157	GSK2656157	BRD-K41104902-001-01-3	PREP046	PERK inhibitor	NA	NA	NA	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	Preclinical	GSK2656157	53469059	PRWSIEBRGXYXAJ-UHFFFAOYSA-N
GSK2830371	GSK2830371	BRD-K17472821-001-01-2	PMTS010	protein phosphatase inhibitor	PPM1D	NA	NA	"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1"	Preclinical	GSK2830371	70983932	IVDUVEGCMXCMSO-FQEVSTJZSA-N
GSK429286A	GSK429286A	BRD-A10523515-001-07-9	PREP037	rho associated kinase inhibitor	ROCK1	NA	NA	"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F"	Preclinical	GSK429286A	11373846	NA
Gsk-461364	GSK461364	BRD-K92428232-001-10-6	PREP038	PLK inhibitor	PLK1	NA	NA	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	Phase 1	Gsk-461364	15983966	ZHJGWYRLJUCMRT-QGZVFWFLSA-N
GSK-650394	GSK650394	BRD-K14991967-001-02-6	PREP037	serum/glucocorticoid regulated kinase inhibitor	"SGK1, SGK2"	NA	NA	"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1"	Preclinical	GSK-650394	25022668	WVSBGSNVCDAMCF-UHFFFAOYSA-N
GSK923295	GSK923295	BRD-K89015388-001-01-7	PREP046	centromere associated protein inhibitor	CENPE	NA	NA	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	Phase 1	GSK923295	46898058	WHMXDBPHBVLYRC-OFVILXPXSA-N
"3-Phenyl-1H-benzofuro[3,2-c]pyrazole"	GTP-14564	BRD-K16664969-001-03-3	PREP040	"FLT3 inhibitor, tyrosine kinase inhibitor"	"CSF1R, FLT3, KIT, PDGFRB"	NA	NA	"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21"	Preclinical	"3-Phenyl-1H-benzofuro[3,2-c]pyrazole"	3385203	DZQLVVLATXPWBK-UHFFFAOYSA-N
Guanidine	guanidine	BRD-K76037122-001-02-5	PREP030	HSP inhibitor	"ALDH2, DLG4, GAMT, RNASE1"	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	"NC(N)=N, NC(N)=N"	Launched	Guanidine	3520	ZRALSGWEFCBTJO-UHFFFAOYSA-N
GW-3965	GW-3965	BRD-K33818169-003-04-6	PREP033	LXR agonist	"NR1H2, NR1H3"	NA	NA	"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1"	Preclinical	GW-3965	447905	NAXSRXHZFIBFMI-UHFFFAOYSA-N
GW-405833	GW-405833	BRD-K10705233-001-02-2	PREP036	cannabinoid receptor agonist	CNR2	NA	NA	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	Preclinical	GW-405833	9911463	FSFZRNZSZYDVLI-UHFFFAOYSA-N
GW 441756	GW-441756	BRD-K41312087-001-02-7	PREP037	growth factor receptor inhibitor	NTRK1	NA	NA	"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12"	Preclinical	GW 441756	9943465	NA
Endurobol	GW-501516	BRD-K14880289-001-02-2	PREP026	PPAR receptor agonist	"PPARA, PPARD"	NA	NA	"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F"	Phase 2	Endurobol	9803963	YDBLKRPLXZNVNB-UHFFFAOYSA-N
GW-583340	GW-583340	BRD-K79930101-300-03-7	PREP043	EGFR inhibitor	"EGFR, ERBB2"	NA	NA	"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1"	Preclinical	GW-583340	5329480	MNNXRVSQOABRRP-UHFFFAOYSA-N
GW-788388	GW-788388	BRD-K78086729-001-02-7	PREP041	ALK tyrosine kinase receptor inhibitor	"LCK, MAPK14, TGFBR1"	NA	NA	"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1"	Preclinical	GW-788388	10202642	SAGZIBJAQGBRQA-UHFFFAOYSA-N
GW-842166	GW-842166	BRD-K26823213-001-02-9	PREP027	cannabinoid receptor agonist	CNR2	NA	NA	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Phase 2	GW-842166	10253143	TWQYWUXBZHPIIV-UHFFFAOYSA-N
GW843682X	GW-843682X	BRD-K90382497-001-10-7	PREP033	PLK inhibitor	"PLK1, PLK3"	NA	NA	"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC"	Preclinical	GW843682X	9826308	JSKUWFIZUALZLX-UHFFFAOYSA-N
GZD824	GZD824	BRD-K35329391-334-01-7	PREP014	Bcr-Abl kinase inhibitor	"ABL1, BCR"	NA	NA	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1	Preclinical	GZD824	51038269	TZKBVRDEOITLRB-UHFFFAOYSA-N
HA14-1	HA14-1	BRD-K18163608-001-05-6	PREP042	BCL inhibitor	BCL2	NA	NA	"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC"	Preclinical	HA14-1	3549	SXJDCULZDFWMJC-UHFFFAOYSA-N
Halcinonide	halcinonide	BRD-A88138582-001-04-8	PREP035	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl"	Launched	Halcinonide	443943	MUQNGPZZQDCDFT-JNQJZLCISA-N
Halobetasol propionate	halobetasol-propionate	BRD-K65877271-001-01-8	PREP034	glucocorticoid receptor agonist	"NR3C1, PLA2G1B"	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl	Launched	Halobetasol propionate	6918178	BDSYKGHYMJNPAB-LICBFIPMSA-N
Halofantrine	halofantrine	BRD-A51964809-003-12-6	PREP031	antimalarial agent	"KCNH2, KCNN4"	infectious disease	malaria	CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F	Launched	Halofantrine	37393	FOHHNHSLJDZUGQ-UHFFFAOYSA-N
halofuginone	halofuginone	BRD-K54247840-004-01-3	PREP028	collagenase inhibitor	"COL1A1, MMP2"	rheumatology	scleroderma	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	Launched	halofuginone	400772	LVASCWIMLIKXLA-LSDHHAIUSA-N
Harringtonine	harringtonine	BRD-K96358241-001-01-9	PREP019	protein synthesis inhibitor	NA	NA	NA	COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Phase 3	Harringtonine	276389	HAVJATCHLFRDHY-KSZYUSJVSA-N
Hesperadin	hesperadin	BRD-K58122457-001-02-2	PREP024	Aurora kinase inhibitor	AURKB	NA	NA	"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1"	Preclinical	Hesperadin	135421442	HYHIYZMIFPJROG-UHFFFAOYSA-N
Hexachlorophene	hexachlorophene	BRD-K99792991-001-34-9	PREP016	potassium channel activator	"GLUD1, SDHD"	infectious disease	gram-positive bacterial infections	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	Launched	Hexachlorophene	3598	ACGUYXCXAPNIKK-UHFFFAOYSA-N
Hexaminolevulinate	hexaminolevulinate	BRD-K73753850-003-01-6	PMTS010	NA	NA	radiology	diagnostic agent	CCCCCCOC(=O)CCC(=O)CN	Launched	Hexaminolevulinate	6433083	RYQOILLJDKPETL-UHFFFAOYSA-N
Hexylresorcinol	hexylresorcinol	BRD-K99946902-001-07-5	PREP022	local anesthetic	TYR	infectious disease	"skin infections, first-aid antiseptic"	CCCCCCc1ccc(O)cc1O	Launched	Hexylresorcinol	3610	WFJIVOKAWHGMBH-UHFFFAOYSA-N
Hmn-214	HMN-214	BRD-K70511574-001-06-9	PREP027	PLK inhibitor	PLK1	NA	NA	COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	Phase 1	Hmn-214	9888590	OCKHRKSTDPOHEN-BQYQJAHWSA-N
Omacetaxine mepesuccinate	homoharringtonine	BRD-K76674262-001-03-3	PROS003_PR500	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Launched	Omacetaxine mepesuccinate	NA	NA
Homoquinolinic acid	homoquinolinic-acid	BRD-K30519779-001-03-1	PREP042	glutamate receptor agonist	"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D"	NA	NA	OC(=O)Cc1cccnc1C(O)=O	Preclinical	Homoquinolinic acid	3080554	HQPMJFFEXJELOQ-UHFFFAOYSA-N
Homosalate	homosalate	BRD-A34751532-001-06-9	PREP024	HSP inducer	NA	NA	NA	CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O	Preclinical	Homosalate	8362	WSSJONWNBBTCMG-UHFFFAOYSA-N
Hydrocortisone	hydrocortisone	BRD-K93568044-001-32-0	PREP023	glucocorticoid receptor agonist	NA	"dermatology, neurology/psychiatry"	"eczema, psoriasis, seborrheic dermatitis, itching"	"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO"	Launched	Hydrocortisone	5754	JYGXADMDTFJGBT-VWUMJDOOSA-N
"hydroxytacrine-maleate-(r,s)"	"hydroxytacrine-maleate-(r,s)"	BRD-A98299281-050-09-6	PREP036	cholinesterase inhibitor	ACHE	NA	NA	Nc1c2C(O)CCCc2nc2ccccc12	Preclinical	"hydroxytacrine-maleate-(r,s)"	667530	HLVVITIHAZBPKB-NSHDSACASA-N
Hydroxyurea	hydroxyurea	BRD-K51747290-001-13-1	PREP017	ribonucleotide reductase inhibitor	"RRM1, RRM2, RRM2B"	"hematologic malignancy, oncology"	"chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)"	"NC(=O)NO, NC(=O)NO, NC(=O)NO"	Launched	Hydroxyurea	3657	VSNHCAURESNICA-UHFFFAOYSA-N
Hyodeoxycholic acid	hyodeoxycholic-acid	BRD-K44009692-001-02-3	PREP046	atherosclerosis formation inhibitor	NA	NA	NA	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 1	Hyodeoxycholic acid	5283820	DGABKXLVXPYZII-SIBKNCMHSA-N
Hyoscyamine	hyoscyamine	BRD-K40530731-001-11-6	PREP039	acetylcholine receptor antagonist	"CHRM1, CHRM2, CHRM3, CHRM4"	"gastroenterology, urology, neurology/psychiatry, allergy"	"peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis"	"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1"	Launched	Hyoscyamine	3661	RKUNBYITZUJHSG-UHFFFAOYSA-N
Hypericin	hypericin	BRD-K29673530-001-05-4	PREP024	tyrosine kinase inhibitor	NA	NA	NA	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	Phase 2	Hypericin	3663	YDOIFHVUBCIUHF-UHFFFAOYSA-N
Hypoestoxide	hypoestoxide	BRD-A51571244-001-01-9	PREP025	IKK inhibitor	"IKBKB, IL1B, TNF"	NA	NA	CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C	Phase 1	Hypoestoxide	11199742	HNPAHGHFONBTLV-KSJQNFQUSA-N
Molibresib	I-BET-762	BRD-K08109215-001-06-4	PROS002_PR500	bromodomain inhibitor	"BRD2, BRD3, BRD4"	NA	NA	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12	Phase 2	Molibresib	46943432	NA
I-BET-151	I-BET151	BRD-K36363294-001-04-2	PREP033	bromodomain inhibitor	"BRD2, BRD3, BRD4"	NA	NA	"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C"	Preclinical	I-BET-151	52912189	VUVUVNZRUGEAHB-CYBMUJFWSA-N
Ibrutinib	ibrutinib	BRD-K70301465-001-02-6///BRD-K70301465-001-05-9	PREP017///PROS003_PR500	Bruton's tyrosine kinase (BTK) inhibitor	"BLK, BMX, BTK"	hematologic malignancy	"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)"	"Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C"	Launched	Ibrutinib	24821094	NA
Ibutilide	ibutilide	BRD-A74391928-051-01-3	PREP028	potassium channel blocker	"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6"	cardiology	atrial fibrillation (AF)	"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1"	Launched	Ibutilide	60753	ALOBUEHUHMBRLE-UHFFFAOYSA-N
ICG-001	ICG-001	BRD-K94455792-001-01-8	PREP033	beta-catenin inhibitor	CTNNB1	NA	NA	Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	Preclinical	ICG-001	11238147	HQWTUOLCGKIECB-XZWHSSHBSA-N
ICI-162846	ICI-162846	BRD-K11071038-001-01-7	PREP038	histamine receptor antagonist	HRH2	NA	NA	NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F	Phase 1	ICI-162846	134778	ALCSGJCIESECFD-UHFFFAOYSA-N
Icotinib	icotinib	BRD-K31698212-001-02-9	PROS003_PR500	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	Launched	Icotinib	22024915	QQLKULDARVNMAL-UHFFFAOYSA-N
Idarubicin	idarubicin	BRD-K69650333-003-14-0	PREP021	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O"	Launched	Idarubicin	42890	XDXDZDZNSLXDNA-TZNDIEGXSA-N
Idasanutlin	idasanutlin	BRD-K62627508-001-01-5	PROS003_PR500	MDM inhibitor	"MDM2, TP53"	NA	NA	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	Phase 3	Idasanutlin	53358942	TVTXCJFHQKSQQM-LJQIRTBHSA-N
Idazoxan	idazoxan	BRD-A18696154-003-22-6	PREP045	adrenergic receptor antagonist	ADRA2A	NA	NA	"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1"	Phase 3	Idazoxan	54459	HPMRFMKYPGXPEP-UHFFFAOYSA-N
Idelalisib	idelalisib	BRD-K60866521-001-07-1	PROS003_PR500	PI3K inhibitor	"PIK3CA, PIK3CB, PIK3CD, PIK3CG"	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	Launched	Idelalisib	11625818	NA
Idoxuridine	idoxuridine	BRD-K76634210-001-14-7	PREP035	DNA directed DNA polymerase inhibitor	NA	infectious disease	virus herpes simplex (HSV)	"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O"	Launched	Idoxuridine	5905	XQFRJNBWHJMXHO-RRKCRQDMSA-N
IDRA-21	IDRA-21	BRD-A14344385-001-03-2	PREP024	glutamate receptor positive allosteric modulator	"GRIA1, GRIA2, GRIA3, GRIA4"	NA	NA	"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1"	Preclinical	IDRA-21	3688	VZRNTCHTJRLTMU-UHFFFAOYSA-N
Idronoxil	idronoxil	BRD-K74671368-001-01-8	PMTS010	XIAP inhibitor	"ENOX2, SPHK1"	NA	NA	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1	Phase 3	Idronoxil	219100	ZZUBHVMHNVYXRR-UHFFFAOYSA-N
"N-(1-Adamantylmethyl)-1,5-pentanediamine"	IEM1754	BRD-K80060353-303-03-9	PREP036	glutamate receptor antagonist	GRIA1	NA	NA	"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2"	Preclinical	"N-(1-Adamantylmethyl)-1,5-pentanediamine"	9887868	UWWMQHVWAYFCDT-UHFFFAOYSA-N
Ifosfamide	ifosfamide	BRD-A67097164-001-18-7	PREP029	DNA alkylating agent	"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1"	"oncology, urology"	"testicular carcinoma, hemorrhagic cystitis"	"ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl"	Launched	Ifosfamide	3690	HOMGKSMUEGBAAB-UHFFFAOYSA-N
IKK.16	IKK-16	BRD-K14618467-001-04-6	PREP040	IKK inhibitor	IKBKB	NA	NA	"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1"	Preclinical	IKK.16	NA	NA
IMD 0354	IKK-2-inhibitor-V	BRD-K74305673-001-06-2	PREP039	"IKK inhibitor, NFkB pathway inhibitor"	IKBKB	NA	NA	"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F"	Phase 1	IMD 0354	5081913	CHILCFMQWMQVAL-UHFFFAOYSA-N
Ilomastat	ilomastat	BRD-K51662849-001-08-8	PREP019	matrix metalloprotease inhibitor	"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9"	NA	NA	"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO"	Phase 3	Ilomastat	132519	NITYDPDXAAFEIT-DYVFJYSZSA-N
Imatinib	imatinib	BRD-K92723993-001-17-4///BRD-K92723993-001-06-7	PROS001_PR500///PREP031	"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor"	"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET"	"hematologic malignancy, oncology"	"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)"	"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1"	Launched	Imatinib	5291	KTUFNOKKBVMGRW-UHFFFAOYSA-N
Imidapril	imidapril	BRD-K34332569-001-01-3	PREP029	angiotensin converting enzyme inhibitor	ACE	cardiology	"hypertension, congestive heart failure"	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O	Launched	Imidapril	5464343	KLZWOWYOHUKJIG-BPUTZDHNSA-N
Imiloxan	imiloxan	BRD-A10903566-003-07-7	PREP025	adrenergic receptor antagonist	"ADRA2A, ADRA2B"	NA	NA	CCn1ccnc1CC1COc2ccccc2O1	Phase 1	Imiloxan	133621	UXABARREKCJULM-UHFFFAOYSA-N
Imiquimod	imiquimod	BRD-K26657438-001-15-2	PROS003_PR500	"interferon inducer, toll-like receptor agonist"	"TLR7, TLR8"	"dermatology, infectious disease, oncology"	"actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)"	"CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12"	Launched	Imiquimod	57469	DOUYETYNHWVLEO-UHFFFAOYSA-N
Capmatinib	INC-280	BRD-K81016934-001-02-0	PROS004_PR500	c-Met inhibitor	MET	NA	NA	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	Phase 2	Capmatinib	25145656	LIOLIMKSCNQPLV-UHFFFAOYSA-N
Indibulin	indibulin	BRD-K74057757-001-01-9	PREP019	tubulin polymerization inhibitor	NA	NA	NA	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	Phase 1/Phase 2	Indibulin	2929	SOLIIYNRSAWTSQ-UHFFFAOYSA-N
Indiplon	indiplon	BRD-K90948141-001-01-4	PREP039	benzodiazepine receptor agonist	GABRA1	NA	NA	"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1"	Phase 3	Indiplon	6450813	CBIAWPMZSFFRGN-UHFFFAOYSA-N
Indirubin	indirubin	BRD-K17894950-001-14-3	PROS002_PR500	"CDK inhibitor, glycogen synthase kinase inhibitor"	"CDK1, CDK5, GSK3A"	NA	NA	O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	Phase 2/Phase 3	Indirubin	10177	JNLNPCNGMHKCKO-UHFFFAOYSA-N
Indisulam	indisulam	BRD-K17610631-001-03-3	PROS001_PR500	CDK inhibitor	"CA1, CA12, CA14, CA2, CA6, CA7, CA9"	NA	NA	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	Phase 2	Indisulam	216468	SETFNECMODOHTO-UHFFFAOYSA-N
Indoprofen	indoprofen	BRD-A44090213-001-25-6	PREP035	"cyclooxygenase inhibitor, prostanoid receptor antagonist"	"CXCR1, CXCR2, PTGS1, PTGS2"	NA	NA	CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O	Withdrawn	Indoprofen	3718	RJMIEHBSYVWVIN-UHFFFAOYSA-N
Ingenol mebutate	ingenol-mebutate	BRD-K93779381-001-01-9	PREP035	PKC activator	"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG"	dermatology	actinic keratosis (AK)	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C	Launched	Ingenol mebutate	6918670	VDJHFHXMUKFKET-WDUFCVPESA-N
INH1	INH1	BRD-K70177501-003-01-4	PREP043	Hec1 inhibitor	NDC80	NA	NA	Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1	Preclinical	INH1	959043	JPMOKRWIYQGMJL-UHFFFAOYSA-N
Inosine	inosine	BRD-K79612754-001-19-1	PREP034	neurotrophic agent	"PARP1, PNP"	NA	NA	"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12"	Launched	Inosine	135398641	UGQMRVRMYYASKQ-KQYNXXCUSA-N
Iobenguane	iobenguane	BRD-K43860855-065-11-9	PREP022	antineoplastic agent	NA	"oncology, cardiology, endocrinology"	"neuroblastoma, congestive heart failure, pheochromocytoma"	"NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1"	Launched	Iobenguane	60860	PDWUPXJEEYOOTR-UHFFFAOYSA-N
Iodipamide	iodipamide	BRD-K67261995-001-11-7	PREP028	radiopaque medium	ALB	radiology	contrast agent	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	Launched	Iodipamide	3739	FFINMCNLQNTKLU-UHFFFAOYSA-N
4-Iododexetimide	iododexetimide	BRD-A46813902-001-01-6	PREP019	acetylcholine receptor antagonist	NA	NA	NA	Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1	Phase 2	4-Iododexetimide	11755220	WJLRTFJPHDSXAF-HSZRJFAPSA-N
IOWH032	IOWH032	BRD-K84892605-001-01-1	PREP032	CFTR channel antagonist	CFTR	NA	NA	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	Phase 2	IOWH032	135565181	DSFNLJXHXBIKDS-UHFFFAOYSA-N
Iproniazid	iproniazid	BRD-K88568253-011-19-9	PREP021	monoamine oxidase inhibitor	"MAOA, MAOB"	NA	NA	CC(C)NNC(=O)c1ccncc1	Withdrawn	Iproniazid	3748	NYMGNSNKLVNMIA-UHFFFAOYSA-N
Ipsapirone	ipsapirone	BRD-K90574421-001-03-5	PREP044	serotonin receptor agonist	HTR1A	NA	NA	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	Phase 3	Ipsapirone	56971	TZJUVVIWVWFLCD-UHFFFAOYSA-N
Irinotecan	irinotecan	BRD-K08547377-001-04-4///BRD-K08547377-394-03-5	PROS001_PR500///PREP044	topoisomerase inhibitor	"TOP1, TOP1MT"	oncology	colorectal cancer	"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12"	Launched	Irinotecan	60838	UWKQSNNFCGGAFS-XIFFEERXSA-N
Isoetharine	isoetharine	BRD-A24587114-066-22-5	PREP024	adrenergic receptor agonist	"ADRB1, ADRB2"	pulmonary	"bronchospasm, asthma"	"CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1"	Launched	Isoetharine	3762	HUYWAWARQUIQLE-UHFFFAOYSA-N
Isofloxythepin	isofloxythepin	BRD-A07704283-001-01-3	PREP027	dopamine receptor antagonist	NA	NA	NA	CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1	Phase 2	Isofloxythepin	115193	XDBMBHVYXPBOPL-UHFFFAOYSA-N
Isoflupredone	isoflupredone-acetate	BRD-K29173907-001-09-2	PREP014	NA	NR3C1	NA	NA	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Preclinical	Isoflupredone	127516	WAIJIHDWAKJCBX-BULBTXNYSA-N
Isometheptene-mucate	isometheptene-mucate	BRD-A64743628-001-01-5	PREP023	NA	"ADRA1A, SLC18A2"	neurology/psychiatry	headache	CNC(C)CCC=C(C)C	Launched	Isometheptene-mucate	6604597	XVQUOJBERHHONY-VIFPVBQESA-N
Isopropyl myristate	isopropyl-myristate	BRD-K13409143-001-01-9	PREP048	NA	NA	dermatology	cosmetic	"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C"	Launched	Isopropyl myristate	8042	AXISYYRBXTVTFY-UHFFFAOYSA-N
Isoxsuprine	isoxsuprine	BRD-A16700644-003-04-4	PREP022	adrenergic receptor agonist	ADRB2	"rheumatology, cardiology"	"Raynaud's disease, arteriosclerosis, Buerger's disease"	CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1	Launched	Isoxsuprine	3783	BMUKKTUHUDJSNZ-UHFFFAOYSA-N
Ispinesib	ispinesib	BRD-K64881305-001-03-7	PROS001_PR500	kinesin inhibitor	KIF11	NA	NA	"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1"	Phase 2	Ispinesib	6851740	QJZRFPJCWMNVAV-HHHXNRCGSA-N
Istradefylline	istradefylline	BRD-K87774949-001-03-9	PREP022	adenosine receptor antagonist	"ADORA1, ADORA2A, ADORA2B, ADORA3"	neurology/psychiatry	"Parkinson's Disease, dyskinesia"	"CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O"	Launched	Istradefylline	5311037	NA
Itraconazole	itraconazole	BRD-A23067620-300-01-3	PREP020	cytochrome P450 inhibitor	CYP51A1	infectious disease	"onychomycosis, histoplasmosis, blastomycosis, aspergillosis"	"CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O"	Launched	Itraconazole	14179013	VHVPQPYKVGDNFY-TUJWMRSMSA-N
Ivermectin	ivermectin	BRD-K85554912-001-06-3	PREP030	benzodiazepine receptor agonist	"CHRNA7, GABRB3, GLRA3, P2RX7"	infectious disease	"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies"	"CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2"	Launched	Ivermectin	71749648	AZSNMRSAGSSBNP-NDJJZKGWSA-N
Ixabepilone	ixabepilone	BRD-K03601870-001-01-2	PREP015	microtubule stabilizing agent	"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8"	oncology	breast cancer	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Launched	Ixabepilone	6445540	FABUFPQFXZVHFB-PVYNADRNSA-N
Ixazomib	ixazomib	BRD-K78659596-001-03-9	PREP038	proteasome inhibitor	NA	hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	Launched	Ixazomib	25183872	MXAYKZJJDUDWDS-LBPRGKRZSA-N
Ixazomib-citrate	ixazomib-citrate	BRD-A66419424-001-02-4	PREP046	proteasome inhibitor	NA	hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O	Launched	Ixazomib-citrate	69040311	YTXSYWAKVMZICI-VBKZILBWSA-N
JIB04	JIB04	BRD-K76180386-001-01-6	PREP036	histone lysine demethylase inhibitor	KDM4E	NA	NA	"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1"	Preclinical	JIB04	5825881	YHHFKWKMXWRVTJ-XLNRJJMWSA-N
JK-184	JK-184	BRD-K38860038-001-01-2	PREP041	hedgehog pathway inhibitor	NA	NA	NA	"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1"	Preclinical	JK-184	102041119	NFNSIXSJBWNFOO-KZMWYPEZSA-N
JNJ-16259685	JNJ-16259685	BRD-K25596805-001-01-8	PREP042	glutamate receptor antagonist	GRM1	NA	NA	"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1"	Preclinical	JNJ-16259685	11313361	QOTAQTRFJWLFCR-UHFFFAOYSA-N
Quisinostat	JNJ-26481585	BRD-K83837640-001-04-8	PREP025	HDAC inhibitor	"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2"	NA	NA	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	Phase 2	Quisinostat	11538455	PAWIYAYFNXQGAP-UHFFFAOYSA-N
JNJ-7706621	JNJ-7706621	BRD-K11636097-001-03-1	PREP042	CDK inhibitor	"AURKA, AURKB, CDK1, CDK2"	NA	NA	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	Preclinical	JNJ-7706621	5330790	NA
Josamycin	josamycin	BRD-K25837718-001-03-8	PREP017	bacterial 50S ribosomal subunit inhibitor	NA	pulmonary	bronchitis	CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O	Launched	Josamycin	5282165	XJSFLOJWULLJQS-NGVXBBESSA-N
JQ1-(+)	JQ1-(+)	BRD-K54606188-001-13-1	PREP043	bromodomain inhibitor	"BRD4, BRDT"	NA	NA	"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1"	Preclinical	JQ1-(+)	46907787	DNVXATUJJDPFDM-KRWDZBQOSA-N
Jtc-801	JTC-801	BRD-K17705806-003-04-4	PREP047	opioid receptor antagonist	OPRL1	NA	NA	"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1"	Phase 2	Jtc-801	5311339	NQLIYKXNAXKMBL-UHFFFAOYSA-N
JTE-607	JTE-607	BRD-K81405859-300-01-4	PMTS010	cytokine production inhibitor	"IL10, IL1B, IL6, TNF"	NA	NA	"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O"	Phase 2	JTE-607	9938544	JUJAUEQJEWIWCQ-FJSYBICCSA-N
JZL-184	JZL-184	BRD-K45446451-001-05-0	PREP040	monoacylglucerol lipase inhibitor	MGLL	NA	NA	"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1"	Preclinical	JZL-184	25021165	SEGYOKHGGFKMCX-UHFFFAOYSA-N
K-858	K-858	BRD-A67748489-001-10-0	PREP042	kinesin-like spindle protein inhibitor	KIF11	NA	NA	CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1	Preclinical	K-858	2930014	JEFVYQYZCAVNTP-UHFFFAOYSA-N
K-Ras(G12C)-inhibitor-6	K-Ras(G12C)-inhibitor-6	BRD-K26305185-001-02-1	PREP043	K-ras inhibitor	NA	NA	NA	"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl"	Preclinical	K-Ras(G12C)-inhibitor-6	71815954	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N
Strophanthidin	k-strophanthidin	BRD-A55312468-001-04-7	PREP025	ATPase inhibitor	ATP1A1	NA	NA	C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1	Phase 2	Strophanthidin	6185	ODJLBQGVINUMMR-HZXDTFASSA-N
5-(Tetradecyloxy)-2-furoic acid	KD-023	BRD-K71164191-001-01-0	PREP027	ACAT inhibitor	"ACACA, ACACB"	NA	NA	CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	Phase 2	5-(Tetradecyloxy)-2-furoic acid	115175	CZRCFAOMWRAFIC-UHFFFAOYSA-N
KD025	KD025	BRD-K88506063-001-01-8	PREP027	rho associated kinase inhibitor	ROCK2	NA	NA	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Phase 2	KD025	11950170	GKHIVNAUVKXIIY-UHFFFAOYSA-N
Kenpaullone	kenpaullone	BRD-K37312348-001-15-0	PREP047	"CDK inhibitor, glycogen synthase kinase inhibitor"	"CCNB1, CDK1, CDK5, GSK3B"	NA	NA	"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1"	Preclinical	Kenpaullone	3820	QQUXFYAWXPMDOE-UHFFFAOYSA-N
Xolegel	ketoconazole	BRD-A38350138-001-04-9	PREP023	sterol demethylase inhibitor	"AR, CYP19A1, CYP21A2, KCNA10"	dermatology	seborrheic dermatitis	"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1"	Launched	Xolegel	47576	XMAYWYJOQHXEEK-OZXSUGGESA-N
Ketoprofen	ketoprofen	BRD-A97739905-001-26-5	PREP029	cyclooxygenase inhibitor	"CXCR1, PTGS1, PTGS2, SLC5A8"	rheumatology	"rheumatoid arthritis, osteoarthritis"	"CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1"	Launched	Ketoprofen	3825	DKYWVDODHFEZIM-UHFFFAOYSA-N
KF-38789	KF-38789	BRD-A54927599-001-16-9	PREP047	P selectin inhibitor	SELP	NA	NA	"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1"	Preclinical	KF-38789	135400439	NHFIAAAMCYVRIW-UHFFFAOYSA-N
KI-16425	KI-16425	BRD-A25569250-001-03-3	PREP043	lysophosphatidic acid receptor antagonist	"LPAR1, LPAR3"	NA	NA	CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl	Preclinical	KI-16425	10367662	LLIFMNUXGDHTRO-UHFFFAOYSA-N
Ki8751	KI-8751	BRD-K47150025-001-05-3	PREP015	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	KDR	NA	NA	"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC"	Preclinical	Ki8751	11317348	NA
Kifunensine	kifunensine	BRD-K02898090-001-02-7	PREP045	mannosidase inhibitor	"MAN1B1, MAN2A1"	NA	NA	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	Phase 1	Kifunensine	130611	OIURYJWYVIAOCW-PQMKYFCFSA-N
"2'-Deoxy-5,6-dihydro-5-azacytidine"	KP-1212	BRD-K46690591-001-01-2	PREP025	NA	NA	NA	NA	NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 2	"2'-Deoxy-5,6-dihydro-5-azacytidine"	9859433	LAOLDMMWVYDDID-KVQBGUIXSA-N
KPT185	KPT-185	BRD-K71467466-001-02-3	PREP047	exportin antagonist	XPO1	NA	NA	COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	Preclinical	KPT185	53495165	NA
KPT-276	KPT-276	BRD-K75352575-001-01-3	PREP036	exportin antagonist	XPO1	NA	NA	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1	Preclinical	KPT-276	71496742	JCHAWRDHMUSLMM-UPHRSURJSA-N
Ku-0063794	ku-0063794	BRD-K67566344-001-07-5	PREP037	mTOR inhibitor	MTOR	NA	NA	"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1"	Preclinical	Ku-0063794	16736978	NA
KW-2449	KW-2449	BRD-K21718444-001-06-8	PREP047	"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor"	"ABL1, AURKA, AURKB, FLT3"	NA	NA	O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12	Phase 1	KW-2449	11427553	NA
KW-2478 free base	KW-2478	BRD-K41213548-001-02-0	PREP039	HSP inhibitor	NA	NA	NA	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	Phase 1/Phase 2	KW-2478 free base	23116322	VFUXSYAXEKYYMB-UHFFFAOYSA-N
KX2-391	KX2-391	BRD-K29968218-001-03-2	PREP026	"src inhibitor, tubulin polymerization inhibitor"	SRC	NA	NA	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	Phase 2	KX2-391	23635314	NA
KY02111	KY02111	BRD-K13302470-001-02-7	PREP041	Wnt pathway inhibitor	DKK1	NA	NA	"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC"	Preclinical	KY02111	8582409	LXFKEVQQSKQXPR-UHFFFAOYSA-N
Kynurenic acid	kynurenic-acid	BRD-K85872723-001-15-9	PREP042	glutamate receptor antagonist	"GPR35, GRIN1, GRIN2A, GRIN2B"	NA	NA	"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1"	Preclinical	Kynurenic acid	3845	HCZHHEIFKROPDY-UHFFFAOYSA-N
"L-798,106"	"L-798,106"	BRD-K43905307-001-01-2	PREP041	prostanoid receptor antagonist	PTGER3	NA	NA	"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1"	Preclinical	"L-798,106"	15551229	ODTKFNUPVBULRJ-NTCAYCPXSA-N
Lactitol	lacitol	BRD-K40787673-001-02-1	PREP022	osmosis stimulant	NA	gastroenterology	constipation	"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO"	Launched	Lactitol	157355	VQHSOMBJVWLPSR-JVCRWLNRSA-N
Lafutidine	lafutidine	BRD-A67516570-001-02-8	PREP030	histamine receptor antagonist	HRH2	gastroenterology	"duodenal ulcer disease, peptic ulcer disease (PUD)"	O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1	Launched	Lafutidine	5282136	KMZQAVXSMUKBPD-DJWKRKHSSA-N
Lanatoside C	lanatoside-c	BRD-A64242993-001-05-6	PREP015	cardiac glycoside	NA	NA	NA	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	Preclinical	Lanatoside C	656630	JAYAGJDXJIDEKI-PTGWOZRBSA-N
Lanoconazole	lanoconazole	BRD-A54275602-001-01-0	PREP023	sterol demethylase inhibitor	NA	infectious disease	fungal infection	Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1	Launched	Lanoconazole	3002820	ZRTQSJFIDWNVJW-WYMLVPIESA-N
Lapatinib	lapatinib	BRD-K19687926-379-07-4///BRD-K19687926-001-04-1	PREP030///PROS004_PR500	EGFR inhibitor	"EGFR, ERBB2"	oncology	breast cancer	"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1"	Launched	Lapatinib	208908	BCFGMOOMADDAQU-UHFFFAOYSA-N
Lappaconitine	lappaconite	BRD-A05906449-004-01-1	PREP039	sodium channel blocker	NA	NA	NA	CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O	Phase 2	Lappaconitine	90479327	NWBWCXBPKTTZNQ-QOQRDJBUSA-N
Lasalocid	lasalocid	BRD-A72711497-236-03-8	PREP016	bacterial permeability inducer	NA	infectious disease	coccidiosis	CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	Launched	Lasalocid	5360807	BBMULGJBVDDDNI-OWKLGTHSSA-N
Latanoprost	latanoprost	BRD-K10961822-001-05-1	PREP029	prostanoid receptor agonist	PTGFR	ophthalmology	"ocular hypertension, glaucoma"	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	Launched	Latanoprost	5311221	GGXICVAJURFBLW-CEYXHVGTSA-N
Latrepirdine	latrepirdine	BRD-K55703048-001-07-7	PREP025	glutamate receptor antagonist	"HRH1, HTR6"	NA	NA	"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1"	Phase 3	Latrepirdine	197033	JNODQFNWMXFMEV-UHFFFAOYSA-N
LB42708	LB42708	BRD-K18834913-001-01-1	PREP040	farnesyltransferase inhibitor	NA	NA	NA	"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1"	Preclinical	LB42708	10099206	GUUIRIMAQGOLHT-UHFFFAOYSA-N
LCL161	LCL-161	BRD-K08248804-001-01-8	PREP046	XIAP inhibitor	"BIRC2, XIAP"	NA	NA	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	Phase 2	LCL161	24737642	UFPFGVNKHCLJJO-SSKFGXFMSA-N
LDN-212854	LDN-212854	BRD-K59831625-001-01-6	PREP040	bone morphogenic protein inhibitor	"ABL1, ACVR1, RIPK2"	NA	NA	"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12"	Preclinical	LDN-212854	60182388	BBDGBGOVJPEFBT-UHFFFAOYSA-N
LDN-57444	LDN-57444	BRD-K94485812-001-02-9	PREP014	ubiquitin C-terminal hydrolase inhibitor	NA	NA	NA	"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12"	Preclinical	LDN-57444	16760696	OPQRFPHLZZPCCH-PGMHBOJBSA-N
LE-135	LE-135	BRD-K06593056-001-04-8	PREP036	retinoid receptor agonist	RARB	NA	NA	"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C"	Preclinical	LE-135	10410894	YZZAIQOVMHVWBS-UHFFFAOYSA-N
Lenalidomide	lenalidomide	BRD-A17883755-001-06-1	PREP030	anticancer agent	"CDH5, CRBN, PTGS2, TNF, TNFSF11"	hematologic malignancy	"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)"	Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O	Launched	Lenalidomide	216326	GOTYRUGSSMKFNF-UHFFFAOYSA-N
Lenvatinib	lenvatinib	BRD-K39974922-001-04-3	PROS003_PR500	"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"FLT4, KDR"	oncology	thyroid cancer	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	Launched	Lenvatinib	9823820	NA
Lerisetron	lerisetron	BRD-K62398570-300-01-2	PREP019	serotonin receptor antagonist	HTR3A	NA	NA	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	Phase 3	Lerisetron	65997	PWWDCRQZITYKDV-UHFFFAOYSA-N
Lestaurtinib	lestaurtinib	BRD-A27376179-001-01-3	PREP044	"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor"	"FLT3, NTRK1"	NA	NA	C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13	Phase 3	Lestaurtinib	126565	NA
Letrozole	letrozole	BRD-K88789588-001-14-9	PREP031	aromatase inhibitor	CYP19A1	oncology	breast cancer	"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1"	Launched	Letrozole	3902	HPJKCIUCZWXJDR-UHFFFAOYSA-N
Leucovorin	leucovorin	BRD-A75919782-399-02-6	PREP020	folate receptor ligand	TYMS	oncology	osteosarcoma	"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1"	Launched	Leucovorin	135403648	VVIAGPKUTFNRDU-ABLWVSNPSA-N
Levobunolol	levobunolol	BRD-K31812033-003-11-0	PREP028	adrenergic receptor antagonist	"ADRB1, ADRB2, ADRB3"	ophthalmology	"glaucoma, ocular hypertension"	"CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12"	Launched	Levobunolol	39468	IXHBTMCLRNMKHZ-LBPRGKRZSA-N
Levocarnitine	levocarnitine	BRD-K59647213-001-10-5	PREP020	NA	NA	endocrinology	carnitine deficiency	"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O"	Launched	Levocarnitine	10917	PHIQHXFUZVPYII-ZCFIWIBFSA-N
Levocetirizine	levocetirizine	BRD-K27184429-300-01-3	PREP030	histamine receptor antagonist	HRH1	allergy	"allergic rhinitis, urticaria"	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	Launched	Levocetirizine	1549000	ZKLPARSLTMPFCP-OAQYLSRUSA-N
Levonorgestrel	levonorgestrel///norgestrel	BRD-K35189033-001-26-1///BRD-A14886633-001-01-6	PREP023///PREP029	"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist///progesterone receptor agonist"	"AR, ESR1, PGR, SRD5A1///PGR"	endocrinology	contraceptive	"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C///CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C"	Launched	Levonorgestrel	13109	WWYNJERNGUHSAO-XUDSTZEESA-N
Encorafenib	LGX818	BRD-A56085258-001-01-8	PREP027	RAF inhibitor	BRAF	NA	NA	COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	Phase 3	Encorafenib	50922675	CMJCXYNUCSMDBY-ZDUSSCGKSA-N
Licochalcone a	licochalcone-a	BRD-K26011976-001-01-0	PREP032	topoisomerase inhibitor	PTPN1	NA	NA	COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C	Phase 3	Licochalcone a	5318998	KAZSKMJFUPEHHW-DHZHZOJOSA-N
Lidamidine	lidamidine	BRD-K68693535-001-03-4	PREP023	adrenergic receptor agonist	NA	gastroenterology	diarrhea	CNC(=N)NC(=O)Nc1c(C)cccc1C	Launched	Lidamidine	47510	RRHJHSBDJDZUGL-UHFFFAOYSA-N
Lidocaine	lidocaine	BRD-K52662033-003-21-2	PREP031	histamine receptor agonist	"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A"	"neurology/psychiatry, dermatology, hematology"	"itching, eczema, hemorrhage"	"CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C"	Launched	Lidocaine	3676	NNJVILVZKWQKPM-UHFFFAOYSA-N
Linalool	linalool	BRD-A43082461-001-06-3	PREP048	anticonvulsant	NA	NA	NA	CC(C)=CCCC(C)(O)C=C	Phase 1	Linalool	6549	CDOSHBSSFJOMGT-UHFFFAOYSA-N
Linifanib	linifanib	BRD-K99749624-001-07-0	PROS001_PR500	"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK"	NA	NA	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1	Phase 3	Linifanib	11485656	NA
Linsitinib	linsitinib	BRD-K86118762-001-01-8	PROS002_PR500	IGF-1 inhibitor	"IGF1R, INSR, INSRR"	NA	NA	"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12"	Phase 3	Linsitinib	11640390	PKCDDUHJAFVJJB-UHFFFAOYSA-N
Litronesib	litronesib	BRD-K83029223-001-01-3	PROS005_PR500	kinesin-like spindle protein inhibitor	KIF11	NA	NA	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1	Phase 2	Litronesib	25167017	YVAFBXLHPINSIK-QHCPKHFHSA-N
Lomefloxacin	lomefloxacin	BRD-A75850590-213-01-0	PREP025	bacterial DNA gyrase inhibitor	TOP2A	infectious disease	"respiratory tract infections, urinary tract infections"	"CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12"	Launched	Lomefloxacin	3948	ZEKZLJVOYLTDKK-UHFFFAOYSA-N
Lomitapide	lomitapide	BRD-K92213669-001-01-3	PREP029	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	Launched	Lomitapide	9853053	MBBCVAKAJPKAKM-UHFFFAOYSA-N
Lonafarnib	lonafarnib	BRD-K41599323-001-02-3	PREP027	farnesyltransferase inhibitor	"FNTA, HRAS, KRAS, NRAS"	NA	NA	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	Phase 3	Lonafarnib	148195	DHMTURDWPRKSOA-RUZDIDTESA-N
Lorazepam	lorazepam	BRD-A11990600-001-03-4	PREP034	benzodiazepine receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO"	neurology/psychiatry	status epilepticus	OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O	Launched	Lorazepam	3958	DIWRORZWFLOCLC-UHFFFAOYSA-N
Lorlatinib	lorlatinib	BRD-K99879819-001-02-1	PMTS010	ALK tyrosine kinase receptor inhibitor	ALK	NA	NA	"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N"	Phase 2	Lorlatinib	71731823	IIXWYSCJSQVBQM-LLVKDONJSA-N
Lovastatin	lovastatin	BRD-K09416995-001-39-9	PREP022	HMGCR inhibitor	"HDAC2, HMGCR, ITGAL, NR1I2"	"cardiology, endocrinology"	"coronary heart disease, myocardial infarction, hypercholesterolemia"	"CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12"	Launched	Lovastatin	53232	PCZOHLXUXFIOCF-BXMDZJJMSA-N
N-(N-(3-Carboxyoxirane-2-carbonyl)leucyl)isoamylamine	loxistatin-acid	BRD-K21937671-001-09-2	PREP029	cysteine peptidase inhibitor	CTSB	NA	NA	"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O"	Preclinical	N-(N-(3-Carboxyoxirane-2-carbonyl)leucyl)isoamylamine	123664	SCMSYZJDIQPSDI-SRVKXCTJSA-N
Lucitanib	lucitanib	BRD-K31309378-001-01-5	PREP045	"FGFR inhibitor, VEGFR inhibitor"	"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET"	NA	NA	CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12	Phase 2	Lucitanib	25031915	CUDVHEFYRIWYQD-UHFFFAOYSA-N
Lurasidone	lurasidone	BRD-K51143828-003-03-1	PREP033	"dopamine receptor antagonist, serotonin receptor antagonist"	"ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7"	neurology/psychiatry	schizophrenia	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	Launched	Lurasidone	213046	PQXKDMSYBGKCJA-CVTJIBDQSA-N
LY-2090314	LY2090314	BRD-K78055238-001-01-8	PREP039	glycogen synthase kinase inhibitor	GSK3B	NA	NA	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1	Phase 2	LY-2090314	10029385	HRJWTAWVFDCTGO-UHFFFAOYSA-N
LY2109761	LY2109761	BRD-K47557313-001-02-7	PREP033	TGF beta receptor inhibitor	"TGFBR1, TGFBR2"	NA	NA	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1	Preclinical	LY2109761	11655119	IHLVSLOZUHKNMQ-UHFFFAOYSA-N
LY-2183240	LY2183240	BRD-K37865504-001-04-1	PREP037	"FAAH inhibitor, FAAH reuptake inhibitor"	FAAH	NA	NA	"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1"	Preclinical	LY-2183240	11507802	GZNIYOXWFCDBBJ-UHFFFAOYSA-N
LY2334737	LY2334737	BRD-K04993719-001-01-7	PREP019	"antitumor agent, ribonucleotide reductase inhibitor"	NA	NA	NA	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Phase 1	LY2334737	11646777	MEOYFIHNRBNEPI-UXIGCNINSA-N
Rabusertib	LY2603618	BRD-K14109347-001-03-4	PROS004_PR500	CHK inhibitor	CHEK1	NA	NA	"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1"	Phase 2	Rabusertib	11955855	SYYBDNPGDKKJDU-ZDUSSCGKSA-N
Prexasertib	LY2606368	BRD-K20463415-300-01-4	PMTS010	CHK inhibitor	CHEK1	NA	NA	"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1"	Phase 2	Prexasertib	46700756	DOTGPNHGTYJDEP-UHFFFAOYSA-N
LY2608204	LY2608204	BRD-K12068470-001-02-5	PREP033	glucokinase activator	GCK	NA	NA	"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1"	Phase 2	LY2608204	46832368	QIIVJLHCZUTGSD-CUBQBAPOSA-N
Gandotinib	LY2784544	BRD-K25630527-001-03-8	PREP027	JAK inhibitor	"JAK2, JAK3"	NA	NA	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	Phase 2	Gandotinib	46213929	SQSZANZGUXWJEA-UHFFFAOYSA-N
Merestinib	LY2801653	BRD-K18961567-001-01-1	PROS002_PR500	MET inhibitor	MET	NA	NA	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	Phase 2	Merestinib	44603533	QHADVLVFMKEIIP-UHFFFAOYSA-N
LY-2874455	LY2874455	BRD-K17203476-001-01-9	PREP046	FGFR antagonist	"FGFR1, FGFR2, FGFR3, FGFR4, KDR"	NA	NA	C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	Phase 1	LY-2874455	46944259	GKJCVYLDJWTWQU-CXLRFSCWSA-N
Samotolisib	LY3023414	BRD-K82967180-001-01-6	PMTS010	"PI3K inhibitor, mTOR inhibitor"	MTOR	NA	NA	CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	Phase 2	Samotolisib	57519748	ACCFLVVUVBJNGT-AWEZNQCLSA-N
2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one	LY303511	BRD-K22385716-001-02-5	PREP036	"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor"	"BRD2, BRD3, BRD4"	NA	NA	"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1"	Preclinical	2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one	3971	NGAGMBNBKCDCDJ-UHFFFAOYSA-N
4-(3-Pyridin-2-YL-1H-pyrazol-4-YL)quinoline	LY364947	BRD-K06234293-001-04-2	PREP041	"TGF beta receptor inhibitor, p38 MAPK inhibitor"	TGFBR1	NA	NA	"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1"	Preclinical	4-(3-Pyridin-2-YL-1H-pyrazol-4-YL)quinoline	447966	IBCXZJCWDGCXQT-UHFFFAOYSA-N
6-Methoxy-N-(4-methoxyphenyl)quinazolin-4-amine	LY456236	BRD-K87696786-003-04-4	PREP036	glutamate receptor antagonist	GRM1	NA	NA	"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1"	Preclinical	6-Methoxy-N-(4-methoxyphenyl)quinazolin-4-amine	9926999	XPJOMFBGKIABQW-UHFFFAOYSA-N
m344	M-344	BRD-K45528773-001-07-2	PREP040	HDAC inhibitor	NA	NA	NA	"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO"	Preclinical	m344	3994	MXWDSZWTBOCWBK-UHFFFAOYSA-N
Maprotiline	maprotiline	BRD-K25433859-003-25-4	PREP029	"norepinephrine reputake inhibitor, tricyclic antidepressant"	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2"	neurology/psychiatry	"depression, dysthymic disorder"	"CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21"	Launched	Maprotiline	4011	QSLMDECMDJKHMQ-UHFFFAOYSA-N
Marimastat	marimastat	BRD-K21396683-001-04-8	PREP027	matrix metalloprotease inhibitor	"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9"	NA	NA	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	Phase 3	Marimastat	119031	OCSMOTCMPXTDND-OUAUKWLOSA-N
Masitinib	masitinib	BRD-K71035033-001-07-1	PREP014	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor"	"FGFR3, KIT, PDGFRA, PDGFRB"	dermatology	mastocytoma	"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1"	Launched	Masitinib	10074640	NA
Maxacalcitol	maxacalcitol	BRD-K81332461-001-01-4	PREP033	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H]	Launched	Maxacalcitol	6398761	DTXXSJZBSTYZKE-ZDQKKZTESA-N
Maytansinol isobutyrate	maytansinol-isobutyrate	BRD-K15898725-001-01-7	PREP036	NA	NA	NA	NA	CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2	Preclinical	Maytansinol isobutyrate	54604529	OPQNCARIZFLNLF-VYRZMWHGSA-N
Mebendazole	mebendazole	BRD-K77987382-001-13-2	PREP023	tubulin polymerization inhibitor	"TUBA1A, TUBB, TUBB4B"	infectious disease	"pinworm, whipworm, hookworm, ascariasis"	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	Launched	Mebendazole	4030	OPXLLQIJSORQAM-UHFFFAOYSA-N
Mechlorethamine HCl (nitrogen mustard)	mechlorethamine	BRD-K12829205-003-02-8	PREP048	DNA inhibitor	NA	"hematologic malignancy, hematology, infectious disease, oncology"	"Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma"	"CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl"	Launched	Mechlorethamine HCl (nitrogen mustard)	5935	QZIQJVCYUQZDIR-UHFFFAOYSA-N
Meclizine	meclizine	BRD-A50311610-300-10-4	PREP021	constitutive androstane receptor (CAR) agonist	"HRH1, NR1I3"	"gastroenterology, neurology/psychiatry"	"nausea, vomiting, motion sickness"	"Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1"	Launched	Meclizine	4034	OCJYIGYOJCODJL-UHFFFAOYSA-N
Mefexamide	mefexamide	BRD-K20655524-003-12-0	PREP015	psychoactive drug	NA	NA	NA	CCN(CC)CCNC(=O)COc1ccc(OC)cc1	Preclinical	Mefexamide	4045	HUNIPYLVUPMFCZ-UHFFFAOYSA-N
Meglitinide	meglitinide	BRD-K51324732-001-01-0	PREP018	potassium channel blocker	CCR2	NA	NA	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	Phase 2	Meglitinide	41214	SWLAMJPTOQZTAE-UHFFFAOYSA-N
MEK1-2-inhibitor	MEK1-2-inhibitor	BRD-K12244279-001-05-8	PREP040	MEK inhibitor	MAP2K2	NA	NA	"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F"	Preclinical	MEK1-2-inhibitor	54483521	XQRVCODIGHFXKQ-UHFFFAOYSA-N
Binimetinib	MEK162	BRD-K82244583-001-01-3	PREP046	MEK inhibitor	"MAP2K1, MAP2K2"	NA	NA	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	Phase 3	Binimetinib	10288191	ACWZRVQXLIRSDF-UHFFFAOYSA-N
Melengestrol-acetate	melengestrol-acetate	BRD-A42746051-001-02-9	PREP033	progesterone receptor agonist	NA	NA	NA	CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Preclinical	Melengestrol-acetate	26604442	UDKABVSQKJNZBH-AKZSSJSASA-N
Meloxicam	meloxicam	BRD-A84174393-236-07-1	PREP035	cyclooxygenase inhibitor	"PTGS1, PTGS2"	rheumatology	"osteoarthritis, rheumatoid arthritis"	"CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O"	Launched	Meloxicam	54677470	ZRVUJXDFFKFLMG-UHFFFAOYSA-N
Melphalan	melphalan	BRD-K87827419-001-16-8	PREP017	"DNA alkylating agent, DNA inhibitor"	NA	hematologic malignancy	multiple myeloma	"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O"	Launched	Melphalan	460612	SGDBTWWWUNNDEQ-LBPRGKRZSA-N
Menadione	menadione	BRD-K78126613-001-28-5	PREP028	"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor"	"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1"	"gastroenterology, neurology/psychiatry, dermatology, rheumatology"	"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis"	"CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O"	Launched	Menadione	4055	MJVAVZPDRWSRRC-UHFFFAOYSA-N
Mephenytoin	mephenytoin	BRD-A83937277-001-10-5	PREP020	hydantoin antiepileptic	"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A"	neurology/psychiatry	seizures	CCC1(NC(=O)N(C)C1=O)c1ccccc1	Launched	Mephenytoin	4060	GMHKMTDVRCWUDX-UHFFFAOYSA-N
Mepivacaine	mepivacaine	BRD-A03216249-003-24-3	PREP016	"potassium channel blocker, sodium channel blocker"	SCN10A	neurology/psychiatry	local anesthetic	"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C"	Launched	Mepivacaine	4062	INWLQCZOYSRPNW-UHFFFAOYSA-N
7H-Purine-6-thiol	mercaptopurine	BRD-K91601245-001-12-0	PREP017	"immunosuppressant, protein synthesis inhibitor, purine antagonist"	"HPRT1, IMPDH1, IMPDH2, PPAT"	hematologic malignancy	acute lymphoblastic leukemia (ALL)	"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12"	Launched	7H-Purine-6-thiol	667490	GLVAUDGFNGKCSF-UHFFFAOYSA-N
Mericitabine	mericitabine	BRD-K69726595-001-01-2	PREP026	HCV inhibitor	NA	NA	NA	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	Phase 2	Mericitabine	16122663	MLESJYFEMSJZLZ-MAAOGQSESA-N
Merimepodib	merimepodib	BRD-K09372874-001-01-0	PREP046	inosine monophosphate dehydrogenase inhibitor	IMPDH1	NA	NA	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	Phase 2	Merimepodib	153241	JBPUGFODGPKTDW-SFHVURJKSA-N
Mesna	mesna	BRD-K49954789-001-02-9	PREP034	antioxidant	NA	urology	hemorrhagic cystitis	"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS"	Launched	Mesna	23662354	XOGTZOOQQBDUSI-UHFFFAOYSA-M
Mesoridazine	mesoridazine	BRD-A14395271-074-17-8	PREP016	dopamine receptor antagonist	"DRD2, HTR2A"	neurology/psychiatry	schizophrenia	"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O"	Launched	Mesoridazine	4078	SLVMESMUVMCQIY-UHFFFAOYSA-N
Metaraminol	metaraminol	BRD-K96253961-046-03-1	PREP034	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1"	Launched	Metaraminol	5906	WXFIGDLSSYIKKV-RCOVLWMOSA-N
metatinib	metatinib	BRD-K27182532-001-02-3	PREP032	Bcr-Abl kinase inhibitor	"ABL1, BCR"	NA	NA	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	metatinib	44155856	PDYXPCKITKHFOZ-UHFFFAOYSA-N
Methacycline	methacycline	BRD-A49035384-003-28-9	PREP031	protein synthesis inhibitor	NA	pulmonary	bronchitis	"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O"	Launched	Methacycline	54675785	MHIGBKBJSQVXNH-IWVLMIASSA-N
Methiazole	methiazole	BRD-K02764365-001-13-6	PREP047	anthelmintic agent	NA	NA	NA	COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1	Preclinical	Methiazole	6604471	SXJIZQPZESTWLD-UHFFFAOYSA-N
Methocarbamol	methocarbamol	BRD-A31521121-001-26-4	PREP023	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O"	Launched	Methocarbamol	4107	GNXFOGHNGIVQEH-UHFFFAOYSA-N
Methotrexate	methotrexate	BRD-A55424491-001-19-9	PREP023	dihydrofolate reductase inhibitor	DHFR	"oncology, hematologic malignancy, dermatology, rheumatology"	"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis"	"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O"	Launched	Methotrexate	126941	FBOZXECLQNJBKD-ZDUSSCGKSA-N
Methoxyflurane	methoxyflurane	BRD-K06152156-001-01-8	PREP048	membrane permeability inhibitor	"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1"	neurology/psychiatry	general anaesthetic	"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl"	Launched	Methoxyflurane	4116	RFKMCNOHBTXSMU-UHFFFAOYSA-N
Methscopolamine	methscopolamine	BRD-A03932035-004-04-3	PREP029	acetylcholine receptor antagonist	"CHRM1, CHRM2, CHRM3"	gastroenterology	peptic ulcer disease (PUD)	"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1"	Launched	Methscopolamine	71183	LZCOQTDXKCNBEE-XJMZPCNVSA-N
Methyldopa	methyldopa	BRD-K48578705-001-17-6	PREP033	adrenergic receptor agonist	"ADRA2A, ADRA2B, ADRA2C, DDC"	cardiology	hypertension	"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O"	Launched	Methyldopa	38853	CJCSPKMFHVPWAR-JTQLQIEISA-N
Methylphenidate	methylphenidate	BRD-A19585813-003-03-3	PREP014	dopamine-norepinephrine reuptake inhibitor	"SLC6A2, SLC6A3, SLC6A4"	neurology/psychiatry	"attention-deficit/hyperactivity disorder (ADHD), narcolepsy"	COC(=O)C(C1CCCCN1)c1ccccc1	Launched	Methylphenidate	4158	DUGOZIWVEXMGBE-UHFFFAOYSA-N
Methylprednisolone	methylprednisolone	BRD-K35240538-001-26-2	PREP021	glucocorticoid receptor agonist	NR3C1	"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology"	"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis"	"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12"	Launched	Methylprednisolone	6741	VHRSUDSXCMQTMA-PJHHCJLFSA-N
Metoprolol	metoprolol	BRD-A03623303-045-09-5	PREP017	adrenergic receptor antagonist	"ADRB1, ADRB2"	cardiology	"hypertension, angina pectoris, myocardial infarction"	"COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1"	Launched	Metoprolol	4171	IUBSYMUCCVWXPE-UHFFFAOYSA-N
Metoxibutropate	metoxibutropate	BRD-A71725768-001-01-3	PREP014	cyclooxygenase inhibitor	"PTGS1, PTGS2"	NA	NA	COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1	Launched	Metoxibutropate	4464271	FVRWRGBTEHAPDI-UHFFFAOYSA-N
Metronidazole	metronidazole	BRD-K52020312-001-26-8	PREP031	DNA inhibitor	"CYP2C9, CYP3A4"	dermatology	rosacea	"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O"	Launched	Metronidazole	4173	VAOCPAMSLUNLGC-UHFFFAOYSA-N
Metyrapone	metyrapone	BRD-K46862739-001-14-3	PMTS010	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1"	Launched	Metyrapone	4174	FJLBFSROUSIWMA-UHFFFAOYSA-N
Mevastatin	mevastatin	BRD-K94441233-001-13-0	PREP034	HMGCR inhibitor	HMGCR	NA	NA	"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12"	Preclinical	Mevastatin	64715	AJLFOPYRIVGYMJ-INTXDZFKSA-N
Mexenone	mexeneone	BRD-K18613660-001-05-5	PREP036	NA	NA	NA	NA	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	Preclinical	Mexenone	71645	MJVGBKJNTFCUJM-UHFFFAOYSA-N
Mexiletine	mexiletine	BRD-A64092382-003-18-3	PREP048	sodium channel blocker	"AHR, SCN4A, SCN5A"	cardiology	"ventricular arrhythmias, ventricular tachycardia (VT)"	"CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C"	Launched	Mexiletine	4178	VLPIATFUUWWMKC-UHFFFAOYSA-N
Z-Leu-leu-leu-al	MG-132	BRD-K60230970-001-17-5	PREP041	proteasome inhibitor	PSMB1	NA	NA	"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O"	Preclinical	Z-Leu-leu-leu-al	462382	TZYWCYJVHRLUCT-VABKMULXSA-N
MGCD-265 analog	MGCD-265	BRD-K56277358-001-07-5	PREP040	VEGFR inhibitor	"AXL, MET"	NA	NA	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	Preclinical	MGCD-265 analog	24901704	NA
Mibampator	mibampator	BRD-K42981054-001-01-9	PREP044	glutamate receptor modulator	GRIA1	NA	NA	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	Phase 2	Mibampator	9889366	ULRDYYKSPCRXAJ-KRWDZBQOSA-N
Mibefradil	mibefradil	BRD-K09549677-300-03-4	PREP028	T-type calcium channel blocker	"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4"	NA	NA	"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C"	Withdrawn	Mibefradil	60663	HBNPJJILLOYFJU-VMPREFPWSA-N
Midodrine	midodrine	BRD-A79981887-003-16-4	PREP029	adrenergic receptor agonist	"ADRA1A, ADRA1B, ADRA1D"	cardiology	hypotension	COc1ccc(OC)c(c1)C(O)CNC(=O)CN	Launched	Midodrine	4195	PTKSEFOSCHHMPD-UHFFFAOYSA-N
Midostaurin	midostaurin	BRD-K13646352-001-03-8	PREP018	"FLT3 inhibitor, KIT inhibitor, PKC inhibitor"	"FLT3, PRKCG"	hematologic malignancy	acute myeloid leukemia (AML)	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	Launched	Midostaurin	24202429	BMGQWWVMWDBQGC-PZFYLCKJSA-N
Mifepristone	mifepristone	BRD-K37270826-001-27-6	PREP031	"glucocorticoid receptor antagonist, progesterone receptor antagonist"	"AR, NR1I2, NR3C1, PGR"	endocrinology	"hyperglycemia, diabetes mellitus"	"CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C"	Launched	Mifepristone	55245	VKHAHZOOUSRJNA-GCNJZUOMSA-N
Minocycline	minocycline	BRD-A69651145-003-07-2	PREP021	bacterial 30S ribosomal subunit inhibitor	"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA"	"endocrinology, infectious disease, ophthalmology, urology"	"fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis"	"CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C"	Launched	Minocycline	54675783	FFTVPQUHLQBXQZ-KVUCHLLUSA-N
Mitomycin	mitomycin-c	BRD-A48237631-001-04-8	PREP029	"DNA alkylating agent, DNA synthesis inhibitor"	NA	oncology	"pancreatic cancer, gastric adenocarcinoma"	CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O	Launched	Mitomycin	5746	NWIBSHFKIJFRCO-WUDYKRTCSA-N
Mitoxantrone	mitoxantrone	BRD-K21680192-300-14-4	PREP021	topoisomerase inhibitor	TOP2A	"neurology/psychiatry, oncology, hematologic malignancy"	"multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)"	"OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12"	Launched	Mitoxantrone	4212	KKZJGLLVHKMTCM-UHFFFAOYSA-N
MK-0773	MK-0773	BRD-K38868394-001-01-3	PREP044	androgen receptor modulator	AR	NA	NA	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O	Phase 2	MK-0773	11950726	GBEUKTWTUSPHEE-JWJWXJQQSA-N
MK-0812	MK-0812	BRD-K14175878-001-01-6	PREP038	CC chemokine receptor antagonist	CCR2	NA	NA	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	Phase 2	MK-0812	11180808	MTMDXAIUENDNDL-RJSMDTJLSA-N
Adavosertib	MK-1775	BRD-K54256913-001-08-7	PROS004_PR500	WEE1 kinase inhibitor	WEE1	NA	NA	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	Phase 2	Adavosertib	24856436	NA
MK-2206	MK-2206	BRD-K68065987-300-09-1	PREP024	AKT inhibitor	"AKT1, AKT2, AKT3"	NA	NA	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	Phase 2	MK-2206	46930998	HWUHTJIKQZZBRA-UHFFFAOYSA-N
MK-2461	MK-2461	BRD-K56405753-001-02-4	PREP038	"FGFR inhibitor, VEGFR inhibitor"	"FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB"	NA	NA	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	Phase 1/Phase 2	MK-2461	44137946	JGEBLDKNWBUGRZ-HXUWFJFHSA-N
MK-3207	MK-3207	BRD-K66911501-003-01-2	PREP018	calcitonin antagonist	CALCA	NA	NA	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	Phase 2	MK-3207	25019940	AZAANWYREOQRFB-SETSBSEESA-N
MK-5108	MK-5108	BRD-K53665955-001-03-0	PREP027	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F	Phase 1	MK-5108	24748204	LCVIRAZGMYMNNT-UHFFFAOYSA-N
MK-8245	MK-8245	BRD-K29656036-001-02-5	PREP032	stearoyl-CoA desaturase inhibitor	SCD	NA	NA	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	Phase 2	MK-8245	24988881	UJEAABFSXKCSGI-UHFFFAOYSA-N
MK-8745	MK-8745	BRD-K25279140-001-01-5	PREP046	Aurora kinase inhibitor	AURKA	NA	NA	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	Preclinical	MK-8745	11676373	YCRFPWKUUNKNDN-UHFFFAOYSA-N
N-(4-Methoxybenzyl)-1-(naphthalen-1-yl)methanamine	ML133	BRD-K33743361-003-02-6	PREP040	potassium channel blocker	NA	NA	NA	COc1ccc(CNCc2cccc3ccccc23)cc1	Preclinical	N-(4-Methoxybenzyl)-1-(naphthalen-1-yl)methanamine	781301	GIFYKGIODMXYNT-UHFFFAOYSA-N
MLN8054	MLN-8054	BRD-K83963101-001-06-9	PREP025	Aurora kinase inhibitor	AURKA	NA	NA	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1	Phase 1	MLN8054	11712649	NA
Sapanisertib	MLN0128	BRD-K59317601-001-05-5	PROS004_PR500	mTOR inhibitor	"MTOR, PIK3CA, PIK3CD, PIK3CG"	NA	NA	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	Phase 2	Sapanisertib	45375953	NA
"MNS-(3,4-Methylenedioxy-Nitrostyrene)"	"MNS-(3,4-Methylenedioxy-nitrostyrene)"	BRD-K42205652-001-02-7	PREP042	"src inhibitor, syk inhibitor"	"SRC, SYK"	NA	NA	"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1"	Preclinical	"MNS-(3,4-Methylenedioxy-Nitrostyrene)"	NA	NA
Mocetinostat	mocetinostat	BRD-K16485616-001-08-9	PREP025	HDAC inhibitor	"HDAC1, HDAC11, HDAC2, HDAC3"	NA	NA	"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1"	Phase 2	Mocetinostat	9865515	HRNLUBSXIHFDHP-UHFFFAOYSA-N
Monensin	monensin	BRD-A06627858-236-03-0	PREP023	bacterial permeability inducer	NA	NA	NA	"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C"	Launched	Monensin	441145	GAOZTHIDHYLHMS-KEOBGNEYSA-N
Monobenzone	monobenzone	BRD-K54262262-001-09-0	PREP023	melanin inhibitor	TYR	dermatology	skin depigmentation	"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1"	Launched	Monobenzone	7638	VYQNWZOUAUKGHI-UHFFFAOYSA-N
Morin	morin	BRD-K11590034-002-03-4	PREP042	cytochrome P450 inhibitor	"ADORA2A, ESR2, FASN, MCL1, SLC22A12"	NA	NA	"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O"	Preclinical	Morin	5281670	YXOLAZRVSSWPPT-UHFFFAOYSA-N
Motesanib	motesanib	BRD-K99616396-001-05-1	PROS005_PR500	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"FLT1, FLT4, KDR, KIT"	NA	NA	"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12"	Phase 3	Motesanib	11667893	RAHBGWKEPAQNFF-UHFFFAOYSA-N
Mozavaptan	mozavaptan	BRD-A31095847-001-02-3	PREP017	vasopressin receptor antagonist	"AVPR1A, AVPR1B, AVPR2"	endocrinology	hyponatremia	CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12	Launched	Mozavaptan	119369	WRNXUQJJCIZICJ-UHFFFAOYSA-N
MPI-0479605	MPI-0479605	BRD-K45551181-001-02-1	PREP042	mitotic kinase inhibitor	TTK	NA	NA	"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1"	Preclinical	MPI-0479605	46909588	OVJBNYKNHXJGSA-UHFFFAOYSA-N
MRS 1220	MRS-1220	BRD-K37618799-001-03-0	PREP025	adenosine receptor antagonist	"ADORA2B, ADORA3"	NA	NA	"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1"	Preclinical	MRS 1220	393595	TWWFAXQOKNBUCR-UHFFFAOYSA-N
MTPG	MTPG	BRD-A28329383-001-02-1	PREP043	glutamate receptor antagonist	"GRM2, GRM3"	NA	NA	CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1	Preclinical	MTPG	NA	NA
Mubritinib	mubritinib	BRD-K19061412-001-02-4	PREP025	protein tyrosine kinase inhibitor	"EGFR, ERBB2"	NA	NA	"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1"	Phase 1	Mubritinib	6444692	ZTFBIUXIQYRUNT-MDWZMJQESA-N
Mycophenolate mofetil	mycophenolate-mofetil	BRD-K92428153-001-04-4	PREP022	"dehydrogenase inhibitor, inositol monophosphatase inhibitor"	"IMPDH1, IMPDH2"	transplant	organ rejection	"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1"	Launched	Mycophenolate mofetil	5281078	RTGDFNSFWBGLEC-SYZQJQIISA-N
Mycophenolic acid	mycophenolic-acid	BRD-K63750851-001-20-7	PREP023	"dehydrogenase inhibitor, inositol monophosphatase inhibitor"	"IMPDH1, IMPDH2"	transplant	organ rejection	"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O"	Launched	Mycophenolic acid	446541	HPNSFSBZBAHARI-RUDMXATFSA-N
N-Acetylmannosamine	N-acetylmannosamine	BRD-A92872453-001-01-8	PREP044	NA	CHIT1	NA	NA	CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O	Phase 1	N-Acetylmannosamine	11096158	OVRNDRQMDRJTHS-OZRXBMAMSA-N
Nadide	nadide	BRD-A11132253-001-08-2	PREP021	electron acceptor	"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2"	NA	NA	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	Launched	Nadide	10897651	BAWFJGJZGIEFAR-NNYOXOHSSA-N
Nadifloxacin	nadifloxacin	BRD-A24397426-001-10-4	PREP022	bacterial DNA gyrase inhibitor	NA	"dermatology, infectious disease"	"acne vulgaris (AV), skin infections"	"CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O"	Launched	Nadifloxacin	4410	JYJTVFIEFKZWCJ-UHFFFAOYSA-N
Nafcillin	nafcillin	BRD-K18574842-236-17-7	PREP020	bacterial cell wall synthesis inhibitor	"CYP1A2, CYP3A4, SLC22A6"	infectious disease	gram-positive bacterial infections	"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O"	Launched	Nafcillin	8982	GPXLMGHLHQJAGZ-JTDSTZFVSA-N
Naftidrofuryl	naftidrofuryl	BRD-A67862938-034-14-9	PREP023	adrenergic receptor antagonist	NA	cardiology	claudication	CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12	Launched	Naftidrofuryl	4417	KBAFPSLPKGSANY-UHFFFAOYSA-N
Naftifine	naftifine	BRD-K74141488-003-11-2	PREP031	fungal squalene epoxidase inhibitor	SQLE	infectious disease	"tinea pedis, tinea cruris, tinea corporis"	"CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12"	Launched	Naftifine	47641	OZGNYLLQHRPOBR-DHZHZOJOSA-N
Naloxone	naloxone	BRD-K67511046-001-02-3	PREP021	opioid receptor antagonist	"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4"	pulmonary	respiratory depression	"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O"	Launched	Naloxone	5284596	UZHSEJADLWPNLE-GRGSLBFTSA-N
Naltrexone	naltrexone	BRD-K88172511-003-20-3	PREP016	opioid receptor antagonist	"OPRD1, OPRK1, OPRM1, SIGMAR1"	neurology/psychiatry	abstinence from alcohol	"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O"	Launched	Naltrexone	5360515	DQCKKXVULJGBQN-XFWGSAIBSA-N
NAN-190	NAN-190	BRD-K69195780-004-08-4	PREP047	serotonin receptor agonist	"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F"	NA	NA	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	Preclinical	NAN-190	4431	SJDOMIRMMUGQQK-UHFFFAOYSA-N
Ccris 8440	nanchangmycin	BRD-A73871920-236-03-6	PREP032	other antibiotic	NA	NA	NA	CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C	Preclinical	Ccris 8440	86278937	XMAIRYYXDCNFKP-SEDNIUBGSA-M
Napabucasin	napabucasin	BRD-K22064724-001-01-8	PROS004_PR500	STAT inhibitor	STAT3	NA	NA	"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O"	Phase 3	Napabucasin	10331844	DPHUWDIXHNQOSY-UHFFFAOYSA-N
Naproxen	naproxen	BRD-K59197931-001-04-5	PREP022	cyclooxygenase inhibitor	"PTGS1, PTGS2"	"neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology"	"pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever"	"COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O"	Launched	Naproxen	156391	CMWTZPSULFXXJA-VIFPVBQESA-N
Narasin	narasin	BRD-A25608658-001-01-1	PREP016	antiprotozoal agent	NA	infectious disease	coccidiosis	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O	Launched	Narasin	65452	VHKXXVVRRDYCIK-CWCPJSEDSA-N
Narlaprevir	narlaprevir	BRD-K38287497-001-01-2	PREP026	HCV inhibitor	NA	NA	NA	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Phase 2/Phase 3	Narlaprevir	11857239	RICZEKWVNZFTNZ-LFGITCQGSA-N
Navarixin	navarixin	BRD-K82850175-001-01-1	PREP046	CC chemokine receptor antagonist	"CXCR1, CXCR2"	NA	NA	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	Phase 2	Navarixin	9865554	RXIUEIPPLAFSDF-CYBMUJFWSA-N
Navitoclax	navitoclax	BRD-K82746043-001-19-3///BRD-K82746043-001-15-1	PROS002_PR500///PREP026	BCL inhibitor	"BCL2, BCL2L1, BCL2L2"	NA	NA	"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1"	Phase 2	Navitoclax	24978538	JLYAXFNOILIKPP-KXQOOQHDSA-N
Nefiracetam	nefiracetam	BRD-K65678996-001-05-5	PREP032	"acetylcholine receptor agonist, benzodiazepine receptor agonist"	CHRM1	NA	NA	"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O"	Phase 3	Nefiracetam	71157	NGHTXZCKLWZPGK-UHFFFAOYSA-N
Nelarabine	nelarabine	BRD-K84466663-001-05-4	PREP017	"DNA synthesis inhibitor, T cell inhibitor"	POLA1	hematologic malignancy	"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)"	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	Nelarabine	3011155	IXOXBSCIXZEQEQ-UHTZMRCNSA-N
Emonapride	nemonapride	BRD-M80207679-001-01-5	PREP029	dopamine receptor antagonist	"DRD2, DRD3, DRD4"	neurology/psychiatry	schizophrenia	"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C"	Launched	Emonapride	156333	KRVOJOCLBAAKSJ-RDTXWAMCSA-N
Nemorubicin	nemorubicin	BRD-K51911221-001-01-2	PREP047	topoisomerase inhibitor	"TOP1, TOP2A"	NA	NA	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	Phase 2	Nemorubicin	65907	CTMCWCONSULRHO-UHQPFXKFSA-N
Neratinib	neratinib	BRD-K85606544-001-09-1	PROS004_PR500	EGFR inhibitor	"EGFR, ERBB2, KDR"	NA	NA	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 3	Neratinib	9915743	JWNPDZNEKVCWMY-VQHVLOKHSA-N
Nexturastat A	nexturastat-a	BRD-K70402238-001-02-8	PREP042	HDAC inhibitor	"HDAC1, HDAC6"	NA	NA	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	Preclinical	Nexturastat A	71462653	JZWXMCPARMXZQV-UHFFFAOYSA-N
NH125	NH125	BRD-K31086665-005-04-6	PREP037	eukaryotic translation elongation factor 2 inhibitor	NA	NA	NA	"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C"	Preclinical	NH125	10436839	RVWOHCBHAGBLLT-UHFFFAOYSA-M
Nicotinic acid	niacin	BRD-K60237333-001-27-1	PREP022	"NAD precursor, vitamin B"	"DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT"	endocrinology	hypertriglyceridemia	"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1"	Launched	Nicotinic acid	938	PVNIIMVLHYAWGP-UHFFFAOYSA-N
Niclosamide	niclosamide	BRD-K35960502-001-20-0	PREP030	"DNA replication inhibitor, STAT inhibitor"	STAT3	infectious disease	tapeworm	"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O"	Launched	Niclosamide	4477	RJMUSRYZPJIFPJ-UHFFFAOYSA-N
Nicorandil	nicorandil	BRD-K97752965-001-16-4	PREP031	"nitric oxide donor, potassium channel activator"	KCNJ11	cardiology	angina pectoris	"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1"	Launched	Nicorandil	47528	LBHIOVVIQHSOQN-UHFFFAOYSA-N
Nicotine	nicotine	BRD-A93695607-322-02-5	PREP028	acetylcholine receptor agonist	"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1"	neurology/psychiatry	smoking cessation	"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1"	Launched	Nicotine	89594	SNICXCGAKADSCV-JTQLQIEISA-N
Nilotinib	nilotinib	BRD-K81528515-001-13-8	PREP035	"Abl kinase inhibitor, Bcr-Abl kinase inhibitor"	"ABL1, KIT"	hematologic malignancy	chronic myeloid leukemia (CML)	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	Launched	Nilotinib	644241	HHZIURLSWUIHRB-UHFFFAOYSA-N
Nilutamide	nilutamide	BRD-K23566484-001-15-1	PREP016	androgen receptor antagonist	AR	oncology	prostate cancer	"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O"	Launched	Nilutamide	4493	XWXYUMMDTVBTOU-UHFFFAOYSA-N
Nimorazole	nimorazole	BRD-K79145628-001-05-5	PREP031	bacterial DNA inhibitor	NA	oncology	head and neck squamous cell carcinoma (HNSCC)	[O-][N+](=O)c1cncn1CCN1CCOCC1	Launched	Nimorazole	23009	MDJFHRLTPRPZLY-UHFFFAOYSA-N
Nintedanib	nintedanib	BRD-K49075727-001-08-5	PREP032	"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB"	pulmonary	idiopathic pulmonary fibrosis (IPF)	"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1"	Launched	Nintedanib	135423438	CPMDPSXJELVGJG-UHFFFAOYSA-N
Niraparib	niraparib	BRD-K54955827-001-02-2	PROS001_PR500	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1"	Launched	Niraparib	24958200	PCHKPVIQAHNQLW-CQSZACIVSA-N
Niridazole	niridazole	BRD-K53123955-001-10-5	PREP014	phosphofructokinase inhibitor	NA	infectious disease	schistosomiasis	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	Launched	Niridazole	6093	RDXLYGJSWZYTFJ-UHFFFAOYSA-N
Nisoxetine	nisoxetine	BRD-A95696066-003-13-8	PREP019	norepinephrine reuptake inhibitor	"SLC6A2, SLC6A3, SLC6A4"	NA	NA	CNCCC(Oc1ccccc1OC)c1ccccc1	Phase 1	Nisoxetine	4500	ITJNARMNRKSWTA-UHFFFAOYSA-N
Nitarsone	nitarsone	BRD-K56707426-001-02-0	PREP025	NA	NA	dermatology	blackhead disease	"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O"	Launched	Nitarsone	66826	FUUFQLXAIUOWML-UHFFFAOYSA-N
Nithiamide	nithiamide	BRD-K39467894-001-06-7	PREP035	bacterial DNA inhibitor	NA	NA	NA	"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O"	Preclinical	Nithiamide	8798	UJRRDDHEMZLWFI-UHFFFAOYSA-N
Nitisinone	nitisinone	BRD-K01109406-001-03-7	PREP016	hydroxyphenylpyruvate dioxygenase inhibitor	HPD	metabolism	tyrosinemia	"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F"	Launched	Nitisinone	115355	OUBCNLGXQFSTLU-UHFFFAOYSA-N
nitrocaramiphen	nitrocaramiphen	BRD-K28453807-003-11-2	PREP014	cholinergic receptor antagonist	CHRM1	NA	NA	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	Preclinical	nitrocaramiphen	3941250	NSHMVLOWOAQFTP-UHFFFAOYSA-N
Nizatidine	nizatidine	BRD-K73589491-001-11-2	PREP016	histamine receptor antagonist	HRH2	gastroenterology	"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)"	"CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O"	Launched	Nizatidine	3033637	SGXXNSQHWDMGGP-IZZDOVSWSA-N
Nizofenone	nizofenone	BRD-K84011460-051-01-7	PREP034	ion channel antagonist	NA	neurology/psychiatry	stroke	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	Launched	Nizofenone	4514	WZGBZLHGOVJDET-UHFFFAOYSA-N
NMS-1286937	NMS-1286937	BRD-K83699324-001-01-1	PREP025	PLK inhibitor	"FLT3, PLK1, PLK2, PLK3"	NA	NA	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	Phase 1	NMS-1286937	49792852	QHLVBNKYJGBCQJ-UHFFFAOYSA-N
NMS-873	NMS-873	BRD-K26253904-001-01-5	PREP041	ATPase inhibitor	VCP	NA	NA	"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O"	Preclinical	NMS-873	71521142	UJGTUKMAJVCBIS-UHFFFAOYSA-N
NMS-E973	NMS-E973	BRD-K58770988-001-01-8	PREP015	HSP inhibitor	NA	NA	NA	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	Preclinical	NMS-E973	135566652	YLQODGGPIHWTHR-UHFFFAOYSA-N
Nobiletin	nobiletin	BRD-K06753942-001-14-5	PREP032	MEK inhibitor	MAP2K1	NA	NA	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical	Nobiletin	72344	MRIAQLRQZPPODS-UHFFFAOYSA-N
Nocodazole	nocodazole	BRD-K12539581-001-23-7	PREP040	tubulin polymerization inhibitor	HPGDS	NA	NA	"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1"	Preclinical	Nocodazole	4122	KYRVNWMVYQXFEU-UHFFFAOYSA-N
Nomegestrol acetate	nomegestrol-acetate	BRD-K27351809-001-09-5	PREP022	progesterone receptor agonist	PGR	endocrinology	contraceptive	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	Launched	Nomegestrol acetate	91668	IIVBFTNIGYRNQY-YQLZSBIMSA-N
Nonoxynol-9	nonoxynol-9	BRD-K88625236-001-04-2	PREP035	membrane integrity inhibitor	NA	endocrinology	contraceptive	"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1"	Launched	Nonoxynol-9	72385	FBWNMEQMRUMQSO-UHFFFAOYSA-N
Norepinephrine	norepinephrine	BRD-K87349682-347-03-8	PREP030	adrenergic receptor agonist	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2"	"cardiology, allergy, neurology/psychiatry"	"hypertension, urticaria, headache, seasonal affective disorder"	"NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1"	Launched	Norepinephrine	439260	SFLSHLFXELFNJZ-QMMMGPOBSA-N
Norethindrone	norethindrone///norethindrone-acetate	BRD-K92073408-001-15-7///BRD-K92073408-001-16-5///BRD-A09349126-001-10-7	PMTS005///PREP023///PREP028	progesterone receptor agonist	PGR	"obstetrics/gynecology///endocrinology, orthopedics, obstetrics/gynecology"	"endometriosis///menopause, osteoporosis, vaginal atrophy"	"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C///CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C"	Launched	Norethindrone	6230	VIKNJXKGJWUCNN-XGXHKTLJSA-N
Norethynodrel	noretynodrel	BRD-A00758722-001-04-9	PREP021	progestogen hormone	PGR	endocrinology	contraceptive	C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C	Launched	Norethynodrel	6231	ICTXHFFSOAJUMG-SLHNCBLASA-N
Norfloxacin	norfloxacin	BRD-K11196887-001-22-0	PREP030	bacterial DNA gyrase inhibitor	TOP2A	"infectious disease, urology"	"urinary tract infections, gonorrhea, prostatitis"	"CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1"	Launched	Norfloxacin	4539	OGJPXUAPXNRGGI-UHFFFAOYSA-N
Novobiocin	novobiocin	BRD-K85307935-236-09-5	PREP048	bacterial DNA gyrase inhibitor	NA	obstetrics/gynecology	mastitis	"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C"	Launched	Novobiocin	54675769	YJQPYGGHQPGBLI-KGSXXDOSSA-N
NSC23766	NSC-23766	BRD-A80213327-305-08-3	PREP037	Ras GTPase inhibitor	NA	NA	NA	"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1"	Preclinical	NSC23766	409805	DEFBCZWQLILOJF-UHFFFAOYSA-N
NSC-319726	NSC-319726	BRD-K99170882-001-04-3	PREP014	p53 activator	NA	NA	NA	"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1"	Preclinical	NSC-319726	5351307	XDHBUMNIQRLHGO-UKTHLTGXSA-N
5-Nitroso-8-hydroxyquinoline	NSC-3852	BRD-K13169950-001-14-4	PREP042	HDAC inhibitor	HDAC1	NA	NA	Oc1ccc([N+][O-])c2cccnc12	Preclinical	5-Nitroso-8-hydroxyquinoline	19103	RZWRYPGAUIOOMK-UHFFFAOYSA-N
NSC632839	NSC-632839	BRD-K81197548-003-01-4	PREP043	ubiquitin specific protease inhibitor	"SENP2, USP1, USP2, USP7"	NA	NA	"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1"	Preclinical	NSC632839	5351362	ZOKZLTXPTLIWOJ-BYCVLTJGSA-N
NSC663284	NSC-663284	BRD-K03109492-001-02-2	PREP036	CDC inhibitor	"CDC25A, CDC25B, CDC25C"	NA	NA	"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O"	Preclinical	NSC663284	379077	BMKPVDQDJQWBPD-UHFFFAOYSA-N
2-[(4-Methylphenyl)sulfonyl]-5-nitrofuran	NSC-697923	BRD-K20605374-001-05-4	PREP047	ubiquitin-conjugating enzyme inhibitor	UBE2N	NA	NA	"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O"	Preclinical	2-[(4-Methylphenyl)sulfonyl]-5-nitrofuran	394449	GAUHIPWCDXOLCZ-UHFFFAOYSA-N
"6-Cyclohexylmethyloxy-5-nitroso-pyrimidine-2,4-diamine"	NU6027	BRD-K03294269-001-08-0	PREP047	CDK inhibitor	"CCNA2, CDK2"	NA	NA	Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1	Preclinical	"6-Cyclohexylmethyloxy-5-nitroso-pyrimidine-2,4-diamine"	398148	DGWXOLHKVGDQLN-UHFFFAOYSA-N
Nutlin-3	nutlin-3	BRD-A12230535-001-06-7	PREP015	MDM inhibitor	"MDM2, TP53"	NA	NA	"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1"	Preclinical	Nutlin-3	216345	BDUHCSBCVGXTJM-UHFFFAOYSA-N
Nvp-aew541	NVP-AEW541	BRD-K24696047-001-02-3	PREP036	IGF-1 inhibitor	"IGF1R, INSR"	NA	NA	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1	Preclinical	Nvp-aew541	11476171	AECDBHGVIIRMOI-UHFFFAOYSA-N
Luminespib	NVP-AUY922	BRD-K41859756-001-06-8	PROS005_PR500	HSP inhibitor	"HSP90AA1, HSP90AB1"	NA	NA	"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O"	Phase 2	Luminespib	10096043	SWDZPNJZKUGIIH-QQTULTPQSA-N
Dactolisib	NVP-BEZ235	BRD-K12184916-001-19-6///BRD-K12184916-001-15-4	PROS004_PR500///PREP025	"mTOR inhibitor, PI3K inhibitor"	"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG"	NA	NA	"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1"	Phase 2	Dactolisib	11977753	JOGKUKXHTYWRGZ-UHFFFAOYSA-N
NVP-BHG712	NVP-BHG712	BRD-K79259477-001-04-9	PREP036	ephrin inhibitor	EPHB4	NA	NA	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	NVP-BHG712	16747388	ZCCPLJOKGAACRT-UHFFFAOYSA-N
NVP-BVU972	NVP-BVU972	BRD-K77943374-001-02-8	PREP043	MET inhibitor	MET	NA	NA	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	Preclinical	NVP-BVU972	44206063	RNCNPRCUHHDYPC-UHFFFAOYSA-N
TAE-226	NVP-TAE226	BRD-K21025364-001-05-6	PREP041	protein tyrosine kinase inhibitor	PTK2	NA	NA	"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl"	Preclinical	TAE-226	9934347	UYJNQQDJUOUFQJ-UHFFFAOYSA-N
Nvp-tae 684	NVP-TAE684	BRD-K50140147-001-10-1	PREP042	ALK tyrosine kinase receptor inhibitor	"ALK, INSR"	NA	NA	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Preclinical	Nvp-tae 684	16038120	QQWUGDVOUVUTOY-UHFFFAOYSA-N
Obatoclax	obatoclax	BRD-K15600710-066-05-8///BRD-K15600710-066-04-1	PROS004_PR500///PREP025	BCL inhibitor	BCL2	NA	NA	"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1"	Phase 3	Obatoclax	16681698	NA
Obidoxime	obidoxime	BRD-K33588785-001-01-9	PREP039	cholinesterase reactivator	ACHE	"critical care, neurology/psychiatry"	"poison antidote, nerve gas poisoning"	O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1	Launched	Obidoxime	135412781	HIGRLDNHDGYWQJ-UHFFFAOYSA-P
Octenidine	octenidine	BRD-K04568635-300-01-4	PREP022	membrane integrity inhibitor	NA	NA	NA	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	Launched	Octenidine	51167	ZVXNYZWXUADSRV-UHFFFAOYSA-N
Octopamine	octopamine	BRD-A14240607-003-26-1	PREP014	trace amine associated receptor agonist	"F10, TAAR1"	NA	NA	"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1"	Preclinical	Octopamine	4581	QHGUCRYDKWKLMG-UHFFFAOYSA-N
Odanacatib	odanacatib	BRD-K22822991-001-02-3	PROS001_PR500	cathepsin inhibitor	CTSK	NA	NA	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	Phase 3	Odanacatib	10152654	FWIVDMJALNEADT-SFTDATJTSA-N
Olaparib	olaparib	BRD-K02113016-001-19-6///BRD-K02113016-001-15-4	PROS004_PR500///PREP017	PARP inhibitor	"PARP1, PARP2"	oncology	ovarian cancer	"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1"	Launched	Olaparib	23725625	FDLYAMZZIXQODN-UHFFFAOYSA-N
N-Oleoyldopamine	OLDA	BRD-K95523387-001-09-6	PREP044	TRPV agonist	GPR119	NA	NA	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	Preclinical	N-Oleoyldopamine	5282106	QQBPLXNESPTPNU-KTKRTIGZSA-N
Oleanolic acid	oleanolic-acid	BRD-K90647725-001-07-3	PREP048	G protein-coupled receptor agonist	GPBAR1	NA	NA	"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O"	Preclinical	Oleanolic acid	10494	MIJYXULNPSFWEK-GTOFXWBISA-N
n-Oleoylethanolamine	oleoylethanolamide	BRD-K66956375-001-11-3	PREP015	"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist"	"CNR1, GPR119, GPR55, PPARA"	NA	NA	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	Preclinical	n-Oleoylethanolamine	5283454	BOWVQLFMWHZBEF-KTKRTIGZSA-N
Oligomycin A	oligomycin-a	BRD-A81541225-001-06-8	PREP043	"ATP synthase inhibitor, ATPase inhibitor"	ATP5A1	NA	NA	CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C	Preclinical	Oligomycin A	5472285	MNULEGDCPYONBU-QECWTJOCSA-N
Oltipraz	oltipraz	BRD-K86972824-001-01-4	PROS005_PR500	"nuclear factor erythroid derived, like (NRF2) activator"	ANG	NA	NA	"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1"	Phase 3	Oltipraz	47318	CKNAQFVBEHDJQV-UHFFFAOYSA-N
Omeprazole	omeprazole	BRD-A55962179-001-22-1	PREP022	ATPase inhibitor	"ATP4A, CLCN2"	gastroenterology	heartburn	"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C"	Launched	Omeprazole	4594	SUBDBMMJDZJVOS-UHFFFAOYSA-N
ONC201	ONC201	BRD-K58529924-001-01-5	PROS001_PR500	"AKT inhibitor, MAP kinase inhibitor"	TNFSF10	NA	NA	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O	Phase 2	ONC201	73777259	VLULRUCCHYVXOH-UHFFFAOYSA-N
1-(4-Chlorobenzyl)-1H-indole-3-carbaldehyde	oncrasin-1	BRD-K43449605-001-01-0	PREP043	apoptosis stimulant	NA	NA	NA	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	Preclinical	1-(4-Chlorobenzyl)-1H-indole-3-carbaldehyde	872445	ZDRQMXCSSAPUMM-UHFFFAOYSA-N
ONX-0914	ONX-0914	BRD-K60446698-001-01-2	PREP014	proteasome inhibitor	NA	NA	NA	COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1	Preclinical	ONX-0914	23642227	WQAVPPWWLLVGFK-VTNASVEKSA-N
Oprozomib	oprozomib	BRD-A36331462-001-02-1	PREP044	proteasome inhibitor	NA	NA	NA	COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1	Phase 1/Phase 2	Oprozomib	25067547	SWZXEVABPLUDIO-WSZYKNRRSA-N
Orantinib	orantinib	BRD-K55966568-001-05-4	PREP019	"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB"	NA	NA	"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O"	Phase 3	Orantinib	5329099	NHFDRBXTEDBWCZ-ZROIWOOFSA-N
Oridonin	oridonin	BRD-K23925186-001-02-8	PREP035	BCL inhibitor	BCL2	NA	NA	"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C"	Preclinical	Oridonin	5321010	SDHTXBWLVGWJFT-XKCURVIJSA-N
L-Ornithine	ornithine	BRD-A13561534-003-02-0	PREP048	NFkB pathway modulator	"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4"	NA	NA	NCCCC(N)C(O)=O	Launched	L-Ornithine	6262	AHLPHDHHMVZTML-BYPYZUCNSA-N
Orotic acid	orotic-acid	BRD-K32572029-001-04-4	PREP046	NA	DHODH	NA	NA	"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1"	Phase 2	Orotic acid	967	PXQPEWDEAKTCGB-UHFFFAOYSA-N
Oseltamivir	oseltamivir-phosphate	BRD-K76011241-001-01-8	PREP016	neuraminidase inhibitor	"CES1, NEU1, NEU2"	infectious disease	influenza A virus infection	"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1"	Launched	Oseltamivir	65028	VSZGPKBBMSAYNT-RRFJBIMHSA-N
Osi-027	OSI-027	BRD-K87124298-001-03-4	PREP039	mTOR inhibitor	MTOR	NA	NA	"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12"	Phase 1	Osi-027	44224160	NA
OSI-420	OSI-420	BRD-K73309154-003-02-8	PREP047	EGFR inhibitor	EGFR	NA	NA	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	Preclinical	OSI-420	18924996	BUOXOWNQZVIETJ-UHFFFAOYSA-N
Osi-930	OSI-930	BRD-K25340465-001-11-1	PREP026	"KIT inhibitor, VEGFR inhibitor"	"KDR, KIT"	NA	NA	"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1"	Phase 1	Osi-930	9868037	NA
Osimertinib	osimertinib	BRD-K42805893-001-04-9	PROS003_PR500	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	Launched	Osimertinib	71496458	DUYJMQONPNNFPI-UHFFFAOYSA-N
Otssp167	OTS167	BRD-K53417444-003-03-1	PREP039	maternal embryonic leucine zipper kinase inhibitor	MELK	NA	NA	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O	Phase 1	Otssp167	135398499	DKZYXHCYPUVGAF-UHFFFAOYSA-N
OTX015	OTX015	BRD-K43471985-001-03-0	PREP044	bromodomain inhibitor	"BRD2, BRD3, BRD4"	NA	NA	"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1"	Phase 1/Phase 2	OTX015	9936746	GNMUEVRJHCWKTO-FQEVSTJZSA-N
Ouabain	ouabain	BRD-K33277808-331-01-3	PREP024	ATPase inhibitor	ATP1A1	cardiology	"hypertension, cardiac arrythmia"	"C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O"	Launched	Ouabain	439501	LPMXVESGRSUGHW-HBYQJFLCSA-N
Oxaliplatin	oxaliplatin	BRD-K78960041-001-05-7	PREP048	DNA inhibitor	NA	oncology	colorectal cancer	"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O"	Launched	Oxaliplatin	24197464	PCRKGXHIGVOZKB-BNTLRKBRSA-L
Oxazepam	oxazepam	BRD-A50049929-001-01-9	PREP020	GABA benzodiazepine site receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3"	neurology/psychiatry	anxiety	OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O	Launched	Oxazepam	4616	ADIMAYPTOBDMTL-UHFFFAOYSA-N
Oxcarbazepine	oxcarbazepine	BRD-K04196797-001-24-4	PREP017	sodium channel blocker	"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A"	neurology/psychiatry	seizures	"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12"	Launched	Oxcarbazepine	34312	CTRLABGOLIVAIY-UHFFFAOYSA-N
Methyl (5-propoxy-1H-benzimidazol-2-yl)carbamate	oxibendazole	BRD-K52075715-001-06-7	PREP035	tubulin polymerization inhibitor	"TUBB, TUBB4B"	infectious disease	strongyles	"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1"	Launched	Methyl (5-propoxy-1H-benzimidazol-2-yl)carbamate	4622	RAOCRURYZCVHMG-UHFFFAOYSA-N
Oxiperomide	oxiperomide	BRD-K78096648-001-05-7	PREP039	dopamine receptor antagonist	NA	NA	NA	Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1	Phase 2	Oxiperomide	68634	NVDBBGBUTKLRSN-UHFFFAOYSA-N
Oxiracetam	oxiracetam	BRD-K50677762-001-01-5	PREP031	acetylcholine receptor agonist	NA	NA	NA	NC(=O)CN1C[C@H](O)CC1=O	Launched	Oxiracetam	4626	IHLAQQPQKRMGSS-UHFFFAOYSA-N
Oxonic Acid	oxonic-acid	BRD-K31468676-237-01-8	PREP015	uricase inhibitor	NA	NA	NA	"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1"	Preclinical	Oxonic Acid	4604	RYYCJUAHISIHTL-UHFFFAOYSA-N
Oxprenolol	oxprenolol	BRD-A43671941-003-11-9	PREP016	adrenergic receptor antagonist	"ADRB1, ADRB2"	cardiology	"angina pectoris, hypertension, cardiac arrythmia"	CC(C)NCC(O)COc1ccccc1OCC=C	Launched	Oxprenolol	4631	CEMAWMOMDPGJMB-UHFFFAOYSA-N
Oxymatrine	oxymatrine	BRD-A57833392-001-01-7	PREP015	NA	NA	NA	NA	[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23	Launched	Oxymatrine	114850	XVPBINOPNYFXID-LHDUFFHYSA-N
Oxymetazoline	oxymetazoline	BRD-K16195444-003-26-0	PREP030	adrenergic receptor agonist	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C"	otolaryngology	nasal congestion	"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C"	Launched	Oxymetazoline	4636	WYWIFABBXFUGLM-UHFFFAOYSA-N
Oxyphencyclimine	oxyphencyclimine	BRD-A58193911-003-18-7	PREP048	cholinergic receptor antagonist	"CHRM1, CHRM2, CHRM3"	gastroenterology	peptic ulcer disease (PUD)	CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	Oxyphencyclimine	4642	DUDKAZCAISNGQN-UHFFFAOYSA-N
8-Hydroxyquinoline	oxyquinoline	BRD-K66808046-065-03-7	PREP021	chelating agent	METAP2	dermatology	cosmetic	Oc1cccc2cccnc12	Launched	8-Hydroxyquinoline	1923	MCJGNVYPOGVAJF-UHFFFAOYSA-N
P22077	P22077	BRD-K97714174-001-01-3	PREP043	ubiquitin specific protease inhibitor	USP7	NA	NA	"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O"	Preclinical	P22077	46931953	RMAMGGNACJHXHO-UHFFFAOYSA-N
P-276-00	P276-00	BRD-K51791723-003-01-7	PROS004_PR500	CDK inhibitor	"CDK1, CDK4, CDK9"	NA	NA	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	P-276-00	23643976	QLUYMIVVAYRECT-OCCSQVGLSA-N
P5091	P5091	BRD-K13606314-001-01-3	PREP040	ubiquitin specific protease inhibitor	USP7	NA	NA	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	Preclinical	P5091	2819993	LKZLGMAAKNEGCH-UHFFFAOYSA-N
Pac-1	PAC-1	BRD-K92991072-001-04-9	PREP032	caspase activator	CASP3	NA	NA	"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1"	Phase 1	Pac-1	6851947	NA
Paclitaxel	paclitaxel	BRD-K62008436-001-23-9///BRD-K62008436-001-22-1	PROS005_PR500///PREP017	tubulin polymerization inhibitor	"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1"	oncology	"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)"	"CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1"	Launched	Paclitaxel	36314	RCINICONZNJXQF-MZXODVADSA-N
Pacritinib	pacritinib	BRD-K19034817-001-01-4	PREP018	"FLT3 inhibitor, JAK inhibitor"	"FLT3, JAK1, JAK2, JAK3"	NA	NA	"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3"	Phase 3	Pacritinib	46216796	HWXVIOGONBBTBY-ONEGZZNKSA-N
Palbociclib	palbociclib	BRD-K51313569-001-07-8///BRD-K51313569-003-03-3	PROS003_PR500///PREP021	CDK inhibitor	"CDK4, CDK6"	oncology	breast cancer	"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O"	Launched	Palbociclib	5330286	AHJRHEGDXFFMBM-UHFFFAOYSA-N
Paliperidone	paliperidone	BRD-A99888680-001-03-8	PREP030	"dopamine receptor antagonist, serotonin receptor antagonist"	"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C"	neurology/psychiatry	schizophrenia	"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12"	Launched	Paliperidone	115237	PMXMIIMHBWHSKN-UHFFFAOYSA-N
Palmatine	palmatine-chloride	BRD-K58466253-003-14-0	PREP032	dopamine synthesis inhibitor	CYP3A4	NA	NA	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	Preclinical	Palmatine	19009	QUCQEUCGKKTEBI-UHFFFAOYSA-N
Palmitoylethanolamide	palmitoylethanolamide	BRD-K68095457-001-10-1	PREP017	cannabinoid receptor agonist	"CNR2, GPR119, GPR55"	NA	NA	"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO"	Launched	Palmitoylethanolamide	4671	HXYVTAGFYLMHSO-UHFFFAOYSA-N
Palomid 529	palomid-529	BRD-A50998626-001-02-1	PREP018	"AKT inhibitor, mTOR inhibitor"	MTOR	NA	NA	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1	Phase 1	Palomid 529	11998575	YEAHTLOYHVWAKW-UHFFFAOYSA-N
Panobinostat	panobinostat	BRD-K02130563-001-11-4	PROS002_PR500	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9"	hematologic malignancy	multiple myeloma	"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1"	Launched	Panobinostat	6918837	FPOHNWQLNRZRFC-ZHACJKMWSA-N
Papaverine	papaverine	BRD-K15567136-003-27-2	PREP020	phosphodiesterase inhibitor	"PDE10A, PDE4B, PDE5A"	"cardiology, hematology, gastroenterology"	"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm"	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	Launched	Papaverine	4680	XQYZDYMELSJDRZ-UHFFFAOYSA-N
4-Chlorophenol	parachlorophenol	BRD-K40992116-001-09-7	PREP020	antiinfective drug	NA	NA	NA	Oc1ccc(Cl)cc1	Launched	4-Chlorophenol	4684	WXNZTHHGJRFXKQ-UHFFFAOYSA-N
Parbendazole	parbendazole	BRD-K02407574-001-09-7	PREP015	tubulin polymerization inhibitor	TUBB	NA	NA	CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1	Preclinical	Parbendazole	26596	YRWLZFXJFBZBEY-UHFFFAOYSA-N
Pardoprunox	pardoprunox	BRD-K11851476-003-01-7	PMTS011	"serotonin receptor agonist, dopamine receptor agonist"	"DRD2, DRD3, DRD4, HTR1A, HTR7"	NA	NA	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	Phase 3	Pardoprunox	6918525	YVPUUUDAZYFFQT-UHFFFAOYSA-N
Paricalcitol	paricalcitol	BRD-K60585088-001-01-5	PREP022	vitamin D receptor agonist	VDR	"nephrology, endocrinology"	"chronic kidney disease (CKD), hyperthyroidism"	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1	Launched	Paricalcitol	5281104	BPKAHTKRCLCHEA-UBFJEZKGSA-N
(-)-Parthenolide	parthenolide///parthenolide-(-)	BRD-K98548675-001-05-9///BRD-K34851558-001-02-3	PREP044///PREP033	NFkB pathway inhibitor	HDAC1	NA	NA	"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1///C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1"	Phase 1///Preclinical	(-)-Parthenolide	5420804	KTEXNACQROZXEV-ZRPLFPEYSA-N
Pazopanib	pazopanib	BRD-K74514084-003-09-2///BRD-K74514084-001-03-9	PROS004_PR500///PREP034	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3"	oncology	"renal cell carcinoma (RCC), soft tissue sarcoma (STS)"	"CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1"	Launched	Pazopanib	11525740	MQHIQUBXFFAOMK-UHFFFAOYSA-N
Abexinostat	PCI-24781	BRD-K12867552-001-04-7	PREP047	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC6"	NA	NA	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	Phase 1/Phase 2	Abexinostat	11749858	MAUCONCHVWBMHK-UHFFFAOYSA-N
PD-0325901	PD-0325901	BRD-K49865102-001-08-4	PREP033	MEK inhibitor	MAP2K1	NA	NA	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Phase 2	PD-0325901	9826528	SUDAHWBOROXANE-SECBINFHSA-N
PD 153035	PD-153035	BRD-K26603252-003-04-9	PREP045	EGFR inhibitor	"EGFR, KDR"	NA	NA	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	Phase 1	PD 153035	4705	NA
4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline	PD-168393	BRD-K17702546-001-03-2	PREP037	EGFR inhibitor	"EGFR, ERBB2, SRC"	NA	NA	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	Preclinical	4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline	4708	HTUBKQUPEREOGA-UHFFFAOYSA-N
PD 173074	PD-173074	BRD-K97764662-001-17-3	PREP042	"FGFR inhibitor, VEGFR inhibitor"	"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB"	NA	NA	"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1"	Preclinical	PD 173074	1401	DXCUKNQANPLTEJ-UHFFFAOYSA-N
CI-1040	PD-184352	BRD-K05104363-001-10-0	PREP045	MEK inhibitor	"MAP2K1, MAP3K1, MAP3K2"	NA	NA	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	Phase 2	CI-1040	6918454	GFMMXOIFOQCCGU-UHFFFAOYSA-N
PD-198306	PD-198306	BRD-K88677950-001-03-9	PREP043	"MAP kinase inhibitor, MEK inhibitor"	"MAP2K1, MAP2K2"	NA	NA	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	Preclinical	PD-198306	9956637	UHAXDAKQGVISBZ-UHFFFAOYSA-N
PD318088	PD-318088	BRD-A57798112-001-03-7	PREP033	MEK inhibitor	MAP2K1	NA	NA	OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F	Preclinical	PD318088	10231331	NA
PD-407824	PD-407824	BRD-K82823804-001-04-1	PREP046	PKC inhibitor	WEE1	NA	NA	"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1"	Preclinical	PD-407824	4369491	IAUZTOZLTFSMIE-UHFFFAOYSA-N
PD98059	PD-98059	BRD-K62810658-001-12-2	PREP024	MEK inhibitor	"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1"	NA	NA	"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N"	Preclinical	PD98059	4713	QFWCYNPOPKQOKV-UHFFFAOYSA-N
Pelitinib	pelitinib	BRD-K08799216-001-05-3	PROS002_PR500	EGFR inhibitor	EGFR	NA	NA	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 2	Pelitinib	6445562	NA
Penfluridol	penfluridol	BRD-K15409150-001-05-8	PREP034	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F"	Launched	Penfluridol	33630	MDLAAYDRRZXJIF-UHFFFAOYSA-N
Penicillamine	penicillamine-(D)	BRD-K17518951-001-03-0	PREP048	chelating agent	NA	"metabolism, rheumatology, nephrology"	"Wilson's disease, rheumatoid arthritis, cystinuria"	"CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O"	Launched	Penicillamine	5852	VVNCNSJFMMFHPL-VKHMYHEASA-N
Pentagastrin	pentagastrin	BRD-K78789465-001-01-6	PREP021	CCK receptor agonist	CCKBR	gastroenterology	"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic"	"CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O"	Launched	Pentagastrin	9853654	NEYNJQRKHLUJRU-DZUOILHNSA-N
Pentamidine	pentamidine	BRD-K13183738-317-10-2	PREP020	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1"	Launched	Pentamidine	4735	XDRYMKDFEDOLFX-UHFFFAOYSA-N
Pentostatin	pentostatin	BRD-K91543828-001-02-0	PMTS011	"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor"	ADA	hematologic malignancy	hairy cell leukemia	"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12"	Launched	Pentostatin	439693	FPVKHBSQESCIEP-JQCXWYLXSA-N
Pepstatin	pepstatin	BRD-K13571841-001-14-4	PREP024	aspartic protease inhibitor	"CTSB, CTSD, CTSL, REN"	NA	NA	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	Preclinical	Pepstatin	5478883	FAXGPCHRFPCXOO-LXTPJMTPSA-N
Peruvoside	peruvoside	BRD-A72716251-001-01-5	PREP026	cardiac glycoside	NA	NA	NA	CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O	Phase 1	Peruvoside	12314120	PMTSPAGBAFCORP-HBUONDEYSA-N
Petcm	PETCM	BRD-A93477898-001-04-2	PREP036	caspase activator	CASP3	NA	NA	OC(Cc1ccncc1)C(Cl)(Cl)Cl	Preclinical	Petcm	224859	NGTDJJKTGRNNAU-UHFFFAOYSA-N
Pevonedistat	pevonedistat	BRD-K67844266-003-01-9	PROS003_PR500	nedd activating enzyme inhibitor	"NAE1, UBA3"	NA	NA	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	Phase 2	Pevonedistat	71729979	MPUQHZXIXSTTDU-ZIODWWTISA-N
PF-03758309	PF-03758309	BRD-K37764012-001-04-1	PREP027	p21 activated kinase inhibitor	PAK4	NA	NA	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1	Phase 1	PF-03758309	25227462	NA
PF-03814735	PF-03814735	BRD-K68747584-001-02-0	PREP026	Aurora kinase inhibitor	"AURKA, AURKB"	NA	NA	"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21"	Phase 1	PF-03814735	49830590	RYYNGWLOYLRZLK-UHFFFAOYSA-N
Incb8761(PF-4136309)	PF-04136309	BRD-K94420399-001-01-9	PREP019	CC chemokine receptor antagonist	NA	NA	NA	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	Phase 2	Incb8761(PF-4136309)	11192346	ZNSVOHSYDRPBGI-CBQRAPNFSA-N
PF-04217903	PF-04217903	BRD-K73319509-001-08-0	PREP027	c-Met inhibitor	MET	NA	NA	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	Phase 1	PF-04217903	17754438	PDMUGYOXRHVNMO-UHFFFAOYSA-N
PF-04457845	PF-04457845	BRD-K86816506-001-01-8	PREP039	FAAH inhibitor	FAAH	NA	NA	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	Phase 2	PF-04457845	24771824	BATCTBJIJJEPHM-UHFFFAOYSA-N
PF-04691502	PF-04691502	BRD-K07310275-001-02-5	PREP026	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA"	NA	NA	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O	Phase 2	PF-04691502	25033539	XDLYKKIQACFMJG-UHFFFAOYSA-N
Gedatolisib	PF-05212384	BRD-K07955840-001-02-3	PREP039	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA"	NA	NA	"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1"	Phase 2	Gedatolisib	44516953	DWZAEMINVBZMHQ-UHFFFAOYSA-N
PF-3845	PF-3845	BRD-K68997413-001-05-1	PREP014	FAAH inhibitor	FAAH	NA	NA	"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1"	Preclinical	PF-3845	25154867	NBOJHRYUGLRASX-UHFFFAOYSA-N
PF-477736	PF-477736	BRD-K03063480-001-06-6	PREP026	CHK inhibitor	"CHEK1, CHEK2"	NA	NA	"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O"	Phase 1	PF-477736	135565545	NDEXUOWTGYUVGA-LJQANCHMSA-N
CYP3cide	PF-4981517	BRD-K78318619-001-02-7	PREP041	cytochrome P450 inhibitor	CYP3A4	NA	NA	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	Preclinical	CYP3cide	71315139	WDWIMDKOXZZYHH-FQEVSTJZSA-N
PF-00562271 free base	PF-562271	BRD-K99545815-001-06-3	PREP018	focal adhesion kinase inhibitor	"PTK2, PTK2B"	NA	NA	"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O"	Phase 1	PF-00562271 free base	11713159	MZDKLVOWGIOKTN-UHFFFAOYSA-N
PF-573228	PF-573228	BRD-K79239947-001-06-8	PREP032	focal adhesion kinase inhibitor	"CDK1, CDK2, CDK7, GSK3B, IKBKB"	NA	NA	"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1"	Preclinical	PF-573228	11612883	NA
PFI-1	PFI-1	BRD-K13094524-001-07-5	PREP037	bromodomain inhibitor	BRD4	NA	NA	"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1"	Preclinical	PFI-1	71271629	NA
PFK-015	PFK-015	BRD-K95573441-001-01-2	PREP025	phosphofructokinase inhibitor	PFKFB3	NA	NA	"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1"	Phase 1	PFK-015	25142799	UJJUKZPBUMCSJZ-BQYQJAHWSA-N
Pha-665752	PHA-665752	BRD-K95435023-001-08-5	PREP042	c-Met inhibitor	MET	NA	NA	"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1"	Preclinical	Pha-665752	10461815	OYONTEXKYJZFHA-SSHUPFPWSA-N
PHA-680632	PHA-680632	BRD-K09443272-001-03-3	PREP046	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	Preclinical	PHA-680632	11249084	OBWNXGOQPLDDPS-UHFFFAOYSA-N
PHA-767491	PHA-767491	BRD-K50000283-001-04-4	PREP040	CDC inhibitor	"CDK1, RPS6KB1"	NA	NA	"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1"	Preclinical	PHA-767491	11715767	DKXHSOUZPMHNIZ-UHFFFAOYSA-N
Pha-793887	PHA-793887	BRD-K64800655-001-07-4	PREP038	CDK inhibitor	"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9"	NA	NA	"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C"	Phase 1	Pha-793887	46191454	NA
Milciclib	PHA-848125	BRD-K60997853-001-02-3	PROS004_PR500	"CDK inhibitor, growth factor receptor inhibitor"	"CDK2, CDK4, CDK7, NTRK1"	NA	NA	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	Phase 2	Milciclib	16718576	RXZMYLDMFYNEIM-UHFFFAOYSA-N
Antipyrine	phenazone	BRD-K46937689-001-15-0	PREP021	cyclooxygenase inhibitor	"PTGS1, PTGS2"	neurology/psychiatry	pain relief	"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C"	Launched	Antipyrine	2206	VEQOALNAAJBPNY-UHFFFAOYSA-N
Phenelzine	phenelzine	BRD-K87024524-065-17-7	PREP020	monoamine oxidase inhibitor	"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4"	neurology/psychiatry	depression	"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1"	Launched	Phenelzine	3675	RMUCZJUITONUFY-UHFFFAOYSA-N
Pheniramine	pheniramine	BRD-A23072235-050-18-5	PREP048	histamine receptor antagonist	HRH1	allergy	"allergic rhinitis, urticaria"	"CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1"	Launched	Pheniramine	4761	IJHNSHDBIRRJRN-UHFFFAOYSA-N
Phenylbutazone	phenylbutazone	BRD-K10843433-001-22-7	PREP020	"cyclooxygenase inhibitor, prostanoid receptor antagonist"	"PTGIS, PTGS1, PTGS2"	NA	NA	"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1"	Withdrawn	Phenylbutazone	4781	VYMDGNCVAMGZFE-UHFFFAOYSA-N
Phenylmercuric acetate	phenylmercuric-acetate	BRD-K74193284-001-04-8	PREP048	other antifungal	NA	NA	NA	CC(=O)O[Hg]c1ccccc1	Preclinical	Phenylmercuric acetate	16682730	XEBWQGVWTUSTLN-UHFFFAOYSA-M
Phlorizin	phlorizin	BRD-K24601397-001-01-1	PREP033	sodium/glucose cotransporter inhibitor	"SLC5A1, SLC5A11, SLC5A2, SLC5A3"	NA	NA	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical	Phlorizin	6072	IOUVKUPGCMBWBT-QNDFHXLGSA-N
PI-103	PI-103	BRD-K67868012-001-07-6	PREP040	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC"	NA	NA	"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1"	Preclinical	PI-103	9884685	TUVCWJQQGGETHL-UHFFFAOYSA-N
PI-828	PI-828	BRD-K97365803-001-02-1	PREP014	PI3K inhibitor	NA	NA	NA	"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1"	Preclinical	PI-828	25181195	WUKMIBOGGXMBAC-UHFFFAOYSA-N
Bimiralisib	PI3K-IN-2	BRD-K62374002-001-01-5	PMTS011	PI3K inhibitor	NA	NA	NA	Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 2	Bimiralisib	58507717	ADGGYDAFIHSYFI-UHFFFAOYSA-N
Pibenzimol	pibenzimol	BRD-K17026858-001-01-2	PREP039	DNA inhibitor	NA	NA	NA	"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1"	Phase 2	Pibenzimol	2392	INAAIJLSXJJHOZ-UHFFFAOYSA-N
2-Pyridinecarboxylic acid	picolinic-acid	BRD-K01029106-001-01-4	PREP026	chelating agent	NA	NA	NA	"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1"	Phase 2	2-Pyridinecarboxylic acid	1018	SIOXPEMLGUPBBT-UHFFFAOYSA-N
Pik-75	PIK-75	BRD-K49371609-003-03-8	PREP036	"DNA protein kinase inhibitor, PI3K inhibitor"	"PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC"	NA	NA	CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical	Pik-75	10275789	QTHCAAFKVUWAFI-DJKKODMXSA-N
Pilaralisib	pilaralisib	BRD-K49456274-001-01-9	PREP039	PI3K inhibitor	NA	NA	NA	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	Phase 2	Pilaralisib	56599306	QINPEPAQOBZPOF-UHFFFAOYSA-N
Pilocarpine	pilocarpine	BRD-K85090592-008-22-7	PREP021	acetylcholine receptor agonist	"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5"	"ophthalmology, cardiology"	"glaucoma, hypertension"	"CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O"	Launched	Pilocarpine	5910	QCHFTSOMWOSFHM-WPRPVWTQSA-N
Pindolol	pindolol	BRD-A97701745-001-16-0	PREP029	adrenergic receptor antagonist	"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B"	cardiology	hypertension	"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12"	Launched	Pindolol	4828	JZQKKSLKJUAGIC-UHFFFAOYSA-N
Piperacetazine	piperacetazine	BRD-K16277217-001-10-9	PREP020	dopamine receptor antagonist	NA	neurology/psychiatry	schizophrenia	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched	Piperacetazine	19675	BTFMCMVEUCGQDX-UHFFFAOYSA-N
Piperazine	piperazine	BRD-K13249881-001-02-3	PREP021	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	C1CNCCN1	Launched	Piperazine	4837	GLUUGHFHXGJENI-UHFFFAOYSA-N
Piperine	piperine	BRD-K59522102-001-14-6	PREP039	monoamine oxidase inhibitor	"MAOA, MAOB, TRPV1"	NA	NA	"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1"	Phase 1	Piperine	638024	MXXWOMGUGJBKIW-YPCIICBESA-N
Pirenperone	pirenperone	BRD-K25224017-001-25-0	PREP037	serotonin receptor antagonist	"HTR2A, HTR7"	NA	NA	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	Preclinical	Pirenperone	4847	HXCNRYXBZNHDNE-UHFFFAOYSA-N
Piretanide	piretanide	BRD-K87990216-001-10-2	PREP030	glucocorticoid receptor agonist	"SLC12A1, SLC12A2"	cardiology	"hypertension, edema"	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	Launched	Piretanide	4849	UJEWTUDSLQGTOA-UHFFFAOYSA-N
Piroxicam	piroxicam	BRD-A57382968-001-29-0	PREP015	cyclooxygenase inhibitor	"PTGS1, PTGS2"	rheumatology	"osteoarthritis, rheumatoid arthritis"	"CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O"	Launched	Piroxicam	54676228	QYSPLQLAKJAUJT-UHFFFAOYSA-N
Pitavastatin	pitavastatin	BRD-K75958547-238-01-0	PREP023	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O"	Launched	Pitavastatin	5282452	VGYFMXBACGZSIL-MCBHFWOFSA-N
PJ 34	PJ-34	BRD-K11853856-001-01-7	PREP040	PARP inhibitor	"EEF2, PARP1, PARP15, PARP3"	NA	NA	"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1"	Preclinical	PJ 34	NA	NA
PKI-179	PKI-179	BRD-A28467416-002-01-0	PREP045	"mTOR inhibitor, PI3K inhibitor"	MTOR	NA	NA	O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2	Phase 1	PKI-179	46947264	WXUUCRLKXQMWRY-UHFFFAOYSA-N
Plinabulin	plinabulin	BRD-K99498722-001-02-6	PREP033	tubulin polymerization inhibitor	NA	NA	NA	"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O"	Phase 3	Plinabulin	9949641	UNRCMCRRFYFGFX-TYPNBTCFSA-N
PLX4720	PLX-4720	BRD-K16478699-001-09-2	PREP037	RAF inhibitor	"BRAF, KDR"	NA	NA	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	Preclinical	PLX4720	24180719	YZDJQTHVDDOVHR-UHFFFAOYSA-N
Podofilox	podophyllotoxin	BRD-K47869605-001-32-0	PREP035	"microtubule inhibitor, tubulin polymerization inhibitor"	"IGF1R, TOP2A, TUBA4A, TUBB"	infectious disease	genital warts	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	Launched	Podofilox	10607	YJGVMLPVUAXIQN-XVVDYKMHSA-N
Polydatin	polydatin	BRD-K43236057-001-07-1	PREP034	ICAM1 expression inhibitor	ICAM1	NA	NA	"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O"	Phase 2	Polydatin	5281718	HSTZMXCBWJGKHG-CUYWLFDKSA-N
Pomalidomide	pomalidomide	BRD-A12994259-001-02-1	PREP034	"angiogenesis inhibitor, tumor necrosis factor production inhibitor"	"CRBN, PTGS2, TNF"	hematologic malignancy	multiple myeloma	Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12	Launched	Pomalidomide	134780	UVSMNLNDYGZFPF-UHFFFAOYSA-N
Ponatinib	ponatinib	BRD-K44227013-001-06-4	PROS003_PR500	"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor"	"ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK"	hematologic malignancy	"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)"	"CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1"	Launched	Ponatinib	24826799	PHXJVRSECIGDHY-UHFFFAOYSA-N
Posaconazole	posaconazole	BRD-K06222852-001-03-2	PREP017	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O"	Launched	Posaconazole	468595	RAGOYPUPXAKGKH-XAKZXMRKSA-N
Poziotinib	poziotinib	BRD-K50010139-001-01-5///BRD-K50010139-001-02-3	PROS003_PR500///PMTS011	EGFR inhibitor	"EGFR, ERBB2, ERBB4"	NA	NA	"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C"	Phase 2	Poziotinib	25127713	LPFWVDIFUFFKJU-UHFFFAOYSA-N
PP-1	PP-1	BRD-K47598052-001-15-8	PREP041	src inhibitor	"HCK, RET"	NA	NA	"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C"	Preclinical	PP-1	1400	ZVPDNRVYHLRXLX-UHFFFAOYSA-N
PP-121	PP-121	BRD-K81801188-001-02-8	PREP040	protein tyrosine kinase inhibitor	"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC"	NA	NA	"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12"	Preclinical	PP-121	24905142	NVRXTLZYXZNATH-UHFFFAOYSA-N
PP-2	PP-2	BRD-K95785537-001-23-1	PREP042	src inhibitor	"ABL1, LCK, LYN, RIPK2, SRC"	NA	NA	"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12"	Preclinical	PP-2	4878	PBBRWFOVCUAONR-UHFFFAOYSA-N
PP242	PP242	BRD-K87112191-001-04-5	PREP015	mTOR inhibitor	"MTOR, PASK"	NA	NA	"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12"	Preclinical	PP242	135565635	NA
Propyl pyrazole triol	PPT	BRD-K00312224-001-09-5	PREP041	estrogen receptor agonist	ESR1	NA	NA	"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1"	Preclinical	Propyl pyrazole triol	5040063	IOTXSIGGFRQYKW-UHFFFAOYSA-N
PQ-401	PQ-401	BRD-K67537649-001-04-5	PREP041	IGF-1 inhibitor	IGF1R	NA	NA	"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12"	Preclinical	PQ-401	9549305	YBLWOZUPHDKFOT-UHFFFAOYSA-N
"3,5-Dithiocyanatopyridine-2,6-diamine"	PR-619	BRD-K54395039-001-01-7	PREP046	DUB inhibitor	NA	NA	NA	"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N"	Preclinical	"3,5-Dithiocyanatopyridine-2,6-diamine"	2817763	ZXOBLNBVNROVLC-UHFFFAOYSA-N
Practolol	practolol	BRD-A41304429-001-14-8	PREP023	adrenergic receptor antagonist	ADRB1	NA	NA	"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1"	Withdrawn	Practolol	4883	DURULFYMVIFBIR-UHFFFAOYSA-N
Pralatrexate	pralatrexate	BRD-A74914197-001-02-9	PROS005_PR500	dihydrofolate reductase inhibitor	"DHFR, TYMS"	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Launched	Pralatrexate	148121	OGSBUKJUDHAQEA-WMCAAGNKSA-N
Pranidipine	pranidipine	BRD-A68083442-001-01-6	PREP032	calcium channel blocker	CACNA1C	NA	NA	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	Phase 2	Pranidipine	6436048	XTFPDGZNWTZCMF-DHZHZOJOSA-N
Prazosin	prazosin	BRD-K49111258-003-29-7	PREP031	adrenergic receptor antagonist	"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7"	cardiology	hypertension	"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1"	Launched	Prazosin	4893	IENZQIKPVFGBNW-UHFFFAOYSA-N
Prednisolone	prednisolone///prednisolone-acetate	BRD-A27887842-001-04-0///BRD-A01643550-001-04-9	PREP021///PREP020	glucocorticoid receptor agonist	"NR3C1, NR3C2, SERPINA6///NR3C1"	"ophthalmology, dermatology, infectious disease"	"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis"	"C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO///CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C"	Launched	Prednisolone	5755	OIGNJSKKLXVSLS-VWUMJDOOSA-N
Prednisolone hemisuccinate	prednisolone-hemisuccinate	BRD-A78391468-001-02-8	PREP032	glucocorticoid receptor agonist	NR3C1	NA	NA	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	Preclinical	Prednisolone hemisuccinate	656804	APGDTXUMTIZLCJ-CGVGKPPMSA-N
Prednisolone-tebutate	prednisolone-tebutate	BRD-A53151380-001-01-2	PREP023	anti-inflammatory agent	NA	NA	NA	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C	Launched	Prednisolone-tebutate	155903746	HUMXXHTVHHLNRO-HGVFMWMISA-N
Primaquine	primaquine	BRD-A55913614-316-09-6	PREP015	"antimalarial agent, DNA inhibitor"	"KRT7, NQO2"	infectious disease	malaria	"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1"	Launched	Primaquine	4908	INDBQLZJXZLFIT-UHFFFAOYSA-N
Proflavine	proflavine-hemisulfate	BRD-K68408467-065-01-8	PREP044	topical anesthetic	F2	NA	NA	Nc1ccc2cc3ccc(N)cc3nc2c1	Phase 2	Proflavine	7099	WDVSHHCDHLJJJR-UHFFFAOYSA-N
Propoxycaine	propoxycaine	BRD-K18250272-003-11-0	PREP021	local anesthetic	NA	neurology/psychiatry	anesthetic	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	Launched	Propoxycaine	6843	CAJIGINSTLKQMM-UHFFFAOYSA-N
Propranolol	propranolol	BRD-A10070317-003-28-3	PREP021	adrenergic receptor antagonist	NA	"cardiology, neurology/psychiatry"	"hypertension, angina pectoris, migraine headache"	"CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12"	Launched	Propranolol	4946	AQHHHDLHHXJYJD-UHFFFAOYSA-N
Proscillaridin A	proscillaridin-a	BRD-A11815689-001-01-1	PREP023	NA	NA	cardiology	"congestive heart failure, cardiac arrythmia"	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O	Launched	Proscillaridin A	222154	MYEJFUXQJGHEQK-OWBILYANSA-N
Protirelin	protirelin	BRD-A16997652-001-02-3	PREP016	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1	Launched	Protirelin	638678	XNSAINXGIQZQOO-SRVKXCTJSA-N
Cerdulatinib	PRT062070	BRD-K25835157-001-01-4	PREP032	"JAK inhibitor, syk inhibitor"	SYK	NA	NA	"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1"	Phase 1	Cerdulatinib	44595079	BGLPECHZZQDNCD-UHFFFAOYSA-N
PRT062607	PRT062607	BRD-K53734668-003-02-0	PREP030	syk inhibitor	"FGR, MAP3K9, SYK"	NA	NA	"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1"	Phase 2	PRT062607	44462758	TXGKRVFSSHPBAJ-JKSUJKDBSA-N
PSB-1115	PSB-1115	BRD-K49027941-001-01-1	PREP041	adenosine receptor antagonist	"ADORA1, ADORA2B, ADORA3"	NA	NA	"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O"	Preclinical	PSB-1115	5311479	UYDRRQPGDSIMNU-UHFFFAOYSA-N
Unii-V14CN8M621	PSI-7976	BRD-K05674516-001-01-7	PREP030	HCV inhibitor	NA	NA	NA	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Preclinical	Unii-V14CN8M621	45375809	TTZHDVOVKQGIBA-YBSJRAAASA-N
PTC-209	PTC-209	BRD-K83834509-001-01-1	PREP041	BMI-1 inhibitor	NA	NA	NA	"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1"	Preclinical	PTC-209	NA	NA
Pterostilbene	pterostilbene	BRD-K53097745-001-01-5	PREP019	"cyclooxygenase inhibitor, PPAR receptor agonist"	PTGS2	NA	NA	COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1	Phase 2/Phase 3	Pterostilbene	5281727	VLEUZFDZJKSGMX-ONEGZZNKSA-N
PU-H71	PU-H71	BRD-K36529613-001-02-6	PREP045	HSP inhibitor	HSP90AA1	NA	NA	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	Phase 1	PU-H71	54613037	HUAKDRZHOBLKGD-UHFFFAOYSA-N
Puromycin	puromycin	BRD-A28970875-300-04-9	PREP014	protein synthesis inhibitor	"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1"	NA	NA	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	Preclinical	Puromycin	439530	RXWNCPJZOCPEPQ-NVWDDTSBSA-N
Pyrimethamine	pyrimethamine	BRD-K88429204-001-35-1	PREP017	dihydrofolate reductase inhibitor	"DHFR, SLC47A1"	infectious disease	malaria	"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1"	Launched	Pyrimethamine	4993	WKSAUQYGYAYLPV-UHFFFAOYSA-N
Pyrithione Zinc	pyrithione-zinc	BRD-K16136380-001-01-7	PREP048	ATP synthase inhibitor	"KCNQ1, KCNQ2, KCNQ4, KCNQ5"	dermatology	dandruff	"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1"	Launched	Pyrithione Zinc	NA	NA
Pyritinol	pyritinol	BRD-K82181219-001-04-3	PREP022	NA	NA	"rheumatology, neurology/psychiatry"	"rheumatoid arthritis, senile dementia"	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	Launched	Pyritinol	14190	SIXLXDIJGIWWFU-UHFFFAOYSA-N
Pyroxamide	pyroxamide	BRD-K11663430-001-02-3	PREP046	HDAC inhibitor	HDAC1	NA	NA	"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1"	Phase 1	Pyroxamide	4996	PTJGLFIIZFVFJV-UHFFFAOYSA-N
Quinethazone	quinethazone	BRD-A59303141-001-10-4	PREP020	thiazide diuretic	"CA1, CA2, SLC12A1, SLC12A2, SLC12A3"	cardiology	hypertension	CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O	Launched	Quinethazone	6307	AGMMTXLNIQSRCG-UHFFFAOYSA-N
Quinidine	quinidine	BRD-K59632282-052-03-1	PREP015	sodium channel blocker	"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4"	"infectious disease, cardiology"	"malaria, atrial fibrillation (AF), ventricular arrhythmias"	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	Quinidine	441074	LOUPRKONTZGTKE-LHHVKLHASA-N
Quizartinib	quizartinib	BRD-K93918653-001-08-9	PREP027	FLT3 inhibitor	"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET"	NA	NA	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	Phase 3	Quizartinib	24889392	NA
R-306465	R306465	BRD-K86687746-001-01-3	PREP044	HDAC inhibitor	NA	NA	NA	ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	Phase 1	R-306465	10309899	MUTBJZVSRNUIHA-UHFFFAOYSA-N
R406 Benzenesulfonate	R406	BRD-K20285085-074-04-5	PREP018	SYK inhibitor	"RET, SYK"	NA	NA	"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC"	Phase 1	R406 Benzenesulfonate	11984591	UXDRJPYSTZHIOE-UHFFFAOYSA-N
R547	R547	BRD-K52233191-001-02-4	PREP024	CDK inhibitor	"CDK1, CDK2, CDK4, CDK7"	NA	NA	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	Phase 1	R547	6918852	JRNJNYBQQYBCLE-UHFFFAOYSA-N
Rabeprazole	rabeprazole	BRD-A39390670-236-10-7	PREP023	"ATPase inhibitor, gastrin inhibitor"	ATP4A	gastroenterology	"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome"	"COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C"	Launched	Rabeprazole	5029	YREYEVIYCVEVJK-UHFFFAOYSA-N
Racecadotril	racecadotril	BRD-A08187463-001-12-9	PREP028	enkephalinase inhibitor	MME	gastroenterology	diarrhea	"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1"	Launched	Racecadotril	107751	ODUOJXZPIYUATO-UHFFFAOYSA-N
Raclopride	raclopride	BRD-K04111260-001-10-0	PREP017	dopamine receptor antagonist	"DRD2, DRD3, HTR1A"	NA	NA	"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC"	Launched	Raclopride	3033769	WAOQONBSWFLFPE-VIFPVBQESA-N
Radezolid	radezolid	BRD-K84683831-001-01-0	PREP024	"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor"	NA	NA	NA	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1	Phase 2	Radezolid	11224409	BTTNOGHPGJANSW-IBGZPJMESA-N
Raf265(chir-265)	RAF265	BRD-K93123848-001-04-1	PREP045	"RAF inhibitor, VEGFR inhibitor"	BRAF	NA	NA	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	Phase 2	Raf265(chir-265)	11656518	YABJJWZLRMPFSI-UHFFFAOYSA-N
Raloxifene	raloxifene	BRD-K63828191-003-32-1	PREP023	"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)"	"ESR1, ESR2"	"orthopedics, oncology"	"osteoporosis, breast cancer"	"Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1"	Launched	Raloxifene	5035	GZUITABIAKMVPG-UHFFFAOYSA-N
Raltitrexed	raltitrexed	BRD-K89839824-001-05-3	PREP031	thymidylate synthase inhibitor	"FPGS, TYMS"	oncology	mesothelioma	"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O"	Launched	Raltitrexed	135400182	IVTVGDXNLFLDRM-HNNXBMFYSA-N
Ramatroban	ramatroban	BRD-K08586861-001-01-1	PREP028	prostanoid receptor antagonist	"PTGDR2, TBXA2R"	"cardiology, pulmonary"	"coronary artery disease (CAD), asthma"	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	Launched	Ramatroban	123879	LDXDSHIEDAPSSA-OAHLLOKOSA-N
Ramifenazone	ramifenazone	BRD-K85333151-003-13-4	PREP021	cyclooxygenase inhibitor	NA	"neurology/psychiatry, endocrinology"	"pain relief, fever"	"CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O"	Launched	Ramifenazone	5037	XOZLRRYPUKAKMU-UHFFFAOYSA-N
Ranitidine	ranitidine	BRD-K70505054-003-12-4	PREP023	histamine receptor antagonist	HRH2	gastroenterology	heartburn	"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O"	Launched	Ranitidine	3001055	VMXUWOKSQNHOCA-UKTHLTGXSA-N
Refametinib	refametinib	BRD-K85751432-001-03-3	PREP025	MEK inhibitor	"MAP2K1, MAP2K2"	NA	NA	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	Phase 2	Refametinib	44182295	RDSACQWTXKSHJT-NSHDSACASA-N
Regorafenib	regorafenib	BRD-K16730910-001-10-7///BRD-K16730910-001-07-3	PROS004_PR500///PREP016	"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor"	"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK"	oncology	"colorectal cancer, gastrointestinal stromal tumors (GIST)"	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	Launched	Regorafenib	11167602	NA
Remoxipride	remoxipride	BRD-K54094468-003-11-1	PREP022	dopamine receptor antagonist	"DRD2, DRD3, DRD4, HTR2A, SIGMAR1"	NA	NA	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	Withdrawn	Remoxipride	54477	GUJRSXAPGDDABA-NSHDSACASA-N
Repaglinide	repaglinide	BRD-K82846253-001-15-4	PREP032	insulin secretagogue	"ABCC8, KCNJ11, PPARG"	endocrinology	diabetes mellitus	"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O"	Launched	Repaglinide	65981	FAEKWTJYAYMJKF-QHCPKHFHSA-N
RepSox	repsox	BRD-K80480517-001-02-4	PREP040	TGF beta receptor inhibitor	TGFBR1	NA	NA	"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1"	Preclinical	RepSox	449054	LBPKYPYHDKKRFS-UHFFFAOYSA-N
Resatorvid	resatorvid	BRD-K61567297-001-01-9	PREP039	toll-like receptor antagonist	TLR4	NA	NA	"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl"	Phase 3	Resatorvid	11703255	LEEIJTHMHDMWLJ-CQSZACIVSA-N
Resiquimod	resiquimod	BRD-K76210423-001-01-6	PROS001_PR500	toll-like receptor agonist	"TLR7, TLR8"	NA	NA	"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O"	Phase 3	Resiquimod	159603	BXNMTOQRYBFHNZ-UHFFFAOYSA-N
Resminostat	resminostat	BRD-K28822270-001-03-7///BRD-K28822270-001-01-1	PROS002_PR500///PREP024	HDAC inhibitor	"HDAC1, HDAC3, HDAC6, HDAC8"	NA	NA	"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO"	Phase 2	Resminostat	11609955	FECGNJPYVFEKOD-VMPITWQZSA-N
N-Phthalyl-L-tryptophan	RG108	BRD-K89391146-001-08-0	PREP032	DNA methyltransferase inhibitor	"DNMT1, DNMT3B"	NA	NA	"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O"	Preclinical	N-Phthalyl-L-tryptophan	344265	HPTXLHAHLXOAKV-UHFFFAOYSA-N
RG2833	RG2833	BRD-K02389548-001-02-5	PREP026	HDAC inhibitor	"HDAC1, HDAC3"	NA	NA	"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N"	Phase 1	RG2833	56654642	VOPDXHFYDJAYNS-UHFFFAOYSA-N
RGFP966	RGFP966	BRD-K61688984-001-02-9	PREP014	HDAC inhibitor	HDAC3	NA	NA	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	Preclinical	RGFP966	56650312	BLVQHYHDYFTPDV-VCABWLAWSA-N
Physcion	rheochrysidin	BRD-K67772619-001-05-1	PREP033	protein tyrosine kinase inhibitor	PTPN1	NA	NA	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	Preclinical	Physcion	10639	FFWOKTFYGVYKIR-UHFFFAOYSA-N
RI-1	RI-1	BRD-K79555887-001-01-0	PREP041	NA	RAD51	NA	NA	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1	Preclinical	RI-1	1074953	MWSUIZKGNWELRF-UHFFFAOYSA-N
Ribavirin	ribavirin	BRD-K60369935-001-18-3	PREP035	antiviral	"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2"	infectious disease	hepatitis C	"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O"	Launched	Ribavirin	37542	IWUCXVSUMQZMFG-AFCXAGJDSA-N
Xylitol	ribitol	BRD-K49313711-001-05-4	PREP043	NA	NA	NA	NA	OC[C@H](O)[C@H](O)[C@H](O)CO	Preclinical	Xylitol	6912	HEBKCHPVOIAQTA-NGQZWQHPSA-N
Ribociclib	ribociclib	BRD-K36788280-001-01-2	PROS001_PR500	CDK inhibitor	"CDK4, CDK6"	oncology	breast cancer	"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1"	Launched	Ribociclib	44631912	RHXHGRAEPCAFML-UHFFFAOYSA-N
Riboflavin	riboflavin	BRD-K70246307-001-04-1	PREP017	vitamin B2	"BLVRB, RFK"	gastroenterology	jaundice	"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C"	Launched	Riboflavin	493570	AUNGANRZJHBGPY-SCRDCRAPSA-N
Rifampicin	rifampin	BRD-K01507359-001-22-9	PREP030	RNA polymerase inhibitor	"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3"	infectious disease	"tuberculosis, meningitis"	"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C"	Launched	Rifampicin	25141428	FZYOVNIOYYPUPY-AMSHPFMVSA-N
Rigosertib	rigosertib	BRD-K55187425-236-05-2	PROS004_PR500	"cell cycle inhibitor, PLK inhibitor"	PLK1	NA	NA	"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1"	Phase 3	Rigosertib	6918736	NA
Riluzole	riluzole	BRD-K21283037-001-21-5	PREP020	glutamate inhibitor	"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11"	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1"	Launched	Riluzole	5070	FTALBRSUTCGOEG-UHFFFAOYSA-N
Rimexolone	rimexolone	BRD-K31627533-001-09-5	PREP015	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	ophthalmology	anterior uveitis	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	Rimexolone	49868107	QTTRZHGPGKRAFB-SNLFSWRFSA-N
Riociguat	riociguat	BRD-K84783599-001-01-0	PREP020	guanylate cyclase stimulant	"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3"	cardiology	hypertension	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Launched	Riociguat	11304743	WXXSNCNJFUAIDG-UHFFFAOYSA-N
Rita	RITA	BRD-K00317371-001-06-1	PREP015	MDM inhibitor	MDM2	NA	NA	"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1"	Preclinical	Rita	374536	KZENBFUSKMWCJF-UHFFFAOYSA-N
Yutopar	ritodrine	BRD-K14003026-003-09-0	PREP031	adrenergic receptor agonist	ADRB2	obstetrics/gynecology	premature labor	"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1"	Launched	Yutopar	33572	IOVGROKTTNBUGK-SJCJKPOMSA-N
RKI-1447	RKI-1447	BRD-K19333160-001-01-3	PREP037	rho associated kinase inhibitor	"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2"	NA	NA	"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1"	Preclinical	RKI-1447	60138149	GDVRVPIXWXOKQO-UHFFFAOYSA-N
"2,4-Dichloro-N-isopropyl-N-(2-isopropylaminoethyl)benzenesulfonamide"	RN-1734	BRD-K95581532-001-01-5	PREP036	TRPV antagonist	TRPV4	NA	NA	"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl"	Preclinical	"2,4-Dichloro-N-isopropyl-N-(2-isopropylaminoethyl)benzenesulfonamide"	3601086	IHYZMEAZAIFMTN-UHFFFAOYSA-N
Ro-04-5595	Ro-04-5595	BRD-A63546914-003-02-0	PREP041	NA	GRIN2B	NA	NA	"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O"	Preclinical	Ro-04-5595	46740	DSTWURHEHMZWEI-UHFFFAOYSA-N
Ro-10-5824	Ro-10-5824	BRD-K79684402-300-02-8	PREP037	dopamine receptor agonist	DRD4	NA	NA	"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1"	Preclinical	Ro-10-5824	16759175	KABDATZAOUSYES-UHFFFAOYSA-N
"6-(Benzenesulfinyl)tetrazolo[1,5-b]pyridazine"	Ro-106-9920	BRD-A53134341-001-03-2	PREP040	NFkB pathway inhibitor	NA	NA	NA	"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1"	Preclinical	"6-(Benzenesulfinyl)tetrazolo[1,5-b]pyridazine"	3906779	JFSXSNSCPNFCDM-UHFFFAOYSA-N
Ro-4987655	Ro-4987655	BRD-K64538373-001-01-4	PREP018	MEK inhibitor	MAP2K1	NA	NA	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Phase 1	Ro-4987655	11548630	FIMYFEGKMOCQKT-UHFFFAOYSA-N
Ro-90-7501	Ro-90-7501	BRD-K58299615-001-03-5	PREP037	NA	APP	NA	NA	"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1"	Preclinical	Ro-90-7501	824226	PAGZCEHLFCJSPV-UHFFFAOYSA-N
Ro-9187	Ro-9187	BRD-K57284066-001-01-6	PREP040	HCV inhibitor	NA	NA	NA	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	Preclinical	Ro-9187	11514721	ODLGMSQBFONGNG-XZMZPDFPSA-N
Rociletinib	rociletinib	BRD-K33610132-001-02-9	PROS002_PR500	EGFR inhibitor	EGFR	NA	NA	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	Phase 3	Rociletinib	57335384	HUFOZJXAKZVRNJ-UHFFFAOYSA-N
Romidepsin	romidepsin	BRD-K61397605-001-03-4	PREP014	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C	Launched	Romidepsin	5352062	OHRURASPPZQGQM-GCCNXGTGSA-N
Roquinimex	roquinimex	BRD-K03384561-001-02-7	PREP019	"angiogenesis inhibitor, tumor necrosis factor production inhibitor"	NA	NA	NA	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	Phase 3	Roquinimex	54676478	SGOOQMRIPALTEL-UHFFFAOYSA-N
RS-16566	RS-16566	BRD-K80725821-300-02-9	PREP041	serotonin receptor antagonist	NA	NA	NA	CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2	Preclinical	RS-16566	6604794	OGXMGJGFLBSEJW-HNNXBMFYSA-N
RS-17053	RS-17053	BRD-K76840893-003-02-5	PREP040	adrenergic receptor antagonist	"ADRA1A, ADRA1D"	NA	NA	"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1"	Preclinical	RS-17053	3894573	XLZHXAXXJVKTFM-UHFFFAOYSA-N
RS-504393	RS-504393	BRD-K87510569-001-02-8	PREP040	CC chemokine receptor antagonist	"CCL2, CCR2"	NA	NA	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	Preclinical	RS-504393	9953769	ODNICNWASXKNNQ-UHFFFAOYSA-N
RS-67506	RS-67506	BRD-K50018155-003-02-1	PREP044	serotonin receptor partial agonist	HTR4	NA	NA	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical	RS-67506	133076	UATDVRSFFGFTAI-UHFFFAOYSA-N
RU-58841	RU-58841	BRD-K62762455-001-01-3	PREP025	androgen receptor antagonist	AR	NA	NA	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	Phase 2	RU-58841	132981	ARBYGDBJECGMGA-UHFFFAOYSA-N
Rubitecan	rubitecan	BRD-K79821389-001-03-5	PMTS011	topoisomerase inhibitor	TOP1	NA	NA	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	Phase 3	Rubitecan	472335	VHXNKPBCCMUMSW-FQEVSTJZSA-N
4-Butylresorcinol	rucinol	BRD-K61036791-001-01-6	PREP027	tyrosinase inhibitor	TYR	NA	NA	CCCCc1ccc(O)cc1O	Phase 1	4-Butylresorcinol	205912	CSHZYWUPJWVTMQ-UHFFFAOYSA-N
Rutin	rutin	BRD-K20482099-001-09-4	PREP031	"antioxidant, capillary stabilizing agent, nitric oxide scavenger"	AKR1C3	"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy"	"joint pain, nasal congestion, constipation, irritability, allergic rhinitis"	"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O"	Launched	Rutin	5280805	IKGXIBQEEMLURG-NVPNHPEKSA-N
Ruxolitinib	ruxolitinib	BRD-K53972329-001-07-0	PROS003_PR500	JAK inhibitor	"JAK1, JAK2, JAK3, TYK2"	"hematologic malignancy, hematology"	"myelofibrosis, polycythemia vera"	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched	Ruxolitinib	25126798	NA
Ryuvidine	ryuvidine	BRD-K06426971-001-02-7	PREP032	histone lysine methyltransferase inhibitor	"CDK2, CDK4"	NA	NA	"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O"	Preclinical	Ryuvidine	481747	HFPLHASLIOXVGS-UHFFFAOYSA-N
S-Methyl-L-cysteine	S-methylcysteine	BRD-K63123526-001-01-2	PREP038	NA	"CTSD, MGMT"	NA	NA	"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O"	Phase 1	S-Methyl-L-cysteine	24417	IDIDJDIHTAOVLG-VKHMYHEASA-N
S26948	S26948	BRD-K48826825-001-01-8	PREP033	PPAR receptor agonist	PPARG	NA	NA	"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC"	Preclinical	S26948	9958279	NSMJEHGOMXSLCW-UHFFFAOYSA-N
Salidroside	salidroside	BRD-K66030860-001-03-6	PREP032	beta amyloid protein neurotoxicity inhibitor	APP	NA	NA	"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O"	Preclinical	Salidroside	159278	ILRCGYURZSFMEG-RKQHYHRCSA-N
Salinomycin	salinomycin	BRD-A28301258-001-03-0	PREP029	NA	NA	infectious disease	coccidiosis	"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O"	Launched	Salinomycin	3085092	KQXDHUJYNAXLNZ-XQSDOZFQSA-N
Salvianolic acid B	salvianolic-acid-B	BRD-K18898553-001-01-1	PMTS011	"metalloproteinase inhibitor, EGFR inhibitor"	MMP9	NA	NA	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	Phase 2	Salvianolic acid B	11629084	SNKFFCBZYFGCQN-PDVBOLEISA-N
Salvinorin A	salvinorin-a	BRD-K19284129-001-02-6	PREP038	opioid receptor agonist	"OPRD1, OPRK1, OPRM1"	NA	NA	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	Phase 1	Salvinorin A	128563	OBSYBRPAKCASQB-AGQYDFLVSA-N
Sangivamycin	sangivamycin	BRD-A64064900-001-02-3	PREP025	DNA inhibitor	NA	NA	NA	NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12	Phase 1	Sangivamycin	14978	OBZJZDHRXBKKTJ-JTFADIMSSA-N
SAR131675	SAR131675	BRD-K38904395-001-02-3	PREP042	VEGFR inhibitor	FLT4	NA	NA	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	Preclinical	SAR131675	71295845	PFMPOBVAYMTUOX-GOSISDBHSA-N
Saracatinib	saracatinib	BRD-K19540840-001-09-4	PROS004_PR500	src inhibitor	"ABL1, LCK, SRC, YES1"	NA	NA	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	Phase 2/Phase 3	Saracatinib	10302451	OUKYUETWWIPKQR-UHFFFAOYSA-N
Sarafloxacin	sarafloxacin	BRD-K08525451-003-05-2	PREP028	bacterial DNA gyrase inhibitor	NA	NA	NA	"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O"	Launched	Sarafloxacin	56208	XBHBWNFJWIASRO-UHFFFAOYSA-N
Satraplatin	satraplatin	BRD-K42497885-001-01-1	PREP045	DNA alkylating agent	NA	NA	NA	"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O"	Phase 3	Satraplatin	6918220	TWEQNPPRXJRHHM-UHFFFAOYSA-L
Saxagliptin	saxagliptin	BRD-A81513827-001-03-6	PREP016	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2	Launched	Saxagliptin	11243969	QGJUIPDUBHWZPV-SGTAVMJGSA-N
SB-200646	SB-200646	BRD-K77677632-003-02-6	PREP047	serotonin receptor antagonist	"HTR2B, HTR2C"	NA	NA	"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12"	Preclinical	SB-200646	126769	OJZZJTLBYXHUSJ-UHFFFAOYSA-N
SB-205384	SB-205384	BRD-A22707317-001-10-8	PREP037	GABA receptor modulator	"GABRA3, GABRA5, GABRA6"	NA	NA	"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N"	Preclinical	SB-205384	197690	JDTZAGLGBRRCJT-UHFFFAOYSA-N
SB-216641	SB-216641	BRD-K30867024-003-03-3	PREP040	serotonin receptor antagonist	"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C"	NA	NA	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	Preclinical	SB-216641	3292447	JRNUKVFYILMMLX-UHFFFAOYSA-N
SB 218078	SB-218078	BRD-A06352508-001-03-7	PREP043	CHK inhibitor	CHEK1	NA	NA	"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13"	Preclinical	SB 218078	3387354	OTPNDVKVEAIXTI-UHFFFAOYSA-N
SB-218795	SB-218795	BRD-K61097567-001-08-5	PREP042	tachykinin antagonist	TACR3	NA	NA	"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1"	Preclinical	SB-218795	6604858	IUMQXQJZIHWLIN-HSZRJFAPSA-N
SB-225002	SB-225002	BRD-K61323504-001-04-0	PREP044	CC chemokine receptor antagonist	CXCR2	NA	NA	"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O"	Preclinical	SB-225002	3854666	MQBZVUNNWUIPMK-UHFFFAOYSA-N
SB-228357	SB-228357	BRD-K15424032-001-03-6	PREP015	serotonin receptor antagonist	"HTR2A, HTR2B, HTR2C"	NA	NA	"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F"	Preclinical	SB-228357	443390	RRJLJKRFFRZRAF-UHFFFAOYSA-N
SB-2343	SB-2343	BRD-K98795921-001-01-7	PREP039	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	Phase 1	SB-2343	46912230	QYBGBLQCOOISAR-UHFFFAOYSA-N
SB-239063	SB-239063	BRD-K82091397-001-03-0	PREP043	p38 MAPK inhibitor	"MAPK11, MAPK14, PTGS2"	NA	NA	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1	Preclinical	SB-239063	5166	ZQUSFAUAYSEREK-UHFFFAOYSA-N
SB-242235	SB-242235	BRD-K19412355-001-01-0	PREP024	p38 MAPK inhibitor	"HSPB1, MAPK14"	NA	NA	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	Phase 1	SB-242235	9863367	PDTYLGXVBIWRIM-UHFFFAOYSA-N
N-(3-Methoxyphenyl)-4-chlorocinnamanilide	SB-366791	BRD-K61536336-001-01-7	PREP032	TRPV antagonist	TRPV1	NA	NA	"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1"	Preclinical	N-(3-Methoxyphenyl)-4-chlorocinnamanilide	667594	RYAMDQKWNKKFHD-JXMROGBWSA-N
SB-431542	SB-431542	BRD-K67298865-001-09-0	PREP040	TGF beta receptor inhibitor	"ACVR1C, TGFBR1"	NA	NA	"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1"	Preclinical	SB-431542	4521392	NA
SB 505124	SB-505124	BRD-K40109029-001-02-9	PREP040	ALK tyrosine kinase receptor inhibitor	TGFBR1	NA	NA	Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C	Preclinical	SB 505124	9858940	NA
SB-525334	SB-525334	BRD-K37720887-001-07-8	PREP024	TGF beta receptor inhibitor	TGFBR1	NA	NA	"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C"	Preclinical	SB-525334	9967941	NA
SB590885	SB-590885	BRD-K78809024-001-05-7	PREP040	RAF inhibitor	BRAF	NA	NA	"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1"	Preclinical	SB590885	11316960	DPCXEUSDRQOOGZ-QLYXXIJNSA-N
SB-657510	SB-657510	BRD-K95292280-001-01-3	PREP042	urotensin receptor antagonist	UTS2R	NA	NA	"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1"	Preclinical	SB-657510	11272107	KQCZCINJGIRLCD-CYBMUJFWSA-N
SB-743921	SB-743921	BRD-K68532323-003-02-8	PREP018	kinesin-like spindle protein inhibitor	KIF11	NA	NA	"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1"	Phase 1/Phase 2	SB-743921	9936388	NA
Pracinostat	SB-939	BRD-K86797399-001-05-1	PREP027	HDAC inhibitor	"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9"	NA	NA	"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO"	Phase 2	Pracinostat	49855250	JHDKZFFAIZKUCU-ZRDIBKRKSA-N
Vidofludimus	SC-12267	BRD-K40797222-001-01-8	PREP019	dihydroorotate dehydrogenase inhibitor	IL17A	NA	NA	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1	Phase 2	Vidofludimus	9820008	XPRDUGXOWVXZLL-UHFFFAOYSA-N
SC-144	SC-144	BRD-K55305701-001-01-2	PREP041	P glycoprotein inhibitor	NA	NA	NA	"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21"	Preclinical	SC-144	400169	UEADAWQSJOWXBK-UHFFFAOYSA-N
SCH-58261	SCH-58261	BRD-K81225797-001-02-3	PREP042	adenosine receptor antagonist	"ADORA1, ADORA2A, ADORA2B, ADORA3"	NA	NA	"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1"	Preclinical	SCH-58261	176408	UTLPKQYUXOEJIL-UHFFFAOYSA-N
SCH-900776	SCH-900776	BRD-K75009076-001-02-1	PROS004_PR500	CHK inhibitor	"CDK2, CHEK1"	NA	NA	"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1"	Phase 2	SCH-900776	46239015	GMIZZEXBPRLVIV-SECBINFHSA-N
Sclareol	sclareol	BRD-A23127772-001-02-3	PREP033	NA	NA	NA	NA	CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C	Preclinical	Sclareol	163263	XVULBTBTFGYVRC-HHUCQEJWSA-N
Scriptaid	scriptaid	BRD-K22503835-001-11-0	PREP037	HDAC inhibitor	"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	NA	NA	"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23"	Preclinical	Scriptaid	5186	JTDYUFSDZATMKU-UHFFFAOYSA-N
SCS	SCS	BRD-K78496197-001-03-9	PREP025	NA	NA	NA	NA	"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O"	Preclinical	SCS	76707	OMCYEZUIYGPHDJ-UHFFFAOYSA-N
Sdz-wag-994	SDZ-WAG-994	BRD-K39558284-001-01-2	PREP033	adenosine receptor agonist	ADORA1	NA	NA	"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12"	Phase 2	Sdz-wag-994	164305	JAKAFSGZUXCHLF-LSCFUAHRSA-N
Se-methylselenocysteine	se-methylselenocysteine	BRD-K74227499-001-01-1	PREP032	NA	NA	NA	NA	"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O"	Phase 2	Se-methylselenocysteine	147004	XDSSPSLGNGIIHP-VKHMYHEASA-N
Secnidazole	secnidazole	BRD-A70083328-001-23-5	PREP017	"acetylcholinesterase inhibitor, microtubule inhibitor"	NA	infectious disease	protozoan infection	"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O"	Launched	Secnidazole	71815	KPQZUUQMTUIKBP-UHFFFAOYSA-N
Securinine	securinine	BRD-K49071277-001-04-7	PREP041	"GABA receptor antagonist, TP53 activator"	GABRA1	NA	NA	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31	Preclinical	Securinine	442872	SWZMSZQQJRKFBP-WZRBSPASSA-N
Selamectin	selamectin	BRD-A58564983-001-04-6	PREP022	nematocide	NA	infectious disease	flea control	CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O	Launched	Selamectin	9578507	AFJYYKSVHJGXSN-XHKIUTQPSA-N
Selinexor	selinexor	BRD-K21361524-001-01-1	PREP047	exportin antagonist	XPO1	NA	NA	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	Phase 2/Phase 3	Selinexor	71481097	NA
Selumetinib	selumetinib	BRD-K57080016-001-15-9	PROS002_PR500	MEK inhibitor	MAP2K1	NA	NA	"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO"	Phase 3	Selumetinib	10127622	CYOHGALHFOKKQC-UHFFFAOYSA-N
Semaxanib	semaxanib	BRD-K63504947-001-14-7///BRD-K63504947-001-15-4	PROS002_PR500///PREP024	VEGFR inhibitor	"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET"	NA	NA	"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1"	Phase 3	Semaxanib	5329098	WUWDLXZGHZSWQZ-WQLSENKSSA-N
Serdemetan	serdemetan	BRD-K65924316-001-03-1	PREP024	MDM inhibitor	MDM2	NA	NA	"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1"	Phase 1	Serdemetan	11609586	CEGSUKYESLWKJP-UHFFFAOYSA-N
Sertindole	sertindole	BRD-K69116396-001-04-1	PREP016	"dopamine receptor antagonist, serotonin receptor antagonist"	"ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2"	NA	NA	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	Withdrawn	Sertindole	60149	GZKLJWGUPQBVJQ-UHFFFAOYSA-N
Sevelamer	sevelamer	BRD-U45393375-000-01-6	PREP016	phosphate antagonist	NA	nephrology	chronic kidney disease (CKD)	", NCC=C.ClCC1CO1"	Launched	Sevelamer	3085017	ZNSIZMQNQCNRBW-UHFFFAOYSA-N
Sevoflurane	sevoflurane	BRD-K05638300-001-01-2	PREP048	membrane integrity inhibitor	"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1"	neurology/psychiatry	anesthetic	"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F"	Launched	Sevoflurane	5206	DFEYYRMXOJXZRJ-UHFFFAOYSA-N
SGI-1027	SGI-1027	BRD-K61228301-001-01-2	PREP037	DNA methyltransferase inhibitor	"DNMT1, DNMT3A, DNMT3B"	NA	NA	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	Preclinical	SGI-1027	24858111	QSYLKMKIVWJAAK-UHFFFAOYSA-N
SGI-1776	SGI-1776	BRD-K80700417-001-04-2	PREP026	Pim kinase inhibitor	"FLT3, PIM1, PIM2, PIM3"	NA	NA	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	Phase 1	SGI-1776	NA	NA
6-Methyl-2-(phenylazo)-3-pyridinol	SIB-1757	BRD-K98157055-001-10-9	PREP024	glutamate receptor antagonist	GRM5	NA	NA	Cc1ccc(O)c(N=Nc2ccccc2)n1	Preclinical	6-Methyl-2-(phenylazo)-3-pyridinol	5218788	LOCPVWIREQIGNQ-UHFFFAOYSA-N
SID-7969543	SID-7969543	BRD-A43885598-001-08-1	PREP042	steroidogenic factor antagonist	NR5A1	NA	NA	"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O"	Preclinical	SID-7969543	2149494	KWMBIIQCLUIHDI-OAHLLOKOSA-N
Simvastatin	simvastatin	BRD-K22134346-001-24-9	PREP031	HMGCR inhibitor	"HMGCR, ITGB2"	"endocrinology, cardiology, neurology/psychiatry"	"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia"	"CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12"	Launched	Simvastatin	54454	RYMZZMVNJRMUDD-HGQWONQESA-N
Sirolimus	sirolimus	BRD-K84937637-001-09-9	PREP031	mTOR inhibitor	"FGF2, FKBP1A, MTOR"	"transplant, pulmonary"	"organ rejection, lymphangioleiomyomatosis"	"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O"	Launched	Sirolimus	5284616	QFJCIRLUMZQUOT-HPLJOQBZSA-N
Skepinone-L	skepinone-l	BRD-K83607951-001-02-2	PREP036	p38 MAPK inhibitor	MAPK14	NA	NA	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	Preclinical	Skepinone-L	45279963	NA
SKF-96365	SKF-96365	BRD-A72703248-003-04-9	PREP024	calcium channel blocker	"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2"	NA	NA	COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1	Preclinical	SKF-96365	104955	FWLPKVQUECFKSW-UHFFFAOYSA-N
SKI-II	SKI-II	BRD-K20755323-001-05-9	PREP043	sphingosine kinase inhibitor	SPHK1	NA	NA	"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1"	Preclinical	SKI-II	753704	ZFGXZJKLOFCECI-UHFFFAOYSA-N
SMI-4a	SMI-4a	BRD-K70159787-001-01-1	PREP041	Pim kinase inhibitor	PIM1	NA	NA	FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O	Preclinical	SMI-4a	1361334	NGJLOFCOEOHFKQ-YVMONPNESA-N
SN-38	SN-38	BRD-K89561498-001-01-7	PREP030	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12"	Launched	SN-38	104842	FJHBVJOVLFPMQE-QFIPXVFZSA-N
SNS-314	SNS-314	BRD-K71512533-066-02-8	PREP026	Aurora kinase inhibitor	"AURKA, AURKB, AURKC"	NA	NA	"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1"	Phase 1	SNS-314	24995524	FAYAUAZLLLJJGH-UHFFFAOYSA-N
Snx-2112	SNX-2112	BRD-K71281111-001-04-3	PREP018	HSP inhibitor	NA	NA	NA	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1	Phase 1	Snx-2112	24772860	ZFVRYNYOPQZKDG-UHFFFAOYSA-N
Snx-5422	SNX-5422	BRD-K73197500-001-02-2	PREP044	HSP inhibitor	HSP90AA1	NA	NA	"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1"	Phase 1/Phase 2	Snx-5422	44195571	AVDSOVJPJZVBTC-UHFFFAOYSA-N
Sobetirome	sobetirome	BRD-K85406984-001-01-0	PREP024	thyroid hormone receptor agonist	"THRA, THRB"	NA	NA	"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O"	Phase 1	Sobetirome	9862248	QNAZTOHXCZPOSA-UHFFFAOYSA-N
Sodium glucoheptonate	sodium-glucoheptonate	BRD-K35952844-236-01-6	PREP020	NA	NA	NA	NA	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched	Sodium glucoheptonate	517057	FMYOMWCQJXWGEN-UHFFFAOYSA-M
Stibogluconic acid	sodium-stibogluconate	BRD-A60786380-412-01-5	PREP048	tyrosine phosphatase inhibitor	"PTPN6, TOP1"	infectious disease	leishmaniasis	OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O	Launched	Stibogluconic acid	90661669	YVTOSJPXMJSKEV-XCCFGPONSA-N
Tanshinone iia sulfonic acid	sodium-tanshinone-ii-a-sulfonate	BRD-K84798689-236-02-9	PREP032	potassium channel activator	NA	NA	NA	Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	Phase 2	Tanshinone iia sulfonic acid	125782	UJCACMLMPLLRGW-UHFFFAOYSA-N
Sonidegib	sonidegib	BRD-K19796430-001-05-6	PROS004_PR500	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1"	Launched	Sonidegib	24775005	NA
Sorafenib	sorafenib	BRD-K23984367-001-07-5///BRD-K23984367-075-15-2	PROS001_PR500///PREP029	"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor"	"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET"	oncology	"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)"	"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1"	Launched	Sorafenib	216239	MLDQJTXFUGDVEO-UHFFFAOYSA-N
Sparfloxacin	sparfloxacin	BRD-K07612980-001-05-3	PREP034	bacterial DNA gyrase inhibitor	TOP2A	NA	NA	"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1"	Withdrawn	Sparfloxacin	60464	DZZWHBIBMUVIIW-DTORHVGOSA-N
Spermidine	spermidine	BRD-K40438880-305-06-6	PREP047	glutamate receptor modulator	"KCNJ4, TXNRD1"	NA	NA	NCCCCNCCCN	Preclinical	Spermidine	1102	ATHGHQPFGPMSJY-UHFFFAOYSA-N
Spermine	spermine	BRD-K18375018-376-02-3	PREP033	NA	"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5"	NA	NA	NCCCNCCCCNCCCN	Preclinical	Spermine	1103	PFNFFQXMRSDOHW-UHFFFAOYSA-N
Spiradoline	spiradoline	BRD-K28192623-066-08-1	PREP018	opioid receptor agonist	OPRK1	NA	NA	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Phase 2	Spiradoline	55652	NYKCGQQJNVPOLU-ONTIZHBOSA-N
Spironolactone	spironolactone	BRD-K90027355-001-13-3	PREP028	mineralocorticoid receptor antagonist	"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG"	"endocrinology, cardiology, gastroenterology, rheumatology"	"hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia"	"CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12"	Launched	Spironolactone	5833	LXMSZDCAJNLERA-ZHYRCANASA-N
Lintitript	SR-27897	BRD-K35629949-001-02-0	PREP038	CCK receptor antagonist	CCKAR	NA	NA	"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl"	Phase 2	Lintitript	122077	ILNRQFBVVQUOLP-UHFFFAOYSA-N
SR-33805	SR-33805	BRD-K43002771-034-01-6	PREP044	calcium channel blocker	NA	NA	NA	"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC"	Phase 1	SR-33805	9850876	GCVFQRRBTCHIPK-UHFFFAOYSA-N
4-Amino-1-(6-chloro-2-pyridyl)-piperidine hydrochloride	SR-57227A	BRD-K09397065-003-06-1	PREP047	serotonin receptor agonist	HTR3A	NA	NA	NC1CCN(CC1)c1cccc(Cl)n1	Phase 2	4-Amino-1-(6-chloro-2-pyridyl)-piperidine hydrochloride	131746	FUMINTAAUJUVMP-UHFFFAOYSA-N
SRT-1720	SRT1720	BRD-K95926480-003-03-6	PREP036	SIRT activator	SIRT1	NA	NA	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	Preclinical	SRT-1720	24180125	NA
Apilimod	STA-5326	BRD-K41783120-001-02-8	PREP038	interleukin synthesis inhibitor	IL12A	NA	NA	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	Phase 2	Apilimod	10173277	HSKAZIJJKRAJAV-KOEQRZSOSA-N
Stattic	stattic	BRD-K17061841-001-03-5	PREP046	NA	NA	NA	NA	[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1	Preclinical	Stattic	2779853	ZRRGOUHITGRLBA-UHFFFAOYSA-N
StemRegenin 1	stemregenin-1	BRD-K36739687-001-03-0	PREP042	aryl hydrocarbon receptor antagonist	AHR	NA	NA	CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	Preclinical	StemRegenin 1	46199207	NA
STF-118804	STF-118804	BRD-K39171998-001-01-1	PREP041	NAMPT inhibitor	NAMPT	NA	NA	"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1"	Preclinical	STF-118804	20916937	DLFCEZOMHBPDGI-UHFFFAOYSA-N
Streptozocin	streptozotocin	BRD-K34411947-001-12-5	PREP022	DNA alkylating agent	SLC2A2	oncology	pancreatic cancer	"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O"	Launched	Streptozocin	29327	ZSJLQEPLLKMAKR-GKHCUFPYSA-N
SU-14813	SU014813	BRD-K75911534-001-01-6	PREP039	"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	KDR	NA	NA	Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	Phase 2	SU-14813	10138259	CTNPALGJUAXMMC-PMFHANACSA-N
Halicin	SU3327	BRD-K32730239-001-01-0	PREP037	JNK inhibitor	MAPK8	NA	NA	"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1"	Preclinical	Halicin	11837140	NQQBNZBOOHHVQP-UHFFFAOYSA-N
Sufentanil	sufentanil	BRD-K21547160-001-01-4	PREP029	opioid receptor modulator	"OPRD1, OPRK1, OPRM1"	neurology/psychiatry	anesthetic	CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1	Launched	Sufentanil	41693	GGCSSNBKKAUURC-UHFFFAOYSA-N
Sulconazole	sulconazole	BRD-A70649075-008-30-8	PREP017	sterol demethylase inhibitor	NA	infectious disease	"tinea pedis, tinea cruris, tinea corporis"	"Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1"	Launched	Sulconazole	5318	AFNXATANNDIXLG-UHFFFAOYSA-N
Sulfabenzamide	sulfabenzamide	BRD-K59983611-001-21-9	PREP044	bacterial antifolate	NA	NA	NA	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	Launched	Sulfabenzamide	5319	PBCZLFBEBARBBI-UHFFFAOYSA-N
Sulfamethazine	sulfamethazine	BRD-K11640013-236-10-1	PREP014	PABA antagonist	NA	gastroenterology	"enteritis, enteritis"	"Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1"	Launched	Sulfamethazine	5327	ASWVTGNCAZCNNR-UHFFFAOYSA-N
Sulfanilamide	sulfanilamide	BRD-K02594908-001-16-4	PREP020	carbonic anhydrase inhibitor	"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4"	infectious disease	vulvovaginal candidiasis	"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O"	Launched	Sulfanilamide	5333	FDDDEECHVMSUSB-UHFFFAOYSA-N
Sulfasalazine	sulfasalazine	BRD-K10670311-001-15-5	PREP021	cyclooxygenase inhibitor	"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1"	gastroenterology	ulcerative colitis	"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1"	Launched	Sulfasalazine	5353980	NCEXYHBECQHGNR-UHFFFAOYSA-N
Sulmazole	sulmazole	BRD-A22081593-001-11-1	PREP038	adenosine receptor antagonist	NA	NA	NA	COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O	Phase 1	Sulmazole	5353	XMFCOYRWYYXZMY-UHFFFAOYSA-N
Sunitinib	sunitinib	BRD-K42828737-001-03-3///BRD-K42828737-044-09-0	PROS001_PR500///PREP029	"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor"	"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET"	oncology	"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)"	"CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C"	Launched	Sunitinib	5329102	WINHZLLDWRZWRT-ATVHPVEESA-N
Suxibuzone	suxibuzone	BRD-K78815826-001-14-6	PREP017	cyclooxygenase inhibitor	NA	"rheumatology, neurology/psychiatry"	"joint pain, muscle pain"	"CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1"	Launched	Suxibuzone	5362	ONWXNHPOAGOMTG-UHFFFAOYSA-N
Tacalcitol	tacalcitol	BRD-K73237276-001-01-0	PREP016	vitamin D receptor agonist	VDR	dermatology	"psoriasis, chapped lips"	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	Tacalcitol	5283734	BJYLYJCXYAMOFT-RSFVBTMBSA-N
Tacedinaline	tacedinaline	BRD-K52313696-001-12-3	PROS004_PR500	HDAC inhibitor	HDAC1	NA	NA	"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N"	Phase 3	Tacedinaline	2746	NA
Tacrolimus	tacrolimus	BRD-K69608737-001-10-2	PREP016	calcineurin inhibitor	FKBP1A	transplant	organ rejection	"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC"	Launched	Tacrolimus	445643	QJJXYPPXXYFBGM-LFZNUXCKSA-N
D-Tagatose	tagatose	BRD-A73556557-001-06-4	PREP039	phosphorylase inhibitor	PYGL	NA	NA	"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO"	Phase 3	D-Tagatose	439312	LKDRXBCSQODPBY-OEXCPVAWSA-N
Tak-285	TAK-285	BRD-K80343549-001-02-6	PREP045	EGFR inhibitor	ERBB2	NA	NA	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	Phase 1	Tak-285	11620908	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N
TAK-632	TAK-632	BRD-K31866293-001-01-6	PREP046	RAF inhibitor	BRAF	NA	NA	Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	Preclinical	TAK-632	46209401	OJFKUJDRGJSAQB-UHFFFAOYSA-N
Tak-715	TAK-715	BRD-K52751261-001-06-1	PREP019	p38 MAPK inhibitor	MAPK14	NA	NA	"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1"	Phase 2	Tak-715	9952773	NA
TAK-733	TAK-733	BRD-K26667523-001-02-5	PREP027	MEK inhibitor	MAP2K1	NA	NA	"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O"	Phase 1	TAK-733	24963252	RCLQNICOARASSR-SECBINFHSA-N
Tak-901	TAK-901	BRD-K01683783-001-02-6	PREP039	Aurora kinase inhibitor	AURKB	NA	NA	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	Phase 1	Tak-901	16124208	WKDACQVEJIVHMZ-UHFFFAOYSA-N
Talazoparib	talazoparib	BRD-K95142244-001-01-5	PROS003_PR500	PARP inhibitor	PARP2	oncology	NA	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	Phase 3	Talazoparib	135565082	NA
Talmapimod	talmapimod	BRD-K17555800-003-02-3///BRD-K17555800-003-01-5	PROS002_PR500///PREP047	p38 MAPK inhibitor	"MAPK11, MAPK14"	NA	NA	"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C"	Phase 2	Talmapimod	9871074	ZMELOYOKMZBMRB-DLBZAZTESA-N
Taltirelin	taltirelin	BRD-K93869735-001-01-1	PREP028	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	Launched	Taltirelin	114750	LQZAIAZUDWIVPM-SRVKXCTJSA-N
Taltobulin	taltobulin	BRD-K87512222-019-01-7	PREP044	tubulin polymerization inhibitor	NA	NA	NA	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1	Phase 1	Taltobulin	6918637	CNTMOLDWXSVYKD-PSRNMDMQSA-N
Tame	TAME	BRD-K72231366-001-02-3	PREP015	NA	NA	NA	NA	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	Preclinical	Tame	1550286	FKMJXALNHKIDOD-LBPRGKRZSA-N
Tamibarotene	tamibarotene	BRD-K36627727-001-05-4	PROS005_PR500	retinoid receptor agonist	"RARA, RARB"	hematologic malignancy	acute promyelocytic leukemia (APL)	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	Launched	Tamibarotene	108143	MUTNCGKQJGXKEM-UHFFFAOYSA-N
Tamoxifen	tamoxifen	BRD-K93754473-048-20-2	PREP034	"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)"	"EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ"	oncology	breast cancer	"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1"	Launched	Tamoxifen	25010734	FQZYTYWMLGAPFJ-OQKDUQJOSA-N
Tanaproget	tanaproget	BRD-K99604664-001-01-1	PREP018	progesterone receptor agonist	PGR	NA	NA	"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N"	Phase 2	Tanaproget	4369524	PYVFWTPEBMRKSR-UHFFFAOYSA-N
Tandutinib	tandutinib	BRD-K89162000-001-06-4	PREP026	"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor"	"CSF1R, FLT3, KIT, PDGFD, PDGFRB"	NA	NA	"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1"	Phase 2	Tandutinib	3038522	NA
Tanespimycin	tanespimycin	BRD-K81473043-001-19-5///BRD-K81473043-001-14-6	PROS005_PR500///PREP035	HSP inhibitor	HSP90AA1	NA	NA	"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O"	Phase 3	Tanespimycin	6505803	AYUNIORJHRXIBJ-TXHRRWQRSA-N
Tanshinone I	tanshinone-i	BRD-K34073885-001-09-3	PREP026	AP inhibitor	IFNG	NA	NA	"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12"	Phase 2	Tanshinone I	114917	AIGAZQPHXLWMOJ-UHFFFAOYSA-N
TAS-103 free base	TAS-103	BRD-K09426783-300-01-0	PREP046	topoisomerase inhibitor	TOP1	NA	NA	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	Phase 1	TAS-103 free base	135413533	ROWSTIYZUWEOMM-UHFFFAOYSA-N
Taselisib	taselisib	BRD-K44844162-001-01-6	PREP032	PI3K inhibitor	PIK3CA	NA	NA	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	Phase 3	Taselisib	51001932	BEUQXVWXFDOSAQ-UHFFFAOYSA-N
Tasisulam	tasisulam	BRD-K42495768-001-01-7	PROS001_PR500	apoptosis stimulant	NA	NA	NA	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	Phase 3	Tasisulam	10160238	WWONFUQGBVOKOF-UHFFFAOYSA-N
Taurine	taurine	BRD-K51474575-001-10-4	PREP024	antioxidant	NA	neurology/psychiatry	"anxiety, irritability, sleeplessness"	"NCCS(O)(=O)=O, NCCS(O)(=O)=O"	Launched	Taurine	1123	XOAAWQZATWQOTB-UHFFFAOYSA-N
Tazemetostat	tazemetostat	BRD-K11215326-001-03-7	PREP019	histone lysine methyltransferase inhibitor	EZH2	NA	NA	"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1"	Phase 2	Tazemetostat	66558664	NSQSAUGJQHDYNO-UHFFFAOYSA-N
TC1	TC1	BRD-A13964793-001-02-6	PREP032	beta-secretase inhibitor	BACE1	NA	NA	OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1	Preclinical	TC1	155903756	FYGREZKTJIXWIH-APDWONGJSA-N
Tecastemizole	tecastemizole	BRD-K48195801-001-01-6	PREP038	histamine receptor antagonist	KCNH2	NA	NA	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	Phase 3	Tecastemizole	123618	SFOVDSLXFUGAIV-UHFFFAOYSA-N
Tedizolid	tedizolid///tedizolid-phosphate	BRD-K59436580-001-01-7///BRD-K89121095-001-01-7	PREP015///PMTS011	bacterial 50S ribosomal subunit inhibitor///protein synthesis inhibitor	NA	infectious disease	skin infections	"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O///Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O"	Launched	Tedizolid	11234049	XFALPSLJIHVRKE-GFCCVEGCSA-N
Telatinib	telatinib	BRD-K84564571-001-02-4	PREP045	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	KDR	NA	NA	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	Phase 2	Telatinib	9808844	QFCXANHHBCGMAS-UHFFFAOYSA-N
Telotristat ethyl	telotristat-ethyl	BRD-K94559059-091-01-6	PREP024	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1"	Launched	Telotristat ethyl	25181577	MDSQOJYHHZBZKA-GBXCKJPGSA-N
Temazepam	temazepam	BRD-A93093700-001-02-9	PREP035	benzodiazepine receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO"	NA	NA	CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1	Withdrawn	Temazepam	5391	SEQDDYPDSLOBDC-UHFFFAOYSA-N
Temocapril	temocapril	BRD-K10784860-003-02-3	PREP038	angiotensin converting enzyme inhibitor	ACE	"cardiology, nephrology"	"hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)"	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	Launched	Temocapril	443874	FIQOFIRCTOWDOW-BJLQDIEVSA-N
Temoporfin	temoporfin	BRD-K63712959-001-01-8	PROS005_PR500	radical formation stimulant	NA	oncology	head and neck squamous cell carcinoma (HNSCC)	Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2	Launched	Temoporfin	60751	LYPFDBRUNKHDGX-UHFFFAOYSA-N
Temozolomide	temozolomide	BRD-K32107296-001-16-9	PREP016	DNA alkylating agent	MGMT	oncology	"glioblastoma, astrocytoma"	"Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O"	Launched	Temozolomide	5394	BPEGJWRSRHCHSN-UHFFFAOYSA-N
Temsirolimus	temsirolimus	BRD-K42898655-001-01-8	PROS005_PR500	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO	Launched	Temsirolimus	6918289	CBPNZQVSJQDFBE-FUXHJELOSA-N
Teniposide	teniposide	BRD-A35588707-001-05-5	PREP016	topoisomerase inhibitor	"TOP2A, TOP2B"	hematologic malignancy	acute lymphoblastic leukemia (ALL)	"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12"	Launched	Teniposide	452548	NRUKOCRGYNPUPR-QBPJDGROSA-N
Tenovin-6	tenovin-6	BRD-K13949769-001-01-7	PREP040	SIRT inhibitor	"SIRT1, SIRT2, SIRT3"	NA	NA	"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1"	Preclinical	Tenovin-6	24772043	BVJSXSQRIUSRCO-UHFFFAOYSA-N
Tepoxalin	tepoxalin	BRD-K89714990-001-01-5	PREP016	"cyclooxygenase inhibitor, lipoxygenase inhibitor"	ALOX5	"rheumatology, orthopedics"	"rheumatoid arthritis, hip dysplasia"	"COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1"	Launched	Tepoxalin	59757	XYKWNRUXCOIMFZ-UHFFFAOYSA-N
Teprenone	teprenone	BRD-K11510141-001-01-8	PREP029	mucus protecting agent	NA	dermatology	cosmetic	"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C"	Launched	Teprenone	5282199	HUCXKZBETONXFO-NJFMWZAGSA-N
Terbutaline	terbutaline	BRD-A50157456-065-20-6	PREP028	adrenergic receptor agonist	ADRB2	pulmonary	"bronchospasm, bronchitis, emphysema"	"CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1"	Launched	Terbutaline	5403	XWTYSIMOBUGWOL-UHFFFAOYSA-N
Terconazole	terconazole	BRD-K86204871-001-16-2	PREP020	sterol demethylase inhibitor	NA	infectious disease	vulvovaginal candidiasis	"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1"	Launched	Terconazole	441383	BLSQLHNBWJLIBQ-OZXSUGGESA-N
Terfenadine	terfenadine	BRD-A06352418-001-25-9	PREP021	histamine receptor antagonist	"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2"	NA	NA	"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1"	Withdrawn	Terfenadine	5405	GUGOEEXESWIERI-UHFFFAOYSA-N
Teriflunomide	teriflunomide	BRD-A42699921-001-03-6	PREP035	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F"	Launched	Teriflunomide	54684141	UTNUDOFZCWSZMS-YFHOEESVSA-N
Triglycidyl isocyanurate	teroxirone	BRD-A39935389-001-05-9	PREP027	DNA inhibitor	NA	NA	NA	O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1	Phase 1	Triglycidyl isocyanurate	17142	OUPZKGBUJRBPGC-UHFFFAOYSA-N
tetrahydropapaverine	tetrahydropapaverine	BRD-A91831168-003-02-5	PREP037	NA	NA	NA	NA	COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC	Preclinical	tetrahydropapaverine	5418	YXWQTVWJNHKSCC-UHFFFAOYSA-N
TETRAHYDROURIDINE	tetrahydrouridine	BRD-A86248581-001-01-4	PREP038	cytidine deaminase inhibitor	CDA	NA	NA	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O	Phase 2	TETRAHYDROURIDINE	270480	UCKYOOZPSJFJIZ-UHFFFAOYSA-N
Tetramethylthiuram monosulfide	tetramethylthiuram-monosulfide	BRD-K36889451-001-01-1	PREP042	NA	NA	NA	NA	CN(C)C(=S)SC(=S)N(C)C	Preclinical	Tetramethylthiuram monosulfide	7347	REQPQFUJGGOFQL-UHFFFAOYSA-N
Tetrandrine	tetrandrine	BRD-K08078237-001-19-8	PREP034	calcium channel blocker	SLC6A3	NA	NA	"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34"	Preclinical	Tetrandrine	73078	WVTKBKWTSCPRNU-KYJUHHDHSA-N
Tezacaftor	tezacaftor	BRD-K97101532-001-02-8	PREP018	CFTR channel agonist	NA	pulmonary	cystic fibrosis	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	Launched	Tezacaftor	46199646	MJUVRTYWUMPBTR-MRXNPFEDSA-N
Zotiraciclib	TG-02	BRD-K14560436-001-01-4	PREP037	"CDK inhibitor, FLT3 inhibitor, JAK inhibitor"	"CDK1, CDK2, CDK7, CDK9, FLT3, JAK2"	NA	NA	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2	Phase 1	Zotiraciclib	16739650	VXBAJLGYBMTJCY-NSCUHMNNSA-N
TG-100572	TG-100572	BRD-K18424115-003-01-3	PREP037	"src inhibitor, VEGFR inhibitor"	"KDR, SRC"	NA	NA	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	Preclinical	TG-100572	11712625	AQSSMEORRLJZLU-UHFFFAOYSA-N
"3-(2,4-Diaminopteridin-6-yl)phenol"	TG-100713	BRD-K46392623-001-02-5	PREP040	PI3K inhibitor	NA	NA	NA	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	Preclinical	"3-(2,4-Diaminopteridin-6-yl)phenol"	17751063	UOORQSPLBHUQDQ-UHFFFAOYSA-N
TG-101209	TG-101209	BRD-K39841531-001-02-1	PREP043	JAK inhibitor	"JAK2, JAK3"	NA	NA	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	Preclinical	TG-101209	16722832	JVDOKQYTTYUYDV-UHFFFAOYSA-N
Fedratinib	TG-101348	BRD-K12502280-001-08-0	PREP032	"FLT3 inhibitor, JAK inhibitor"	"BRD4, JAK1, JAK2, JAK3, TYK2"	NA	NA	"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C"	Phase 3	Fedratinib	16722836	JOOXLOJCABQBSG-UHFFFAOYSA-N
TG-100-115	TG100-115	BRD-K64785675-001-04-0	PREP039	PI3K inhibitor	"PIK3CA, PIK3CB, PIK3CD, PIK3CG"	NA	NA	Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	Phase 1/Phase 2	TG-100-115	10427712	NA
Evofosfamide	TH-302	BRD-K20958582-001-01-4	PREP044	DNA alkylating agent	NA	NA	NA	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	Phase 3	Evofosfamide	11984561	UGJWRPJDTDGERK-UHFFFAOYSA-N
nuelin	theophylline	BRD-K97799481-001-16-0	PREP028	adenosine receptor antagonist	NA	pulmonary	"asthma, emphysema, bronchitis"	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	nuelin	2153	ZFXYFBGIUFBOJW-UHFFFAOYSA-N
Thiamine	thiamine	BRD-K95785345-300-14-8	PREP034	vitamin B	"SLC19A2, SLC19A3, TPK1"	metabolism	thiamine deficiency	"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N"	Launched	Thiamine	23423984	MYVIATVLJGTBFV-UHFFFAOYSA-M
Thiocolchicoside	thiocolchicoside	BRD-K26619122-001-02-1	PREP016	GABA receptor antagonist	"GABRA1, GABRB2, GABRG2, GLRA1, GLRB"	neurology/psychiatry	muscle relaxant	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	Launched	Thiocolchicoside	71752520	LEQAKWQJCITZNK-ASKLJRATSA-N
"7H-Purine-6-thiol, 2-amino-"	thioguanine	BRD-K49350383-001-14-5	PREP028///PROS002_PR500///PREP019	purine antagonist	"IMPDH1, IMPDH2"	hematologic malignancy	acute myeloid leukemia (AML)	"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1///Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1"	Launched///Phase 2	"7H-Purine-6-thiol, 2-amino-"	2723601	WYWHKKSPHMUBEB-UHFFFAOYSA-N
Thimerosal	thiomersal	BRD-K61443650-236-13-1	PREP030	other antibiotic	OXCT1	NA	NA	CC[Hg]Sc1ccccc1C(O)=O	Launched	Thimerosal	16684434	RTKIYNMVFMVABJ-UHFFFAOYSA-L
Thioproperazine	thioproperazine	BRD-K08619574-334-05-4	PREP023	dopamine receptor antagonist	"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A"	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	Thioproperazine	9429	VZYCZNZBPPHOFY-UHFFFAOYSA-N
Thiostrepton	thiostrepton	BRD-K58049875-001-04-7	PREP024	"FOXM1 inhibitor, protein synthesis inhibitor"	FOXM1	obstetrics/gynecology	mastitis	"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O"	Launched	Thiostrepton	16129666	NSFFHOGKXHRQEW-DVRIZHICSA-N
Thiram	thiram	BRD-K29254801-001-14-7	PREP021	NA	JAK2	ophthalmology	contact dermatitis	CN(C)C(=S)SSC(=S)N(C)C	Launched	Thiram	5455	KUAZQDVKQLNFPE-UHFFFAOYSA-N
Thonzonium	thonzonium	BRD-K13387373-004-14-5	PREP028	ATPase inhibitor	NA	NA	NA	"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1"	Launched	Thonzonium	5456	IOYZYMQFUSNATM-UHFFFAOYSA-N
Tiagabine	tiagabine	BRD-K60160658-003-11-2	PREP022	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C"	Launched	Tiagabine	60648	PBJUNZJWGZTSKL-MRXNPFEDSA-N
Tideglusib	tideglusib	BRD-K81330143-001-04-8	PREP047	glycogen synthase kinase inhibitor	GSK3B	NA	NA	"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1"	Phase 2	Tideglusib	11313622	PMJIHLSCWIDGMD-UHFFFAOYSA-N
Tiletamine	tiletamine	BRD-A30582499-003-05-1	PREP021	glutamate receptor antagonist	NA	neurology/psychiatry	anesthetic	CCNC1(CCCCC1=O)c1cccs1	Launched	Tiletamine	26533	QAXBVGVYDCAVLV-UHFFFAOYSA-N
Tilmicosin	tilmicosin	BRD-K26634012-001-04-9	PREP016	bacterial 50S ribosomal subunit inhibitor	NA	pulmonary	bovine respiratory disease (BRD)	"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC"	Launched	Tilmicosin	5282521	JTSDBFGMPLKDCD-XVFHVFLVSA-N
Tiludronic Acid	tiludronate	BRD-K10845183-304-01-6	PREP020	"bone resorption inhibitor, osteoclast inhibitor"	"ATP6V1A, MMP2, PTPN1"	orthopedics	navicular syndrome	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	Launched	Tiludronic Acid	60937	DKJJVAGXPKPDRL-UHFFFAOYSA-N
Tiotidine	tiotidine	BRD-K15071410-001-01-1	PREP038	histamine receptor antagonist	HRH2	NA	NA	"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N"	Phase 2	Tiotidine	50287	YDDXVAXDYKBWDX-UHFFFAOYSA-N
Tioxolone	tioxolone	BRD-K41876534-001-13-7	PREP033	carbonic anhydrase inhibitor	CA2	NA	NA	"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1"	Preclinical	Tioxolone	72139	SLYPOVJCSQHITR-UHFFFAOYSA-N
Tipifarnib	tipifarnib	BRD-K62965247-001-04-9	PREP018	farnesyltransferase inhibitor	"FNTA, FNTB"	NA	NA	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	Phase 3	Tipifarnib	159324	PLHJCIYEEKOWNM-HHHXNRCGSA-N
Tipiracil	tipiracil	BRD-K11973162-003-01-8	PREP035	thymidine phosphorylase inhibitor	TYMP	oncology	colorectal cancer	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	Launched	Tipiracil	6323266	QQHMKNYGKVVGCZ-UHFFFAOYSA-N
Tipranavir	tipranavir	BRD-A10039652-001-01-2	PREP044	HIV protease inhibitor	NA	infectious disease	human immunodeficiency virus (HIV-1)	"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1"	Launched	Tipranavir	54682461	SUJUHGSWHZTSEU-FYBSXPHGSA-N
Tirapazamine	tirapazamine	BRD-K92968657-001-01-6	PREP018	DNA inhibitor	NA	NA	NA	"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]"	Phase 3	Tirapazamine	54724399	QENGMPDKFVBFSH-UHFFFAOYSA-N
Tivantinib	tivantinib	BRD-K33379087-001-07-5	PROS004_PR500	tyrosine kinase inhibitor	MET	NA	NA	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	Phase 3	Tivantinib	11494412	NA
Tivozanib	tivozanib	BRD-K53414658-001-08-2	PROS001_PR500	VEGFR inhibitor	"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB"	NA	NA	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	Phase 3	Tivozanib	9911830	SPMVMDHWKHCIDT-UHFFFAOYSA-N
TMC-353121	TMC-353121	BRD-K66097663-001-01-8	PREP045	RSV fusion inhibitor	NA	NA	NA	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	Phase 2	TMC-353121	11249932	DKORMNNYNRPTBJ-UHFFFAOYSA-N
"2,3',4,5'-Tetramethoxystilbene"	TMS	BRD-K96233303-001-01-9	PREP037	NA	NA	NA	NA	"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1"	Preclinical	"2,3',4,5'-Tetramethoxystilbene"	5354004	JDBCWSHYEQUBLW-AATRIKPKSA-N
Tofogliflozin	tofogliflozin	BRD-K96344439-002-02-7	PMTS011	sodium/glucose cotransporter inhibitor	GCK	endocrinology	"diabetes mellitus, diabetes mellitus"	"CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1"	Launched	Tofogliflozin	46908929	VWVKUNOPTJGDOB-BDHVOXNPSA-N
Topotecan	topotecan	BRD-K55696337-003-24-4	PMTS011	topoisomerase inhibitor	"TOP1, TOP1MT"	oncology	"small cell lung cancer, cervical cancer"	"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O"	Launched	Topotecan	11972519	DGHHQBMTXTWTJV-BQAIUKQQSA-N
Torsemide	torasemide	BRD-K30480208-001-18-5	PREP028	"electrolyte reabsorption inhibitor, thromboxane receptor antagonist"	SLC12A1	cardiology	"edema, congestive heart failure, hypertension"	"CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1"	Launched	Torsemide	41781	NGBFQHCMQULJNZ-UHFFFAOYSA-N
Torcetrapib	torcetrapib	BRD-K55675242-001-03-0	PREP038	cholesteryl ester transfer protein inhibitor	CETP	NA	NA	"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F"	Phase 3	Torcetrapib	159325	CMSGWTNRGKRWGS-NQIIRXRSSA-N
Toremifene	toremifene	BRD-K51350053-048-16-5	PREP030	"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)"	ESR1	oncology	breast cancer	"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1"	Launched	Toremifene	3005573	XFCLJVABOIYOMF-QPLCGJKRSA-N
Torin 1	torin-1	BRD-K40175214-001-11-6	PREP040	mTOR inhibitor	MTOR	NA	NA	"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1"	Preclinical	Torin 1	49836027	AKCRNFFTGXBONI-UHFFFAOYSA-N
Torin 2	torin-2	BRD-K68174511-001-06-6	PREP041	mTOR inhibitor	MTOR	NA	NA	"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1"	Preclinical	Torin 2	51358113	GUXXEUUYCAYESJ-UHFFFAOYSA-N
Tosedostat	tosedostat	BRD-K92241597-001-06-0	PREP018	peptidase inhibitor	"ANPEP, LAP3, NPEPPS"	NA	NA	"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1"	Phase 2	Tosedostat	15547703	FWFGIHPGRQZWIW-SQNIBIBYSA-N
Tozasertib	tozasertib	BRD-K59369769-001-20-3///BRD-K59369769-001-22-9	PREP039///PROS003_PR500	"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor"	"AURKA, AURKB, AURKC, LCK"	NA	NA	"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1"	Phase 2	Tozasertib	5494449	GCIKSSRWRFVXBI-UHFFFAOYSA-N
TPCA-1	TPCA-1	BRD-K51575138-001-13-2	PREP043	IKK inhibitor	IKBKB	NA	NA	"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1"	Preclinical	TPCA-1	9903786	NA
Trametinib	trametinib	BRD-K12343256-001-08-9///BRD-K12343256-001-14-7	PREP035///PROS003_PR500	MEK inhibitor	"MAP2K1, MAP2K2"	oncology	melanoma	"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O"	Launched	Trametinib	11707110	LIRYPHYGHXZJBZ-UHFFFAOYSA-N
Tranilast	tranilast	BRD-K17849083-001-32-9	PREP030	angiogenesis inhibitor	"HPGDS, HRH1"	pulmonary	asthma	"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC"	Launched	Tranilast	5282230	NZHGWWWHIYHZNX-CSKARUKUSA-N
4-Hydroxycrotonic acid	trans-4-Hydroxycrotonic-acid	BRD-K91614056-001-02-2	PREP048	gamma hydroxybutyric acid ligand	NA	NA	NA	OC\C=C\C(O)=O	Preclinical	4-Hydroxycrotonic acid	6155526	RMQJECWPWQIIPW-OWOJBTEDSA-N
Trapidil	trapidil	BRD-K95763993-001-19-3	PREP030	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	CCN(CC)c1cc(C)nc2ncnn12	Launched	Trapidil	5531	GSNOZLZNQMLSKJ-UHFFFAOYSA-N
Tremorine	tremorine	BRD-K08619838-300-05-7	PREP046	acetylcholine receptor agonist	NA	NA	NA	C(C#CCN1CCCC1)N1CCCC1	Preclinical	Tremorine	5534	JSUAJTLKVREZHV-UHFFFAOYSA-N
Trequinsin	trequinsin	BRD-K84663978-003-02-9	PREP036	phosphodiesterase inhibitor	PDE5A	NA	NA	"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC"	Phase 1	Trequinsin	5537	MCMSJVMUSBZUCN-UHFFFAOYSA-N
Triamcinolone	triamcinolone	BRD-K77554836-001-11-6	PREP035	glucocorticoid receptor agonist	"NR3C1, SERPINA6"	dermatology	corticosteroid-responsive dermatoses	"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO"	Launched	Triamcinolone	31307	GFNANZIMVAIWHM-OBYCQNJPSA-N
Triamcinolone acetonide	triamcinolone-acetonide	BRD-A92439610-001-05-7	PREP022	"glucocorticoid receptor agonist, immunosuppressant"	NR3C1	dermatology	corticosteroid-responsive dermatoses	"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO"	Launched	Triamcinolone acetonide	6436	YNDXUCZADRHECN-JNQJZLCISA-N
Triamterene	triamterene	BRD-K92049597-001-20-8	PREP016	sodium channel blocker	"SCNN1A, SCNN1B, SCNN1D, SCNN1G"	"endocrinology, cardiology"	"hypokalemia, hypertension, edema"	"Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1"	Launched	Triamterene	5546	FNYLWPVRPXGIIP-UHFFFAOYSA-N
Triapine	triapine	BRD-K01669786-001-02-2	PREP035	ribonucleotide reductase inhibitor	"RRM1, RRM2"	NA	NA	"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N"	Phase 2	Triapine	9571836	XMYKNCNAZKMVQN-NYYWCZLTSA-N
Trichostatin.A	trichostatin-a	BRD-K68202742-001-16-5	PREP042	HDAC inhibitor	"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"	NA	NA	"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C"	Preclinical	Trichostatin.A	NA	RTKIYFITIVXBLE-WKWSCTOISA-N
Triciribine	triciribine	BRD-K80431395-001-07-3	PREP030	AKT inhibitor	"AKT1, AKT2, AKT3"	NA	NA	"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23"	Phase 1/Phase 2	Triciribine	65399	HOGVTUZUJGHKPL-HTVVRFAVSA-N
Triclabendazole	triclabendazole	BRD-K81916719-001-13-9	PREP035	microtubule inhibitor	DNMT1	infectious disease	tapeworm	"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1"	Launched	Triclabendazole	50248	NQPDXQQQCQDHHW-UHFFFAOYSA-N
Trifluridine	trifluridine	BRD-K03243820-001-23-8	PREP034	"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor"	TYMS	infectious disease	virus herpes simplex (HSV)	"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F"	Launched	Trifluridine	6256	VSQQQLOSPVPRAZ-RRKCRQDMSA-N
Trimebutine	trimebutine	BRD-A92630576-050-24-1	PREP029	opioid receptor agonist	"OPRD1, OPRK1, OPRM1"	gastroenterology	irritable bowel syndrome	"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1"	Launched	Trimebutine	5573	LORDFXWUHHSAQU-UHFFFAOYSA-N
Triptolide	triptolide	BRD-K39484304-001-16-5	PREP018	RNA polymerase inhibitor	RELA	NA	NA	"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O"	Phase 3	Triptolide	107985	DFBIRQPKNDILPW-CIVMWXNOSA-N
Trolox	trolox	BRD-A17846016-001-13-9	PREP029	antioxidant	NA	NA	NA	Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O	Launched	Trolox	40634	GLEVLJDDWXEYCO-UHFFFAOYSA-N
"2-Amino-2-hydroxymethyl-propane-1,3-diol"	trometamol	BRD-K47978074-001-02-4	PREP017	NA	"AMD1, CANT1, DCN, NEIL1, VEGFA"	NA	NA	"NC(CO)(CO)CO, NC(CO)(CO)CO"	Launched	"2-Amino-2-hydroxymethyl-propane-1,3-diol"	6503	LENZDBCJOHFCAS-UHFFFAOYSA-N
Tropisetron	tropisetron	BRD-K50866992-003-10-3	PREP029	serotonin receptor antagonist	"GLRA1, GLRA2, GLRB, HTR3A, HTR4"	gastroenterology	"nausea, vomiting, nausea, vomiting"	"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12"	Launched	Tropisetron	656665	ZNRGQMMCGHDTEI-FUNVUKJBSA-N
Trovafloxacin	trovafloxacin	BRD-K00494077-066-01-9	PREP028	bacterial DNA gyrase inhibitor	TOP2A	NA	NA	"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F"	Withdrawn	Trovafloxacin	62959	WVPSKSLAZQPAKQ-SOSAQKQKSA-N
"Indolo[2,1-b]quinazoline-6,12-dione"	tryptanthrin	BRD-K76973696-001-12-6	PREP043	cyclooxygenase inhibitor	IDO1	NA	NA	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	Preclinical	"Indolo[2,1-b]quinazoline-6,12-dione"	73549	VQQVWGVXDIPORV-UHFFFAOYSA-N
Azeloyl diethyl salicylate	TU-2100	BRD-K44590731-001-01-7	PREP044	NA	NA	NA	NA	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	Phase 2	Azeloyl diethyl salicylate	4342838	LIBAUACOIKWWKP-UHFFFAOYSA-N
Tucatinib	tucatinib	BRD-K26026438-001-01-0	PROS004_PR500	EGFR inhibitor	ERBB2	NA	NA	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1	Phase 2	Tucatinib	51039094	SDEAXTCZPQIFQM-UHFFFAOYSA-N
TW 37	TW-37	BRD-K28360340-001-08-3	PREP015	BCL inhibitor	"BCL2, BCL2L1, MCL1"	NA	NA	"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O"	Preclinical	TW 37	11455910	PQAPVTKIEGUPRN-UHFFFAOYSA-N
TWS119	TWS-119	BRD-K94176593-001-09-4	PREP043	glycogen synthase kinase inhibitor	"GSK3B, JUN, MYC"	NA	NA	"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1"	Preclinical	TWS119	9549289	VPVLEBIVXZSOMQ-UHFFFAOYSA-N
tyloxapol	tyloxapol	BRD-U25960968-000-01-9	PREP022	NFkB pathway inhibitor	"LPL, NFKB2"	NA	NA	"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1"	Launched	tyloxapol	5610	DZGWFCGJZKJUFP-UHFFFAOYSA-N
Malonoben	tyrphostin-A9	BRD-K40255344-001-17-6	PREP040	"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor"	NA	NA	NA	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	Preclinical	Malonoben	5614	MZOPWQKISXCCTP-UHFFFAOYSA-N
"6,7-Dimethoxy-2-phenylquinoxaline"	tyrphostin-AG-1296	BRD-K76064317-001-07-3	PREP040	FLT3 inhibitor	FLT3	NA	NA	"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1"	Preclinical	"6,7-Dimethoxy-2-phenylquinoxaline"	2049	QNOXYUNHIGOWNY-UHFFFAOYSA-N
AG1478	tyrphostin-AG-1478	BRD-K68336408-001-10-9	PREP043	EGFR inhibitor	"EGFR, MAPK14"	NA	NA	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	Preclinical	AG1478	2051	GFNNBHLJANVSQV-UHFFFAOYSA-N
Tyrphostin B48	tyrphostin-AG-494	BRD-K34533029-001-08-5	PREP043	EGFR inhibitor	EGFR	NA	NA	Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1	Preclinical	Tyrphostin B48	5328771	HKHOVJYOELRGMV-XYOKQWHBSA-N
Tyrphostin A46	tyrphostin-AG-99	BRD-K60184833-001-05-6	PREP043	tyrosine kinase inhibitor	EGFR	NA	NA	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	Preclinical	Tyrphostin A46	5328768	USOXQZNJFMKTKJ-XVNBXDOJSA-N
U-0126	U-0126	BRD-K18787491-001-08-6///BRD-K91701654-001-03-1	PREP037///PREP048	MEK inhibitor	"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1"	NA	NA	"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N"	Preclinical	U-0126	3006531	DVEXZJFMOKTQEZ-JYFOCSDGSA-N
3beta-(2-Diethylaminoethoxy)androst-5-en-17-one hydrochloride	U-18666A	BRD-K22025381-003-01-9	PREP045	oxidosqualene cyclase inhibitor	NA	NA	NA	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1	Preclinical	3beta-(2-Diethylaminoethoxy)androst-5-en-17-one hydrochloride	9954082	GZFYZYBWLCYBMI-MYZJJQSMSA-N
Ubenimex	ubenimex	BRD-K59574735-001-11-8	PREP023	leukotriene synthesis inhibitor	"LTA4H, RNPEP"	hematologic malignancy	acute myeloid leukemia (AML)	"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O"	Launched	Ubenimex	72172	VGGGPCQERPFHOB-RDBSUJKOSA-N
UH-232-(+)	UH-232-(+)	BRD-K66715657-050-01-0	PREP015	dopamine receptor antagonist	"DRD2, DRD3, DRD4, HTR1A"	NA	NA	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical	UH-232-(+)	6604756	BTOJYCTUJJHANF-WMLDXEAASA-N
UK-383367	UK-383367	BRD-K06294530-001-01-5	PREP038	Procollagen C-Endopeptidase Inhibitors	BMP1	NA	NA	"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO"	Phase 1	UK-383367	9818682	ARJCBSRIPGJMAD-LLVKDONJSA-N
Ulipristal	ulipristal	BRD-K64381438-001-03-8	PREP023	progesterone receptor antagonist	PGR	endocrinology	contraceptive	"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12"	Launched	Ulipristal	13559281	HKDLNTKNLJPAIY-WKWWZUSTSA-N
UNBS-5162	UNBS-5162	BRD-K30933884-001-01-0	PREP018	CC chemokine receptor antagonist	NA	NA	NA	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	Phase 1	UNBS-5162	16048966	WCKZRLOUKYFJDY-UHFFFAOYSA-N
UNC0631	UNC0631	BRD-K13060017-001-01-3	PMTS011	histone lysine methyltransferase inhibitor	EHMT2	NA	NA	"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C"	Preclinical	UNC0631	53315868	XFAXSWXKPQWHDW-UHFFFAOYSA-N
UNC2250	UNC2250	BRD-K01773560-001-02-4	PREP014	MER tyrosine kinase inhibitor	MERTK	NA	NA	"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1"	Preclinical	UNC2250	73211763	HSYSSKFCQHXOBP-UHFFFAOYSA-N
Uprosertib	uprosertib	BRD-K38332599-001-01-3	PROS002_PR500	AKT inhibitor	"AKT1, AKT2, AKT3"	NA	NA	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	Phase 2	Uprosertib	51042438	AXTAPYRUEKNRBA-JTQLQIEISA-N
Uracil	uracil	BRD-K80129304-001-08-1	PREP033	NA	"DPYD, UCKL1"	NA	NA	"Oc1ccnc(O)n1, Oc1ccnc(O)n1"	Launched	Uracil	1174	ISAKRJDGNUQOIC-UHFFFAOYSA-N
Uric acid	uric-acid	BRD-K01295354-001-02-8	PREP045	NA	PYGL	NA	NA	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	Phase 3	Uric acid	1175	LEHOTFFKMJEONL-UHFFFAOYSA-N
Uridine	uridine	BRD-K13050303-001-17-3	PREP034	dopamine receptor agonist	"LSM6, TYMP"	NA	NA	"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O"	Phase 2	Uridine	6029	DRTQHJPVMGBUCF-XVFCMESISA-N
Usniacin-(+)	usniacin-(+)	BRD-A12417644-001-07-6	PREP048	MAP kinase activator	PTPN1	NA	NA	"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O"	Preclinical	Usniacin-(+)	NA	NA
Valnemulin	valnemulin	BRD-K33813875-003-01-8	PREP034	bacterial 50S ribosomal subunit inhibitor	NA	"infectious disease, gastroenterology"	"dysentry, colitis, pneumonia"	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3	Launched	Valnemulin	9850878	LLYYNOVSVPBRGV-MVNKZKPCSA-N
Valrubicin	valrubicin	BRD-K72951360-001-01-4	PREP014	"DNA inhibitor, topoisomerase inhibitor"	TOP2A	oncology	bladder cancer	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	Launched	Valrubicin	454216	ZOCKGBMQLCSHFP-KQRAQHLDSA-N
Vandetanib	vandetanib	BRD-K77625799-001-07-7	PROS002_PR500	"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor"	"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA"	oncology	medullary thyroid cancer (MTC)	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	Launched	Vandetanib	3081361	UHTHHESEBZOYNR-UHFFFAOYSA-N
Vanoxerine	vanoxerine	BRD-K32501161-300-06-2	PREP038	dopamine uptake inhibitor	SLC6A3	NA	NA	"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1"	Phase 3	Vanoxerine	104920	MIBSKSYCRFWIRU-UHFFFAOYSA-N
Vatalanib	vatalanib	BRD-K70163715-300-05-7	PREP027	"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor"	"EGFR, FLT1, FLT4, KDR, PDGFRB"	NA	NA	"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1"	Phase 3	Vatalanib	151194	NA
VE821	VE-821	BRD-K26756394-001-02-2	PREP037	ATR kinase inhibitor	ATR	NA	NA	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	Preclinical	VE821	51000408	DUIHHZKTCSNTGM-UHFFFAOYSA-N
VE-822	VE-822	BRD-K04701033-001-03-9	PMTS011	ATR kinase inhibitor	"ATM, ATR, MTOR, PIK3CG"	NA	NA	"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C"	Phase 2	VE-822	59472121	JZCWLJDSIRUGIN-UHFFFAOYSA-N
Vemurafenib	vemurafenib	BRD-K56343971-001-14-8///BRD-K56343971-001-10-6	PROS004_PR500///PREP022	RAF inhibitor	"BRAF, RAF1"	oncology	melanoma	"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F"	Launched	Vemurafenib	42611257	GPXBXXGIAQBQNI-UHFFFAOYSA-N
Venetoclax	venetoclax	BRD-K62391742-001-09-7///BRD-K62391742-001-03-0	PROS001_PR500///PREP045	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1"	Launched	Venetoclax	49846579	NA
VER-49009	VER-49009	BRD-K38548312-001-01-0	PREP040	HSP inhibitor	HSP90AA1	NA	NA	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	Preclinical	VER-49009	4369536	HUNAOTXNHVALTN-UHFFFAOYSA-N
Verubulin	verubulin	BRD-K42673188-001-01-1	PMTS011	tubulin polymerization inhibitor	TUBB	NA	NA	"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12"	Phase 2	Verubulin	11414799	SNHCRNMVYDHVDT-UHFFFAOYSA-N
Vidarabine	vidarabine	BRD-K72093121-001-16-3	PREP016	antiviral	ADA	infectious disease	"virus herpes simplex (HSV), varicella-zoster virus (VZV)"	"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O"	Launched	Vidarabine	21704	OIRDTQYFTABQOQ-UHTZMRCNSA-N
Vinblastine	vinblastine	BRD-K06519765-065-01-6	PMTS011	"microtubule inhibitor, tubulin polymerization inhibitor"	"JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1"	"hematologic malignancy, infectious disease, oncology"	"Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma"	"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC"	Launched	Vinblastine	13342	JXLYSJRDGCGARV-CFWMRBGOSA-N
Vincamine	vincamine	BRD-K89704198-001-12-3	PREP031	adrenergic receptor antagonist	"CHRM1, CHRM2, CHRM3, CHRM4"	NA	NA	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC	Withdrawn	Vincamine	15376	RXPRRQLKFXBCSJ-GIVPXCGWSA-N
Vincristine	vincristine	BRD-K12251893-065-04-7	PREP038	tubulin polymerization inhibitor	"TUBA4A, TUBB"	hematologic malignancy	acute lymphoblastic leukemia (ALL)	"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC"	Launched	Vincristine	5978	NA
Vindesine	vindesine	BRD-K59753975-001-02-6	PMTS011	tubulin polymerization inhibitor	"TUBB, TUBB1"	oncology	"breast cancer, non-small cell lung cancer (NSCLC), melanoma"	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O	Launched	Vindesine	40839	HHJUWIANJFBDHT-KOTLKJBCSA-N
Javlor	vinflunine	BRD-K64120610-001-01-4	PMTS011	microtubule inhibitor	NA	oncology	bladder cancer	"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC"	Launched	Javlor	6918295	NMDYYWFGPIMTKO-HBVLKOHWSA-N
Vinorelbine	vinorelbine	BRD-K69280563-001-01-8	PREP017	tubulin polymerization inhibitor	"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8"	oncology	non-small cell lung cancer (NSCLC)	"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC"	Launched	Vinorelbine	25136944	UUHYRRXICWUZHW-RPZOAHRESA-N
Vismodegib	vismodegib	BRD-K44827188-001-06-0	PROS003_PR500	"hedgehog pathway inhibitor, smoothened receptor antagonist"	SMO	oncology	basal cell carcinoma (BCC)	Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O	Launched	Vismodegib	24776445	BPQMGSKTAYIVFO-UHFFFAOYSA-N
VLX600	VLX600	BRD-K89053832-001-01-0	PREP038	ubiquitin C-terminal hydrolase inhibitor	USP14	NA	NA	C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	Phase 1	VLX600	6410104	UQOSBPRTQFFUOA-SRZZPIQSSA-N
Volasertib	volasertib	BRD-K69776681-001-03-8	PROS003_PR500	PLK inhibitor	PLK1	NA	NA	"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O"	Phase 3	Volasertib	10461508	NA
Vosaroxin	voreloxin	BRD-K23677682-003-01-2	PREP026	topoisomerase inhibitor	TOP2A	NA	NA	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	Phase 3	Vosaroxin	9952884	XZAFZXJXZHRNAQ-STQMWFEESA-N
Vorinostat	vorinostat	BRD-K81418486-001-47-5///BRD-K81418486-001-44-2	PREP048///PROS001_PR500	HDAC inhibitor	"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9"	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1"	Launched	Vorinostat	5311	WAEXFXRVDQXREF-UHFFFAOYSA-N
Voxtalisib	voxtalisib	BRD-K56291712-001-01-0	PREP038	"mTOR inhibitor, PI3K inhibitor"	"MTOR, PIK3CA"	NA	NA	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	Phase 2	Voxtalisib	16123056	RGHYDLZMTYDBDT-UHFFFAOYSA-N
VS-4718	VS-4718	BRD-K09877029-001-01-2	PREP041	focal adhesion kinase inhibitor	NA	NA	NA	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	Phase 1	VS-4718	25073775	IGUBBWJDMLCRIK-UHFFFAOYSA-N
VTP-27999	VTP-27999	BRD-K81694556-003-01-9	PREP025	renin inhibitor	REN	NA	NA	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	Phase 1	VTP-27999	16126898	NXWASIVXQMMPLM-ZXMXYHOLSA-N
1-(4-Methoxybenzyl)-5-trifluoromethoxyisatin	VU0238429	BRD-K24187789-001-01-7	PREP036	acetylcholine receptor allosteric modulator	CHRM5	NA	NA	"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1"	Preclinical	1-(4-Methoxybenzyl)-5-trifluoromethoxyisatin	42633508	CKLGZXFOLMHCMC-UHFFFAOYSA-N
N-(4-Chloro-3-methoxyphenyl)pyridine-2-carboxamide	VU0361737	BRD-K45462423-001-03-7	PREP036	glutamate receptor positive allosteric modulator	GRM4	NA	NA	"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl"	Preclinical	N-(4-Chloro-3-methoxyphenyl)pyridine-2-carboxamide	44191096	ARYUXFNGXHNNDM-UHFFFAOYSA-N
N-(3-Chlorophenyl)picolinamide	VU0364770	BRD-K66527818-001-02-6	PREP040	glutamate receptor positive allosteric modulator	GRM4	NA	NA	Clc1cccc(NC(=O)c2ccccn2)c1	Preclinical	N-(3-Chlorophenyl)picolinamide	836002	SUYUTNCKIOLMAJ-UHFFFAOYSA-N
VX-702	VX-702	BRD-K07736136-001-04-6	PREP019	p38 MAPK inhibitor	"MAPK11, MAPK12, MAPK14"	NA	NA	"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F"	Phase 2	VX-702	10341154	FYSRKRZDBHOFAY-UHFFFAOYSA-N
Belnacasan	VX-765	BRD-K26712974-001-01-5	PREP019	caspase inhibitor	CASP1	NA	NA	CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	Phase 2	Belnacasan	11398092	SJDDOCKBXFJEJB-MOKWFATOSA-N
Warfarin	warfarin	BRD-A24514565-001-09-7	PREP028	vitamin K antagonist	VKORC1	"hematology, cardiology"	"deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction"	CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O	Launched	Warfarin	54678486	PJVWKTKQMONHTI-UHFFFAOYSA-N
WAY-170523	WAY-170523	BRD-K36198571-001-02-0	PREP033	metalloproteinase inhibitor	MMP13	NA	NA	"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO"	Preclinical	WAY-170523	9830392	FARMEEAGJWMFSZ-UHFFFAOYSA-N
WAY-600	WAY-600	BRD-K85920262-001-02-1	PREP043	mTOR inhibitor	MTOR	NA	NA	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	Preclinical	WAY-600	25229526	FPEIJQLXFHKLJV-UHFFFAOYSA-N
WHI-P154	WHI-P154	BRD-K07487750-001-03-3	PREP041	JAK inhibitor	"EGFR, JAK1, JAK2, JAK3"	NA	NA	"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC"	Preclinical	WHI-P154	3795	CBIAKDAYHRWZCU-UHFFFAOYSA-N
WP1066	WP1066	BRD-K05445342-001-05-3	PREP027	STAT inhibitor	STAT3	NA	NA	"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1"	Phase 1	WP1066	11210478	VFUAJMPDXIRPKO-LQELWAHVSA-N
Degrasyn	WP1130	BRD-K43644456-001-04-0	PREP040	deubiquitinase inhibitor	"JAK2, UCHL5, USP14, USP9X"	NA	NA	"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1"	Preclinical	Degrasyn	11222830	NA
WYE-125132	WYE-125132	BRD-A45498368-001-07-1	PREP041	mTOR inhibitor	MTOR	NA	NA	CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1	Preclinical	WYE-125132	25260757	QLHHRYZMBGPBJG-UHFFFAOYSA-N
WYE-354	WYE-354	BRD-K77008974-001-03-2	PREP037	mTOR inhibitor	MTOR	NA	NA	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	Preclinical	WYE-354	44219749	IMXHGCRIEAKIBU-UHFFFAOYSA-N
WZ-3146	WZ-3146	BRD-K73293050-001-03-1	PREP042	EGFR inhibitor	EGFR	NA	NA	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	WZ-3146	44607360	APHGZZPEOCCYNO-UHFFFAOYSA-N
WZ4002	WZ-4002	BRD-K72420232-001-12-3	PREP036	EGFR inhibitor	"EGFR, ERBB2"	NA	NA	"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1"	Preclinical	WZ4002	44607530	NA
WZ8040	WZ8040	BRD-K81728688-001-04-4	PREP043	EGFR inhibitor	EGFR	NA	NA	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	WZ8040	44607531	NA
Xanomeline	xanomeline	BRD-K72815923-034-01-2	PREP047	acetylcholine receptor agonist	"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7"	NA	NA	"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1"	Phase 3	Xanomeline	60809	JOLJIIDDOBNFHW-UHFFFAOYSA-N
Emapunil	XBD173	BRD-K45875383-001-01-2	PREP046	benzodiazepine receptor ligand	TSPO	NA	NA	"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1"	Phase 2	Emapunil	6433109	NBMBIEOUVBHEBM-UHFFFAOYSA-N
Xilobam	xilobam	BRD-K79633074-001-01-8	PREP046	NA	NA	NA	NA	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	Phase 1	Xilobam	39689	PAXRPWSXCPTPCA-UHFFFAOYSA-N
Tesevatinib	XL-647	BRD-K03765900-001-01-9	PROS002_PR500	"EGFR inhibitor, VEGFR inhibitor"	"EGFR, EPHB4, ERBB2, FLT4, KDR"	NA	NA	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	Phase 3	Tesevatinib	10458325	HVXKQKFEHMGHSL-GOOCMWNKSA-N
XL388	XL388	BRD-K03549949-001-01-0	PREP046	mTOR inhibitor	MTOR	NA	NA	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	Preclinical	XL388	59604787	LNFBAYSBVQBKFR-UHFFFAOYSA-N
XL888	XL888	BRD-A03506276-001-01-5	PREP026	HSP inhibitor	NA	NA	NA	CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O	Phase 1	XL888	57748689	LHGWWAFKVCIILM-LAQKFSSHSA-N
Xylazine	xylazine	BRD-K21565985-001-22-5	PREP017	adrenergic receptor agonist	"ADRA2A, ADRA2B, ADRA2C"	neurology/psychiatry	anesthetic	"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1"	Launched	Xylazine	5707	BPICBUSOMSTKRF-UHFFFAOYSA-N
Y-27632 Dihydrochloride	Y-27632	BRD-K44084986-300-08-4	PREP044	rho associated kinase inhibitor	"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2"	NA	NA	"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1"	Preclinical	Y-27632 Dihydrochloride	448042	IYOZTVGMEWJPKR-VOMCLLRMSA-N
Y-320	Y-320	BRD-K96259238-001-01-4	PREP042	interleukin inhibitor	IL17A	NA	NA	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	Preclinical	Y-320	22227931	BWZNJVZTAWBIFG-UHFFFAOYSA-N
Y-39983	Y-39983	BRD-K56751279-300-01-4	PREP026	rho associated kinase inhibitor	"ROCK1, ROCK2"	NA	NA	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	Phase 2	Y-39983	9810884	NA
Sepantronium bromide	YM-155	BRD-K76703230-004-04-1	PREP027	survivin inhibitor	BIRC5	NA	NA	"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C"	Phase 2	Sepantronium bromide	11178236	QBIYUDDJPRGKNJ-UHFFFAOYSA-M
YM201636	YM-201636	BRD-K48488978-001-05-3	PREP036	PI3K inhibitor	NA	NA	NA	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical	YM201636	9956222	NA
YM-976	YM-976	BRD-K12932420-001-02-3	PREP047	phosphodiesterase inhibitor	PDE4A	NA	NA	"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1"	Phase 1	YM-976	6604918	MNHXYNNKDDXKNP-UHFFFAOYSA-N
DBZ	YO-01027	BRD-K04622161-001-02-3	PREP032	gamma secretase inhibitor	NA	NA	NA	"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O"	Preclinical	DBZ	11454028	NA
Zaldaride	zaldaride	BRD-A26032986-050-02-1	PREP027	calmodulin antagonist	CALM1	NA	NA	"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12"	Phase 3	Zaldaride	65909	HTGCJAAPDHZCHL-UHFFFAOYSA-N
Zaleplon	zaleplon	BRD-K92657060-001-05-7	PREP030	benzodiazepine receptor agonist	"GABRA1, GABRB1, GABRG2, TSPO"	neurology/psychiatry	insomnia	CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N	Launched	Zaleplon	5719	HUNXMJYCHXQEGX-UHFFFAOYSA-N
Zardaverine	zardaverine	BRD-K37561857-001-15-5	PREP045	phosphodiesterase inhibitor	PDE4D	NA	NA	"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1"	Phase 2	Zardaverine	5723	HJMQDJPMQIHLPB-UHFFFAOYSA-N
Ziprasidone	ziprasidone	BRD-K29582115-066-01-2	PREP035	"dopamine receptor antagonist, serotonin receptor antagonist"	"ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4"	neurology/psychiatry	"schizophrenia, bipolar disorder"	"Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12"	Launched	Ziprasidone	60854	MVWVFYHBGMAFLY-UHFFFAOYSA-N
6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester	ZK-93423	BRD-K33882852-003-02-8	PREP038	benzodiazepine receptor agonist	"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2"	NA	NA	"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC"	Phase 3	6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester	121926	ALBKMJDFBZVHAK-UHFFFAOYSA-N
ZK-93426	ZK-93426	BRD-K68392338-003-02-0	PREP027	benzodiazepine receptor antagonist	"GABRA1, GABRA2, GABRA3, GABRA5"	NA	NA	"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C"	Phase 1	ZK-93426	115210	VMDUABMKBUKKPG-UHFFFAOYSA-N
ZK811752	ZK811752	BRD-K91825936-001-01-2	PREP031	CC chemokine receptor antagonist	CCR1	NA	NA	"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O"	Phase 2	ZK811752	NA	NA
ZLN005	ZLN005	BRD-K73073971-001-01-7	PREP042	NA	NA	NA	NA	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	Preclinical	ZLN005	899323	LQUNNCQSFFKSSK-UHFFFAOYSA-N
ZM-306416	ZM-306416	BRD-K41337261-001-03-0	PREP037	"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor"	"EGFR, FLT1, FLT4, KDR"	NA	NA	"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC"	Preclinical	ZM-306416	5329006	YHUIUSRCUKUUQA-UHFFFAOYSA-N
ZM-447439	ZM-447439	BRD-K72703948-001-10-1	PREP037	Aurora kinase inhibitor	"AURKA, AURKB"	NA	NA	"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1"	Preclinical	ZM-447439	9914412	OGNYUTNQZVRGMN-UHFFFAOYSA-N
Zolantidine	zolantidine	BRD-K08996725-332-01-7	PREP025	histamine receptor antagonist	NA	NA	NA	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	Preclinical	Zolantidine	91769	KUBONGDXTUOOLM-UHFFFAOYSA-N
Zolmitriptan	zolmitriptan	BRD-K54314721-001-10-2	PREP034	serotonin receptor agonist	"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F"	neurology/psychiatry	migraine headache	"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12"	Launched	Zolmitriptan	60857	ULSDMUVEXKOYBU-ZDUSSCGKSA-N
ZSTK474	ZSTK-474	BRD-K63068307-001-08-9	PREP047	PI3K inhibitor	"PIK3CB, PIK3CD, PIK3CG"	NA	NA	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	Phase 1/Phase 2	ZSTK474	11647372	NA